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Summary 
i 
 
 In the field of medicinal and synthetic chemistry, steroids have been one of the most 
attractive areas for investigation due to their pharmacological properties. Steroids are 
important class of polycyclic compounds which exhibit diverse biological activities. It is 
proved that a number of biologically important properties of modified steroids are 
dependent upon structural features of the steroid ring system or side chain so this 
modification of the steroid skeleton provides a way to alter the functional groups and 
numerous structure-activity relationships (SAR) have been established by such synthetic 
alterations chemical. Bioorganic chemists have reported a number of modifications in 
natural steroids resulting in the promotion of their activities. Even a small change in 
steroid moiety can elicit an extensive biological response. All these facts have attracted 
researchers to explore these molecules after modifying them suitably to induce various 
pharmacological properties. This is still to be a fascinating field worldwide. Our research 
group is concerned with the synthesis of steroidal compounds their identification by 
chemical and spectral studies and evaluation of their biological behavior. The work 
embodied in this thesis describes the synthesis of steroidal heterocycles and their 
biological evaluation. The identification of newly synthesized compounds has been 
ascertained by IR, 1H NMR, 13C NMR, MS and elemental analysis. The whole work is 
divided into four chapters namely, 
        
 CHAPTER 1:  Synthesis of nitrogen containing steroidal heterocycles 
                                       (a) Steroidal tetrazoles 
                                       (b) Steroidal spiroazetidinones 
 CHAPTER 2:  Synthesis of steroidal thiazoles 
 CHAPTER 3:  Synthesis of steroidal spirooxadiazolines 
 CHAPTER 4:  Biological evaluation of newly synthesized steroidal    
                                      heterocycles  
  
        Following results are summarized as: 
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                                                                                                                    CHAPTER-1 
                                                  Nitrogen containing steroidal heterocycles 
                                                                                     (a) Steroidal tetrazoles 
 
Tetrazole moiety containing molecules have been reported to exhibit a broad spectrum of 
biological activities such as antibacterial, anti-inflammatory, antifungal, antiviral, anti-
tuberculous, cyclo-oxygenase inhibitors, anti-nociceptive, hypoglycemic and anti-cancer 
activities. The above pharmaceutical interest prompted us to synthesize steroids 
substituted tetrazole derivatives (VII-IX). The substrates selected for initial studies 
include 3β-Acetoxy-5α-cholestan-6-one (I), 3β-chloro-5α-cholestan-6-one (II) and 5α-
cholestan-6-one (III). The products obtained have been characterized on the basis of their 
spectral (IR, 1H NMR, 13C NMR, MS) studies and elemental analysis. 
 
 
 
 
 
 
 
 
 
 
Design, synthesis and biological evaluation of steroidal tetrazoles as antiproliferative 
and antioxidant agents. Shamsuzzaman, Mohd Asif, Abad Ali, Ashraf Mashrai, Hena 
Khanam, Asif Sherwani, Mohammad Owais. Eur. Chem. Bull., 2014, 3(11), 1075-1080 
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                                                                                   (b) Steroidal spiroazetidinone 
 
The 2-azetidinones (β-lactams) are an important class of heterocycles that have been 
intensively investigated across diverse scientific disciplines as well as the pharmaceutical 
industry because of their potent antibacterial activity. They have served humanity for 
several decades in its war against the infections caused by bacteria and are responsible for 
saving millions of lives. Further 2-azetidinones have been reported to possess other 
relevant biological activities which include human cytomegalovirus (HCMV) inhibitor, 
human leukocyte elastase (HLE) inhibitor, thrombin inhibitor , porcine pancreatic elastase 
(PPE) inhibitor  and HIV-1 protease inhibitor. Keeping this in consideration, the synthesis 
of some steroidal spiroazetidinone has been carried out. 3β-chlorocholest-5-ene-7-one (X) 
and cholest-5-ene-7-one (XI) reacted in two steps to yield 3β-chlorocholest-5-en-7-spiro-
1′-phenyl-3′-chloro-azetidin-2′-one (XIV) and cholest-5-en-7-spiro-1′-phenyl-3′-chloro-
azetidin-2′-one (XV). 
 
 
 
 
 
 
Design, synthesis and docking studies of novel spiroazetidinone substituted steroidal 
derivatives possessing potent diversified pharmacological properties. Shamsuzzaman, 
Khan A. A. Abdul Baqi, Mohd Asif, Abad Ali Hena Khanam, Ashraf Mashrai, Anis 
Ahmad, Asad U Khan. Eur. Chem. Bull., 2015, 4(3), 154-164. 
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                                                                                                                    CHAPTER-2        
                                                                                            Steroidal thiazoles 
 
Thiazoles are one of the most commonly encountered heterocycles among the compounds 
found in the bioactive natural product of microbial and marine origin where they exhibit 
important biological activities such as antitumor, antifungal, antibiotic, antiviral as well as 
acting as peptide mimetics. Thiazoles occupy a prominent position in the drug discovery 
process, and this system found in the several marketed drugs. Due to their biological 
significance there is a need to develop a new protocol for the synthesis of these 
compounds. This prompted us to synthesize new steroidal thiazoles (XVI-XVIII, XX) 
using steroidal ketones (I-III, XIX) in microwave condition. 
 
 
 
 
Microwave-assisted one pot synthesis, characterization, biological evaluation and 
molecular docking studies of steroidal thiazoles. Mohd Asif, Abad Ali, Atif Zafar, 
Mohd Farhan, Hena Khanam, S.M.Hadi, Shamsuzzaman, J. Photochem. Photobiol .B 
doi:10.1016/j.jphotobiol.2016.11.010 
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                                                                                                                     CHAPTER-3 
                                                                           Steroidal spirooxadiazolines 
 
Oxadiazolines constitute an important class of heterocyclic compounds which showed 
significant pharmacological and biological activities. Oxadiazoline derivatives exhibited 
antibacterial, antifungal, anti-inflammatory, anticancer and insecticidal properties. It is 
also found that compounds having oxadiazoline moiety act as muscle relaxants and 
tyrosinase inhibitors. Furthermore, new studies revealed that these compounds also 
possess antiretroviral activity. Although various modifications of steroids have been tried 
but as far the literature precedents are concerned, little efforts have been made towards 
the efficient synthesis and simultaneous biological analysis of steroid based 
oxadiazolines. Herein we report the synthesis of  some steroidal spirooxadiazolines  
namely 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (XXI), 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (XXII), 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (XXIII), 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (XXVII), 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (XXVIII), 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline 
(XXIX), 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline 
(XXXIII), 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline 
(XXXIV) and 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline (XXXV). 
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                                                                                                                                           CHAPTER-4       
              Biological evaluation of newly synthesized steroidal heterocycles 
 
Steroids, a widespread class of natural organic compounds occurring in animals, plants 
and fungi, have shown great therapeutic value for a broad array of pathologies. They 
comprise a wide repertoire of structurally related natural compounds with important 
functions in vivo, such as physiological regulators, hormones and provitamins. Steroids 
are representative of a rich structural molecular diversity and have the ability to interact 
with various biological targets and pathways. For better understanding on how 
modifications on steroid skeleton can affect biological activity, variety of steroidal 
heterocycles have been synthesized and evaluated in vitro for their anticancer, 
antioxidant, antimicrobial DNA damage and HSA binding studies. In silico and molecular 
docking studies were also performed. 
        The antiproliferative potential of compounds VII-IX were studied  in vitro against 
three cell lines, viz. HeLa (cervical cancer), KCL-22 (myeloid leukemia), MDA-MBA-
231 (breast cancer) and normal cells (PBMCs)  by MTT assay. 
      In vitro antioxidant activities of compounds VII-IX, XIV-XV, XVI-XVIII and XX 
were evaluated by DPPH free radical scavenging assay. In vitro antimicrobial activities of 
steroidal spiroazetidinones (XIV-IX) involved their screening against bacterial cultures of 
Streptococcus pyogenes, Staphylococcus epidermidis, Pseudomonas aeruginosa, 
Kliebsiella pneumonia (Clinical isolate) and Escherichia coli by disc diffusion method 
and fungal strains Candida albicans, Penicillium marneffei, Aspergillus fumigates and 
Trichophyton mentagrophytes by agar diffusion method and subsequently the minimum 
inhibitory concentration (MIC) of all compounds were determined.  
              In silico and physiocochemical properties of compounds VII-IX, XIV-XV and 
XVI-XXIII and XX were studied. 
      DNA damage studies for steroidal thiazoles (XVI-XVIII, XX) were carried out using 
comet assay and reactive oxygen species production assay to know how these derivatives 
acts on DNA. 
HSA binding studies were performed for steroidal spirooxadiazolines (XXI-XXII) using 
multispectroscopic techniques (UV-vis, fluorescence and CD spectroscopy). FRET 
parameters were also calculated for these compounds. 
 
viii 
 
Docking studies for compounds XIV-XV (bacterial DNA gyrase and CY51 protein),   
compounds XVI-XVIII, XX (DNA)   and  compounds XXI-XXIII (HSA) were carried 
out to find out specific binding modes and better comprehension. 
 
  
 
 
Introduction 
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Steroids have been the prime focus of research throughout the scientific history due to 
their fascinating structural framework and their excellent ability to penetrate cell 
membranes and bind to the nuclear and membrane receptors. The chemistry of 
steroids is a rapidly expanding field providing one of the most interesting and 
explored area for the organic chemists. But the recent past has seen an exhaustive 
focus of research being diverted toward these biologically important molecules. These 
compounds turn out to be non-toxic, less vulnerable to multi-drug resistance (MDR) 
and highly bioavailable because of being capable of penetrating the cell wall. This is 
pertinently true of the rational semi synthetic modifications of steroidal molecules. 
Probably, it is because of the various advantages associated with steroid based 
chemotherapeutics. Even a small change in steroid moiety can elicit an extensive 
biological response, so researchers diverted their effort to explore these molecules 
after modifying them suitably to induce various medicinal properties. It is therefore 
not surprising that steroids attract considerably interest not only from chemists, but 
also biologists. 
         During the early and middle years of steroid chemistry, synthetic efforts focused 
primarily upon the ring system and some of the more simple functional side chains. 
These studies were directed primarily towards the development of synthetic methods 
for the construction and modification of the skeleton and were due, of course, to the 
demand for potent pharmaceutical agents. Moreover, progress in synthetic methods 
and separation and identification techniques prompted more detailed studies of these 
derivatives. Within the last decade intensive research on modified steroids has yielded 
many imaginative syntheses of general interest and has contributed much to the 
development of novel biologically potent compounds. While the introduction of the 
heteroatoms in the skeleton of steroids further enhance their biological properties. As 
a result, a number of heterocyclic systems have been introduced into the core structure 
of steroids such as pyrazoles, pyrazolines, isoxazoles, isoxazolines, thiazoles, 
thiadiazoles, pyridines, pyrimidines, imidazoles, etc. 
              Our laboratory is mainly concerned with the synthesis of steroid derivatives 
and their identification by spectral, analytical studies and biological evaluation. The 
aim of the present work is to survey the syntheses of modified heterosteroids as well 
as some relevant chemistry involving transformations of steroids of biological 
importance. This doctoral thesis comprises the synthesis, characterization and 
biological evaluation of steroidal heterocycles.  
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        In the present work an attempt has been made to synthesize some heterocyles 
substituted modified steroids of biological interest such as tetrazoles, azetidinones, 
thiazoles and oxadiazolines. The characterization of these compounds has been 
achieved by elemental and spectral methods employing (IR, 1H NMR, 13C NMR and 
mass spectrometry). Synthesized derivatives were evaluated for their various 
biological activities (anticancer, antimicrobial, antioxidant, DNA damage, HSA 
binding and molecular docking).       
  
 
Chapter 1 
Nitrogen containing 
steroidal heterocycles 
(Steroidal 
tetrazoles/Steroidal 
spiroazetidinones) 
Theoretical
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Tetrazoles 
 
Tetrazoles are one of the most stable nitrogen rich heterocycles which are rarely 
occurs in nature.1 Tetrazoles have gained much attention due to their wide use in drug 
design as an isosteric replacement for carboxylic acids. They act as a cis-peptide bond 
mimetic, precursor to other heterocycles, in high-energy compounds, and as a 
coordinating group in directed ortho-metalation.2 Because of the importance of these 
scaffolds in synthetic organic chemistry and their usefulness as pharmacological 
molecules, much attention has been paid on their synthesis.  Tetrazole unit (1) 
consists of five membered ring containing one carbon and four nitrogen atoms with 
two double bonds. 
                                                                  
 
     Mancheno and Bolm3 developed facile route towards the synthesis of N-(1H)-
tetrazole sulfoximines (3a-g) from N-cyano sulfoximes (2a-g) by [3+2] cycloaddition 
reaction using NaN3  and  ZnBr2 in H2O-MeOH mixtures at 120 °C.  
 
                                 
     Nowrouzi et al.4 synthesized 5-substituted-1H-tetrazoles (5) from substituted 
benzonitriles (4) using NaN3 and 4-(N,N-dimethylamino) pyridinium acetate as 
catalyst under solvent free condition. 
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               R = Ph, 4-Me(C6H5)CN, 4-CF3(C6H5)CN, 3-Cl(C6H5)CN, 4-Cl(C6H5)CN, 2-       
              NH2(C6H5)CN, 2-pyridinecarbonitrile, 4-pyridinecarbonitrile, CN(C6H5)CN 
      
    Zhao et al.5 prepared a series of N-Unsubstituted primary α-aminotetrazole (9a-o) 
based on the Ugi-4 component reaction of aldehydes (6) and isocyanides (7) in 
presence of tritylamine as an ammonia surrogate and trimethylsilyl azide in methanol. 
The deprotection of the  intermediate (8a-o) yield the respective products (9a-o). 
 
     Ek et al. 6 successfully synthesized tricyclic fused tetrazoles (12) by diazotizative 
allylation reaction of aromatic allylic bromides (11). Aromatic allylic bromides (11) 
were obtained from substituted 1-amino benzonitriles (10).   
 
 
                            R= 5-Cl, 5-Br, 4-NO2, 5-NO2, 4-CF3, 4-Cl-5-Br 
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    Faria at el.7 reported the synthesis of 5-(1-aryl-3-methyl-1H-pyrazol-4-yl)-1H-
tetrazoles (16) from pyrazole-4-carbonitriles precursors (15) using NaN3 and 
ammonium chloride in DMF at 130 ᴼC for 14 h. 
 
            R= 3-Cl, 2,4-diCl, 3,5-diCl, 3,4-diCl, 4-Cl, 2-F, 4-F, 3-F, 2-Br, 3-Br, 4-OMe 
     Rahmani et al.8 reported the synthesis of 1-aryl-5-(trifluoromethyl)-1H-tetrazoles 
(18) from N-aryl-2,2,2-trifluoroacetimidoyl chlorides (17) by reaction of NaN3 in 
acetone under microwave condition. 
 
      R= H, 2-Br, 2,4-dimethyl, 4-Cl, 4-CH3, 2-CF3, 4-NO2, 4-OCH3, 2-OCH3, 
Napthalene 
     Jin et al.9 reported the synthesis of 1-substituted tetrazoles (21) via the acid-
catalyzed [3+2] cycloaddition between isocyanides (19) and trimethylsilyl azide (20) 
in presence of methanol. 
 
  R= p-MeO-C6H4, O-MeO-C6H4, 2,6-Dimethyl-C6H3, C6H5, p-CO2Me-C6H4, p-NO2-   
             C6H4,CH3(CH2)3 ,cyclohexyl, t-butyl,Me3SiCH2 
     
      Habibi et al.10 synthesized the isomers of the arylaminotetrazoles (23, 24) by the 
reaction of acrylcyanamides (22) with sodium azide in presence of AlCl3 as lewis acid 
6 
 
catalyst in DMF at 120 ᴼC. If R is electron withdrawing then 5-arylamino-1H-
tetrazole isomers (23) is the major product but if R is electron donating then 1-aryl-5-
amino-1H-tetrazole isomers (24) dominates. 
 
        R= 4-NO2-C6H4, 4-Br-C6H4, 2,5-(Cl)-C6H3,C6H5, 4-Me-C6H4, 2-Me-C6H4, 2,4-  
               (Me)2- C6H3, 1,4-C6H4 
    
  Al-Hourani et al.11 reported the synthesis of series of 1, 5-diaryl-substituted tetrazole 
derivatives (27) from substituted amides (26) using substituted carboxylic acids (25) 
as precursor of amides. 
 
 
R= H, Me, OMe, F, Cl 
     Nikbakht et al.12 describes the efficient route for the diastereoselective synthesis of 
α-hydrazino tetrazoles (32) via a facile Ugi-azide pseudo five component reaction 
involving two equivalents of cyclic ketones (29), hydrazine hydrate (28), isocyanides 
(30) and trimethylsilyl azide (31). 
 
                               R1= 4-tBu, 4-Et, 4-Me, 3-Me  
                               R2= t-Bu, cyclohexyl 
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Azetidinone 
Azetidinone heterocyclic system (33) consists of four membered ring containing one 
nitrogen and three carbon atoms with one carbonyl group.  
                                                        
                                                             
Over the years, the synthesis of 2-azetidinones has received considerable attention 
among the organic and medicinal chemists due to their immense applications.The 2-
azetidinone skeleton, also known as the β-lactam ring, has been recognized as a useful 
building block in the synthesis of biologically important compounds. 2-Azetindinone 
derivatives display interesting biological activities including antimicrobial13, 
antitubercular14, anti-inflammatory15, chymase inhibitory16 and antitumor.17 
 
     Elumalaia et al.18 synthesized pyrazine substituted azetindin-2-ones (38) from 
Staudinger reaction of substituted Schiff base derivatives of pyrazinamide (36) with 
chloroacetyl chloride (37). The intermediate pyrazinamide substituted Schiff bases 
(36) were prepared from pyrazine amide (34) and substituted aldehydes (35). 
 
 
   
R= phenyl, cinnamyl, 2-nitrophenyl, 2-chlorophenyl, 2-hydroxyphenyl, 3-
nitrophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-flurophenyl, 4-methoxyphenyl, 2-
furyl, 4-pyridyl, 3-pyridyl 
      
     Desai and Dodiya19 prepared 2-azetidinone derivatives containing quinoline 
nucleus (44) through multi step reaction on 2-chloro-6-methylquinoline-3-
carbaldehyde (39). 
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R= 2-(Cl)-Phenyl, 3-(Cl)-Phenyl, 4-(Cl)-Phenyl, 2-(NO2)-Phenyl, 3-(NO2)- Phenyl,   
4-(NO2)-Phenyl, 2-(OCH3)-Phenyl, 3-(OCH3)-Phenyl, 4-(OCH3)-Phenyl, 4-(CH3)- 
Phenyl, 2-(F)-Phenyl, 4-(F)-Phenyl 
     
 
      Kayarmar et al.20 prepared the imidazoquinoline based 2-azetidinones (53) from 
series of reactions on 2,4-dihydroxy quinoline (45). 
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        R= 4-Chlorophenyl, Biphenyl, 2-4, Dimethoxyphenyl, 2-4, Dimethoxyphenyl-5-    
              nitrophenyl, 6-methoxy napthyl, 4-hydroxyphenyl, 2,4-Dichloro phenyl 
   
 
 
      Zarei21 synthesized 2-azetidinone derivatives (56a-j) by the reaction of N 
benzylideneanilides (54) and substituted phenoxyacetic acids (55) with triethylamine, 
phosphonitrilic acid as catalyst and dichloromethane as solvent.   
10 
 
                             
 
      
     Buttero et al.22 stereoselectively synthesized 3-phthalimido-4-[tricarbonyl(ƞ6arene) 
chromium(0)] complexed-2- azetidinones (59) via [2+2] cycloaddition of tricarbonyl 
(ƞ6 arene)chromium(0) complexed imines (57). The tricarbonyl(ƞ6arene)chromium(0) 
complexed imines (57) dissolved in dry dichloromethane, were treated at 0°C, with a 
threefold excess of phthalimidoacetylchloride (58) and in the presence of freshly 
distilled triethylamine. Thus, phthalimidoketene generated in situ reacted with the 
imine (57) under the classical Staudinger cycloaddition conditions afforded 3-
phthalimido-4-[tricarbony l(ƞ6arene) chromium(0)] complexed-2-azetidinones (59). 
 
 
R 1 C H = N R 2 + R 3 C H 2 C O O H N 
R 1 R 2 
O R 3 
( 5 4 ) ( 5 5 )                                            ( 5 6   a - j ) 
                           R 1 
                                          R 2                                                     R 3 
( a ) C 6 H 5                                   C 6 H 5                                               P h O 
( b ) 4 - C l C 6 H 4                           4 - E t O C 6 H 4                                        P h O 
( c ) 4 - M e O C 6 H 4                      4 - M e O C 6 H 4                                     P h O 
( d ) C H = C H P h 4 - E t O C 6 H 4 P h O 
( e ) C H = C H P h 4 - E t O C 6 H 4 P h t h N 
( f )                       4 - C l C 6 H 4      
                        4 - M e O C 6 H 4                                  P h t h N 
( g ) 4 - N O 2 C 6 H 4                     4 - M e O C 6 H 4 C H P h t h N 
( h ) 4 - M e O C 6 H 4                        4 - E t O C 6 H 4                                      P h t h N  
( i )                        4 - N O 2 C 6 H 4 C 6 H 5                                         2 - N a p h t h O 
( j )                       4 - M e O C 6 H 4                      4 - M e O C 6 H 4                                2 - N a p h t h O 
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    Karupaiyan et al.23 reported the synthesis of bis-azetidinones (62) linked with an 
ethylene bridge and possessing cis stereochemistry by using different ketenes (61) and 
bis-imines (60). 
                    
 
         Durham and Miller24 synthesized fused bicyclic azetidinones (65) from 
glucuronic acid glycosides (64) using carbohydrate template (63). 
              
 
      
     Abdellaoui and Xu25 reported the synthesis of 4-spiro-cyclohexadienonyl-β-
lactam-3-carbonitriles (69) via the intramolecular nucleophilic cyclization of N-
benzyl-N-(4-hydroxyphenyl)cyanoacetamides (68) using iodobenzene acetate as 
oxidant, 2 eqv. of  potassium hydroxide  and  ethanol as solvent. Intermediate (68) 
was prepared from substituted amino phenols (66) and cyanoacetic acid (67). 
 
N 
N 
C H 
C H 
R 1 
R 1 
R 2 O C 
O 
C l 
N 
N 
O 
O 
O R 2 
H 
H 
R 1 
R 1 
H 
H 
O R 2 
( 6 0 ) ( 6 1 ) ( 6 2 ) 
R 1 = a n i s y l , P h , s t y r l R 2 = P h , A c , B n 
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R= 4-Methylbenzyl, 4-Methoxybenzyl, 3-Methoxybenzyl, 2- Methoxybenzyl, 4-   
Flurobenzyl, 4-Chlorobenzyl, 3-Chlorobenzyl, 4-Bromobenzyl, 4-Cyanobenzyl, 4- 
Nitrobenzyl   
      
     Kim et al.26 reported the synthesis of 2-azetidinone derivatives (72) through 
oxygenative [2+2] cycloaddition of alkynes [70] and imines [71] by using 4-picoline-
N-oxide as oxidant, (5 mol %) Rhodium catalyst and acetonitrile as solvent at 50 ᴼC. 
 
 
R= Phenyl, 4-Methoxyphenyl, 3-Methoxyphenyl, 4-Methylphenyl, 4-Bromophenyl,   
Furyl, 3-Chloropropyl, Biphenyl, Butyl, 2-Phenylethyl 
      
     Singh et al.27 synthesized substituted 3-(1, 2, 3-triazol-1-yl)-β-lactams (77a-f) from 
3-azido-2-azetidinones (75) through click chemistry approaches utilizing azide-alkyne 
cycloaddition in the presence of CuSO4.5H2O/sodium ascorbate in ethanol-water 
mixture at room temperature. 3-azido-2-azetidinone scaffolds (75) were synthesized 
by Staudinger reaction of appropriately functionalized 1-azadienes (73) with azido-
ketene generated in situ from azido-acetic acid (74) in the presence of p-toluene 
sulfonylchloride and triethylamine in dry dichloromethane. 
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Discussion
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Nitrogen heterocycles in particular exhibit diverse biological and pharmacological 
activities due in part to the similarities with many natural and synthetic molecules 
with known biological activity.  
Tetrazoles 
Tetrazoles are well known compounds in synthetic organic chemistry. These 
compounds have been widely used in many applications such as medicine, 
pharmacology and explosives.28 These derivatives have been found to possess 
numerous biological activities such as antibacterial, anti-inflammatory, antifungal, 
antiviral, anti-tuberculous, cyclo-oxygenase inhibitors, anti-nociceptive, 
hypoglycemic and anti-cancer activities.29 Their importance originates from the 
similarity of their pKa values with those of corresponding carboxylic acids and 
regards as biologically equivalent to the carboxylic acid group.30As our research 
group has been involved in the development of new heterosteroids 31 herein we, 
describe the synthesis of  new steroidal tetrazole derivatives (84-86) by [3+2] 
cycloaddition reaction of steroidal cyanoacetylhydrazone derivatives (81-83) with 
sodium azide in presence of DMF as solvent and ammonium chloride. The structures 
of newly synthesized compounds have been confirmed on the basis of analytical and 
spectral (IR, 1H NMR, 13C NMR, MS) studies. 
 
 
Design, synthesis and biological evaluation of steroidal tetrazoles as  
antiproliferative and antioxidant agents. Shamsuzzaman, Mohd Asif, Abad Ali, 
Ashraf Mashrai, Hena Khanam, Asif Sherwani, Mohammad Owais. Eur. Chem. Bull., 
2014, 3(11), 1075-1080. 
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Azetidinones 
The 2-azetidinones (β-lactams) are an important class of heterocycles that have been 
intensively investigated across diverse scientific disciplines as well as the 
pharmaceutical industry because of their potent antibacterial activity.They have 
served humanity for several decades in its war against the infections caused by 
bacteria and are responsible for saving millions of lives.32 Literature survey reveals 
that 2-azetidinones have been reported to possess biological activities33, which 
include human cytomegalovirus (HCMV) inhibitor34, human leukocyte elastase 
(HLE) inhibitor35, thrombin inhibitor36, porcine pancreatic elastase (PPE) inhibitor37 
and HIV-1 protease inhibitor.38 Thus in view of these reports and in continuation of 
our research in field of heterosteroids39  we have synthesized new compounds (91, 92) 
containing azetidinone moiety amalgated with B-ring of steroidal framework. The 
substrates selected for initial studies include 3β-chlorocholest-5-ene-7-one (87) and 
cholest-5-ene-7-one (88). The structures of newly synthesized compounds have been 
established on the basis of analytical and spectral (IR, 1H NMR, 13C NMR, MS) data. 
 
 
 
 
Design, synthesis and docking studies of novel spiroazetidinone substituted 
steroidal derivatives possessing potent diversified pharmacological properties. 
Shamsuzzaman, Khan A. A. Abdul Baqi, Mohd Asif, Abad Ali Hena Khanam, 
Ashraf Mashrai, Anis Ahmad, Asad U Khan. Eur. Chem. Bull., 2015, 4(3), 154-164. 
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Reaction of 3β-acetoxy-5α-cholestan-6-cyanoacetylhydrazone (81) with sodium 
azide: 3β-Acetoxy-5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (84): 
3β-Acetoxy-5α-cholestan-6-cyanoacetylhydrazone (1.0 mmol) (81) in DMF (20 mL) 
was allowed to react with sodium azide (1.0 mmol) in presence of two equimolar  
amount of ammonium chloride under reflux for 12 h. After usual work up and 
recrystallization  from methanol a solid  compound 84 was obtained, m.p. 162-164 ᴼC. 
        
Characterization of compound 84 as 3β-acetoxy-5α-cholestan-6-ylidene-tetrazol-
5yl-acetylhydrazone: 
The elemental analysis of the compound 84 corresponded to the molecular formula 
C32H52N6O3. The IR spectrum provided evidence for the formation of the expected 
product. The IR showed dignostic absorption bands at 3325 and 1735 cm-1 for the 
stretching vibrations of N-H group and acetate group, respectively. The other 
important absorption bands appeared in IR spectrum at 1669, 1625 and 1325 cm-1 
were attributed to C=O, C=N and C-N groups, respectively. The structure of 
compound 84 was well supported by its 1H   NMR and 13C NMR spectra. In 1H NMR 
spectrum of compound 84 a singlet at δ 8.6 (exchangeable with D2O) indicated the 
presence of NH group. A broad multiplet for one proton was observed at δ 4.7 which 
could be assigned to C3α-H and a sharp singlet for three acetoxy group protons was at 
δ 2.03. Angular and side-chain methyl protons were observed at δ 1.18 (C10-CH3), 
0.70 (C13-CH3), 0.97 and 0.83 for other methyl protons. 
13C NMR spectrum of the 
compound also supported the proposed structure and showed signals at δ 172.3, 160.3 
and 158.1 indicating the presence of (NHCO), (NC=N) and (C=N), respectively. 
Remaining carbon atoms were seen in accordance to cholestane series. The structure 
of compound 84 was further supported by its mass spectrum in which distinct 
molecular ion peak m/z 568 [M+.] was observed. 
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     In the light of above discussion the structure of compound 84 can be characterized 
as 3β-acetoxy-5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone. 
 
Reaction of 3β-chloro-5α-cholestan-6-cyanoacetylhydrazone (82) with sodium 
azide: 3β-Chloro- 5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (85): 
3β-Chloro-5α-cholestan-6-cyanoacetylhydrazone (1.0 mmol) (82) in DMF (20 mL) 
was allowed to react with sodium azide (1.0 mmol) in presence of two equimolar  
amount of ammonium chloride under reflux for 13 h. After usual work up and 
recrystallization  from methanol a solid  compound 85 was obtained, m.p. 172-174 ᴼC 
 
 
Characterization of compound 85 as 3β-chloro-5α-cholestan-6-ylidene-tetrazol-5yl-
acetylhydrazone: 
The elemental analysis of the compound 85 corresponded to the molecular formula 
C30H49N6ClO. The IR spectrum provided evidence for the formation of the expected 
product. The IR showed absorption bands at 3328 and 741 cm-1 for the stretching of 
N-H and C-Cl bonds, respectively. The absorption bands at 1670, 1627 and 1328 cm-1 
were attributed to C=O, C=N and C-N groups, respectively. The structure of 
compound 85 was well supported by its 1H NMR and 13C NMR spectra. In its 1H 
NMR spectrum, singlet at δ 8.4 (exchangeable with D2O) indicated the presence of 
NH. A broad multiplet  for one proton was observed at δ 3.8 which could be assigned 
to C3α-H. Angular and side-chain methyl protons were observed at δ 1.18 (C10-CH3), 
0.70 (C13-CH3), 0.97 and 0.83 for other methyl protons. 
13C NMR spectrum of the 
compound also supported the proposed structure and showed signals at δ 171.2, 161.8 
and 157.8 indicating the presence of (NHCO), (NC=N) and (C=N), respectively. 
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Remaining carbon atoms were seen in accordance to cholestane series. The structure 
of compound 85 was further supported by its mass spectrum in which distinct 
molecular ion peak m/z 544/546 [M+.] was observed. 
      On account of above discussion the structure of compound 85 can be 
characterized as 3β-chloro-5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone. 
Reaction of 5α-cholestan-6-cyanoacetylhydrazone (83) with sodium azide: 5α-
Cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (86): 
5α-Cholestan-6-cyanoacetylhydrazone (1.0 mmol) (83) in DMF (20 mL) was allowed 
to react with sodium azide (1.0 mmol) in presence of two equimolar amount of 
ammonium chloride under reflux for 15 h. After usual work up and recrystallization  
from methanol a solid  compound 86 was obtained, m.p. 141-142 ᴼC 
 
Characterization of compound 86 as 5α-cholestan-6-ylidene-tetrazol-5yl-
acetylhydrazone: 
The elemental analysis of the compound 86 corresponded to the molecular formula 
C30H50N6O. The IR data provided evidence for the formation of the expected product. 
The absorption bands at 3337 cm-1 appeared due to stretching vibrations of N-H 
group.  In addition, important absorption bands at 1673, 1635 and 1330 cm-1 were 
attributed to C=O, C=N and C-N groups, respectively. The structure of compound 86 
was well supported by its 1H NMR and 13C NMR spectra. In 1H NMR spectrum of the 
compound 86, a singlet at δ 8.4 (exchangeable with D2O) suggested the presence of 
NH moiety. Angular and side-chain methyl protons were observed at δ 1.18 (C10-
CH3), 0.70 (C13-CH3), 0.97 and 0.83 for other methyl protons. 
13C NMR spectrum of 
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the compound also supported the proposed structure and showed characteristic signals 
at δ 171.8, 161.5 and 157.8 indicating the presence of (NHCO), (NC=N) and (C=N), 
respectively. Remaining carbon atoms were seen in accordance to cholestane series. 
The structure of the compound 86 was further confirmed by its mass spectrum in 
which distinct molecular ion peak was observed at m/z 510 [M+.]. 
     In the light of above discussion the structure of compound 86 can be characterized 
as 5α-Cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone. 
Reaction of 3β-chloro-7-iminophenyl-cholest-5-ene (89) with chloroacetyl chloride: 
3β-Chlorocholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one (91): 
3β-Chloro-7-iminophenyl-cholest-5-ene (1.0 mmol) (89) was dissolved in 
dichloromethane (30 mL)  and to this solution, chloroacetyl chloride (2 mL) and few 
drops of triethylamine were added. Then the reaction mixture was refluxed for 3 h. 
The progress as well as completion of reaction was monitored by TLC. After 
completion of the reaction, the solvents were removed under reduced pressure. The 
crude product thus obtained was purified over silica gel column (petroleum ether-
ether; 10:1). Recrystallization from methanol afforded compound 91, m.p: 175-177 
°C. 
 
 
Characterization of compound 91 as 3β-chlorocholest-5-en-7-spiro-1′-phenyl-3′-
chloro-azetidin-2′-one. 
The elemental analysis of the compound 91 corresponded to the molecular formula 
C35H49Cl2NO. The IR spectrum provided evidence for the formation of the expected 
product. The dignostic absorption bands at 3078, 1583 and 1403 cm-1 were attributed 
to stretching vibrations of aromatic C-H bonds.  In addition, the important absorption 
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bands at 1760, 1624 and 1378 cm-1 were ascribed to C=O, C=C and C-N groups, 
respectively. The two absorption bands at 745 and 752 cm-1 were assigned for two C-
Cl bonds. The structure of compound 91 was well supported by its 1H NMR and 13C 
NMR spectra. In 1H NMR spectrum of compound 91, exhibited a multiplet at δ 7.53-
7.82 for five aromatic protons, a singlet for one proton at δ 5.41 for C6-H and one 
singlet for one proton of azetidinone ring at δ 4.64. A broad multiplet centered at δ 
3.91 for one proton was assigned to C3-αH. Angular and side-chain methyl protons 
were observed at δ 1.10 (C10-CH3), 0.71(C13-CH3), 0.93 and 0.81 for other methyl 
protons. 13C NMR spectrum of the compound also supported the proposed structure 
and showed signals at δ 165.2 (C=O, heterocyclic ring) and 128.3-119.2 (aromatic 
ring). Remaining carbon atoms were seen in accordance to the cholestane series. The 
mass spectrum was also in good agreement with its molecular formula which 
exhibited strong molecular ion at m/z 569/571 [M+.]. 
     In the light of above evidences the structure of compound 91 can be characterized 
as 3β-chlorocholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one. 
 
Reaction of 7-iminophenyl-cholest-5-ene (90) with chloroacetyl chloride: Cholest-5-
en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one (92): 
7-iminophenyl-cholest-5-ene (1.0 mmol) (90) was dissolved in dichloromethane (30 
mL)   and to this solution, chloroacetyl chloride (2 mL) and few drops of 
triethylamine were added. Then the reaction mixture was refluxed for 3.5 h. The 
progress as well as completion of reaction was monitored by TLC. After completion 
of reaction, the solvents were removed under reduced pressure. The crude product 
thus obtained was purified over silica gel column (petroleum ether-ether; 10:1). 
Recrystallization from methanol afforded compound 92, m.p: 169-170 °C. 
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Characterization of compound 92 as cholest-5-en-7-spiro-1′-phenyl-3′-chloro-
azetidin-2′-one. 
The elemental analysis of the compound 92 corresponded to the molecular formula 
C35H50ClNO. Its IR spectrum provided evidence for the formation of the expected 
product. The absorption bands in the region of 3074, 1587 and 1401 cm-1 were due to 
stretching vibrations of aromatic C-H bonds. In addition, the absorption bands at 
1761, 1625 and 1377 cm-1 were ascribed to C=O, C=C and C-N groups, respectively. 
The band at 748 cm-1 was assigned to C-Cl bond. The structure of compound 92 was 
well supported by its 1H NMR and 13C NMR spectra. In 1H NMR spectrum of the 
compound 92 exhibited a multiplet at δ 7.52-7.82 for five aromatic protons, a singlet 
for one proton at δ 5.30 for C6-H and another singlet for one proton of azetidinone 
ring at δ 4.65. Angular and side-chain methyl protons were observed at δ 1.10 (C10-
CH3), 0.71(C13-CH3), 0.93 and 0.81 (other methyl protons).
 13C NMR spectrum of 
the compound also supported the proposed structure and displayed characteristic 
signals at δ 160.3 (C=O, heterocyclic ring) and 128.4-119.1 (aromatic ring). 
Remaining carbon atoms were seen in accordance to the cholestane series. The mass 
spectrum was also in good agreement with its molecular formula which exhibited a 
strong molecular ion peak at m/z 535/537 [M+.]. 
     On the basis of above discussion the structure of compound 92 can be 
characterized as cholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one. 
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Mechanism for the synthesis of tetrazole derivatives 
The following mechanism (Scheme 1) has been proposed for the synthesis of 5α-
cholestan-6-ylidene-tetrazol-5yl-acetylhydrazones (84-86) from 5α-cholestan-6-
cyanoacetylhydrazone derivatives (81-83). Azide ion reacts with nitrile group of 5α-
cholestan-6-cyanoacetylhydrazones through [3+2] cycloaddition reaction to furnish 
5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazones (84-86). 
 
 
  
 Scheme 1. Mechanism tentative for the synthesis of steroidal tetrazoles (84-86) 
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Mechanism for the synthesis of azetidinone derivatives 
The following mechanism (Scheme 2) has been proposed for the conversion of the 7-
iminophenylcholest-5-ene derivatives (88, 90) into cholest-5-en-7-spiro-1′-phenyl-3′-
chloro-azetidin-2′-ones (91, 92). The chloroacetyl chloride anion generated during the   
reaction of triethyl amine on chloroacetyl chloride reacted with 7-iminophenylcholest-
5-ene derivatives by Staudinger [2+2] cycloaddition  reaction to yield corresponding 
cholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-ones (91, 92). 
                           
        
    
      Scheme 2. Mechanism for the synthesis of steroidal spiroazetidinones (91-92).                      
        
Experimental
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General Remark   
Chemicals and solvents used in this study were of ACS grade and used directly 
without further purification. Melting points were determined on a Biogen digital auto 
melting point apparatus. The IR spectra were recorded on KBr pellets with Perkin 
Elmer FT-IR Spectrometer spectrum Two and values are given in cm-1. 1H and 13C 
NMR spectra were run on a Bruker Avance II 400 NMR Spectrometer (operating at 
400 MHz for 1H and at 100 MHz for 13C NMR) with tetramethylsilane (TMS) as 
internal standard and values are given in parts per million (ppm) (δ). Mass spectra 
were recorded on a JEOL D-300 mass spectrometer. Elemental analyses were 
recorded on Perkin Elmer 2400 CHN Elemental Analyzer. Thin layer chromatography 
(TLC) plates were coated with silica gel and exposed to iodine to check the 
homogeneity as well as the progress of reaction. Sodium sulfate (anhydrous) was used 
as a drying agent. 
 
3β-Acetoxycholest-5-ene: 
A mixture of cholesterol (100 g), pyridine (150 mL, freshly distilled over KOH) and 
freshly distilled acetic anhydride (100 mL) was heated on water bath for 2 h. The 
reaction mixture was poured into ice cold water and solid mass thus obtained was 
filtered under suction, washed thoroughly with water until free from pyridine and then 
air dried. Recrystallization of the crude product from acetone gave 3β-acetoxycholest-
5-ene (93 g), m.p. 113 -114 ᴼC (reported, m.p. 115-116 ᴼC).40 
 
3β-Acetoxy-6-nitrocholest-5-ene: 
To a cooled mixture of 3β-acetoxycholest-5-ene (10 g) and conc. nitric acid (250 mL), 
sodium nitrite (10 g) was gradually added with constant stirring over a period of about 
45 minutes. After complete addition of sodium nitrite the stirring was continued for 
additional 2 h. Cold water (300 mL) was added to reaction mixture, yellow solid 
material separated out. The whole mass was extracted with diethyl ether. The ethereal 
layer was washed with water, NaHCO3 solution (5%) (until washings became pink), 
again with water and dried over anhydrous sodium sulfate. Removal of solvents 
provided the nitro compound as an oil which was crystallized from methanol (6.7 g), 
m.p. 104ᴼC (reported m.p. 102-104 ᴼC).41 
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3β -Acetoxy-5α-cholestan-6-one (78): 
3β-Acetoxy-6-nitrocholest-5-ene (6.0 g) was dissolved in glacial acetic acid (120 mL) 
by warming the mixture and zinc dust (12.0 g) was added in small portions with 
shaking. The suspension was heated under reflux for 4 h and water (12 mL) was 
added at regular intervals during the course of heating. The hot solution was filtered, 
cooled to room temperature and diluted with large excess of ice-cold water and 
extracted with diethyl ether. The ethereal solution was washed with water, NaHCO3 
solution (5%), again with water and dried over anhydrous sodium sulfate. Evaporation 
of solvent provided the acetoxy ketone as an oil which was crystallized from 
methanol (4.3 g), 128 ᴼC (reported m.p.127-128 ᴼC).42 
 
3β-Acetoxy-5α-cholestan-6-cyanoacetylhydrazone (81): 
To the solution of 3β-acetoxy-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0 mmol) was added. The reaction mixture was refluxed for 
10 h. The progress of reaction was monitored by TLC. After completion of reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-acetoxy-5α-cholestan-6-cyanoacetylhydrazone43 (0.42 g), m.p. 157-158 
ᴼC.  
 
3β-Chlorocholest-5-ene: 
Freshly purified SOCl2 (20 mL) was added gradually to cholesterol (25 g) at room 
temperature. A vigorous reaction ensured with evolution of gaseous products. When 
the reaction slackened, the mixture was gently heated at temperature (50-60 ᴼC) on 
water bath for 1 hour and then poured into water with stirring. The yellow solid thus 
obtained was filtered under suction, washed several times with ice-cold water and air 
dried. Recrystallization from acetone gave 3β-chlorocholest-5-ene (20 g), m.p. 95-
96ᴼC (reported, m.p. 96-97 ᴼC).44  
 
3β-Chloro-6-nitro-cholest-5-ene: 
A mixture of 3β-chlorocholest-5-ene (14 g), glacial acetic acid (100 ml) and fumic 
nitric acid (28 ml) was stirred at room temperature  below 20 ᴼC and sodium nitrite (3 
g) was gradually added over a period of 1 h. After complete addition of sodium 
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nitrite, the mixture was further stirred for an additional period of 2 h. Ice cold water 
(200 mL) was added to it and the yellowish solid thus obtained was filtered, washed 
with water and air dried. The crude product was recrystallized from methanol to give 
3β-chloro-6-nitrocholest-5-ene as needles  (8.7 g), m.p. 151-152 ᴼC (reported m.p. 153 
ᴼC).45 
 
3β-Chloro-5α-cholestan-6-one (79):  
A mixture of 3β-chloro-6-nitro-cholest-5-ene (8 g) and glacial acetic acid (160 mL) 
was heated just to a clear solution. The zinc dust (16 g) was added gradually in small 
portions with shaking. The suspension was heated under reflux for 4 h and water (16 
mL) was added at regular intervals during the course of heating. The hot solution was 
filtered and the filtrate was diluted with large excess of ice cold water. The organic 
matter was extracted with diethyl ether and the ethereal layer was washed 
successively with water, NaHCO3 solution (5%) and again with water and dried over 
anhydrous sodium sulfate. Removal of the solvents furnished the ketone as oil which 
was crystallized from methanol (5.7 g), m.p 128-129 ᴼC (reported m.p. 129 ᴼC).46 
 
3β-Chloro-5α-cholestan-6-cyanoacetylhydrazone (82): 
To the solution of 3β-Chloro-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0 mmol) was added. The reaction mixture was refluxed for 8 
h. The progress of reaction was monitored by TLC. After completion of reaction, the 
excess solvent was removed under reduced pressure. The reaction mixture was taken 
in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-chloro-5α-cholestan-6-cyanoacetylhydrazone 47 (0.38 g),  m.p. 187-188 
ᴼC. 
 
Cholest-5-ene: 
3β-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20 g) was added to the solution with continuous stirring over the period 
of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, methanol (few mL) was added and the reaction mixture was poured 
into water, acidified with HCl and then allowed to stand overnight. A white solid thus 
obtained was filtered under suction, washed thoroughly with water and air dried. The 
27 
 
crude material was recrystallized from acetone to provide cholest-5-ene as cubes (8.3 
g), m.p. 93 ᴼC (reported m.p. 89-91 ᴼC).48 
 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6 g) in glacial acetic acid (50 mL) 
was vigorously stirred at room temperature for 5 minutes and treated with fuming 
HNO3 (15 mL) followed by the addition of sodium nitrite (3 g)  in small portions over 
a period of  1 h and stirring was continued for further 2 h. The temperature of reaction 
mixture was maintained below 20 ᴼC by external cooling. The reaction mixture was 
poured into cold water and the yellow product thus obtained was extracted with  
diethyl ether. The ethereal layer was washed successively with water, NaHCO3 
solution (5%)  (until the washings became  pink) and again with water and dried over 
anhydrous sodium sulfate. Removal of solvents provided an oil, which was 
crystallized from methanol to give 6-nitrocholest-5-ene as leaflets (4.4 g), m.p. 119-
120 ᴼC (reported m.p.120-121 ᴼC).49 
 
5α-Cholestan-6-one (80): 
6-Nitro-cholest-5-ene (4 g) was dissolved in warm glacial acetic acid (80 mL) and 
zinc dust (8 g) was gradually added with shaking. The mixture was heated under 
reflux for 4 h and water (8 mL) was added during the course of reaction. Zinc dust 
(unreacted) was removed by filtration. To the filtrate, water was added till turbidity 
developed and it was allowed to stand overnight at room temperature. The solid 
material thus separated was filtered under suction and washed thoroughly with water 
in order to remove zinc. The organic solid was air dried and recrystallized from 
methanol (2.5 g), m.p 97-98 ᴼC (reported m.p. 98-100 ᴼC). 50 
 
5α-Cholestan-6-cyanoacetylhydrazone (83): 
To the solution of 5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0 mmol) was added. The reaction mixture was refluxed for 9 
h. The progress of reaction was monitored by TLC. After completion of reaction, the 
excess solvent was removed under reduced pressure. The reaction mixture was taken 
in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
provided 5α-cholestan-6-cyanoacetylhydrazone (0.35 g), m.p. 136-138 οC. 
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Solid, IR (KBr, νmax cm-1): 3327 (NH), 2246(CN),1665 (C=O), 1635 (C=N), 1329 (C-
N); 1H NMR (400 MHz, CDCl3): δ 8.1 (s,1H, NH, exchangeable with D2O), 2.3 (1H, 
C5α-H,J=11 Hz, 5 Hz), 1.19 (s, 3H, C10- CH3), 0.70 (s, 3H, C13-CH3), 0.97 & 0.83 
(other methyl protons); 13C NMR (100 MHz, CDCl3): δ 171.5, 157.8,  114.4, 55.3, 
53.1, 45.9, 44.5, 42.1, 39.3, 38.8, 38.2, 37.3, 36.5, 36.9, 35.7, 35.2, 35.1, 29.2, 28.5, 
27.3, 26.2, 26.0, 25.4, 25.0, 24.5, 22.1, 21.2, 17.3, 16.8, 12.3; Anal. Calc. for 
C30H49N3O: C, 77.08; H, 10.57; N, 8.99 % found: C, 77.05, H, 10.52, N, 8.96 %. MS 
(ESI): m/z 467 [M+.]. 
 
3β-Chlorocholest-5-en-7-one (87) 
A solution of butyl chromate [t-butyl alcohol (60 mL), CrO3 (20 g), acetic acid (84 
mL) and acetic anhydride (10 ml)] 44 was added at 0 ᴼC to a solution of 3β-
chlorocholest-5-ene (8 g) in CCl4 (150 mL), acetic acid (30 mL) and acetic anhydride 
(10 mL). The contents were refluxed for 3 h and then diluted with water. The organic 
layer was washed with NaHCO3 solution (5%), water and then dried over anhydrous 
sodium sulfate. Evaporation of the solvents under reduced pressure furnished 3β-
chlorocholest-5-en-7-one (87) which was recrystallised from methanol (3.3 g)  m.p. 
144 ᴼC (reported, m.p. 144-145 ᴼC).51 
 
Cholest-5-en-7-one (88) 
A solution of butyl chromate [t-butyl alcohol (60 ml), CrO3 (20 g), acetic acid (84 
mL) and acetic anhydride (10 mL)] 44 was added at  0 ᴼC to a solution of cholest-5-ene 
(8 g) in CCl4 (150 mL), acetic acid (30 mL) and acetic anhydride (10 mL). The 
contents were refluxed for 3 h and then diluted with water. The organic layer was 
washed with NaHCO3 solution (5%), water and then dried over anhydrous sodium 
sulfate. Evaporation of the solvents under reduced pressure furnished cholest-5-en-7-
one (88) which was recrystallised from methanol (3.0 g)  m.p. 128 ᴼC (reported, m.p. 
125-129 ᴼC).52 
 
Representative procedure for the synthesis of 5α-cholestan-6-ylidene-tetrazol-5yl-
acetylhydrazones (84-86): 
To a solution of steroidal cyanoacetylhydrazones (1.0 mmol) (81-83) in DMF (20 
mL), sodium azide (1.0 mmol) and two equimolar amount of ammonium chloride 
were added. The reaction mixture was refluxed for 12-15 h. The progress as well as 
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completion of the reaction was monitored by TLC. After completion of the reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
then taken in diethyl ether, washed with water and dried over anhydrous sodium 
sulfate and recrystallization from methanol afforded corresponding 5α-cholestan-6-
ylidene-tetrazol-5yl-acetylhydrazones  (84-86). 
 
3β-Acetoxy-5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (84): 
Yield (80 %); solid m.p. 162-164 οC; IR (KBr, νmax cm-1): 3325 (NH), 1735 
(OCOCH3), 1669 (C=O), 1625 (C=N), 1325 (CN); 
1H NMR (400 MHz, CDCl3): δ 8.6 
(brs, 2H, NH, exchangeable with D2O), 4.7 (m, 1H, C3α-H, W½=15 Hz), 2.7 (dd, 
1H, C5α-H, J =12 Hz, 4 Hz), 2.03 (s, 3H, OCOCH3), 1.18 (s,3H, C10-CH3), 0.70 (s, 
3H, C13-CH3), 0.97 & 0.83 (other methyl protons); 13C NMR (100 MHz, CDCl3): δ 
172.3, 171.3, 160.3, 158.1, 71.5, 58.9, 55.7, 54.0, 46.0, 44.0, 40.0, 39.0, 38.7, 38.1, 
37.5, 36.7, 35.9, 35.0, 29.3, 28.2, 27.3, 26.4, 25.8, 25.0, 24.0, 23.2, 22.0, 20.0, 21.0, 
17.0, 16.5,11.3; Anal. Calc. for C32H52N6O3: C, 67.60, H, 9.21, N, 14.78 % found: C, 
67.64, H, 9.17, N, 14.74 %. MS (ESI): m/z 568 [M+.]. 
 
3β-Chloro-5α-cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (85): 
Yield (73 %); solid m.p. 172-174 οC; IR (KBr, νmax cm-1): 3328 (NH), 1670 (C=O), 
1627 (C=N), 1328 (C-N), 741(C-Cl); 1H NMR (400 MHz, CDCl3): δ 8.4 (brs, 2H, 
NH, exchangeable with D2O), 3.8 (m, 1H, C3α-H, W½ = 17 Hz), 2.6 (dd, 1H, C5α-H, 
J =12.05 Hz, 4.1 Hz), 1.18 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-CH3), 0.97 & 0.83 
(other methyl protons); 13C NMR (100 MHz, CDCl3): δ 171.2 ,161.8, 157.8 ,57.7, 
56.2, 55.6, 45.3, 43.3, 42.6, 39.0, 38.5, 38.3,36.8, 36.2, 35.9, 35.6, 35.0, 29.8, 28.7, 
27.5, 26.7, 26.0, 25.32, 25, 24.2, 23.8, 22.1, 20, 17, 12.1; Anal. Calc. for 
C30H49N6ClO: C, 66.09; H, 9.06; N, 15.41 % found C, 66.05, H, 9.10, N, 15.45 %. 
MS (ESI): m/z 544/546 [M+.]. 
 
5α-Cholestan-6-ylidene-tetrazol-5yl-acetylhydrazone (86): 
Yield (70 %); solid m.p. 141-142 οC; IR (KBr, νmax cm-1): 3337 (NH), 1673 (C=O), 
1635 (C=N), 1330 (C-N); 1H NMR (400 MHz, CDCl3): δ 8.4 (brs, 2H, NH, 
exchangeable with D2O), 1.18 (s, 3H, C10- CH3), 0.70 (s, 3H, C13-CH3), 0.97 & 
0.83 (other methyl protons); 13C NMR (100 MHz, CDCl3): δ 171.8, 161.5, 157.8, 
57.3, 56.1, 45.7, 43.5, 42.2, 39.0, 38.7, 38.1, 37.8, 36.5, 36.1, 35.7, 35.2, 35.0, 29.7, 
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28.3, 27.6, 26.6, 26.0, 25.4, 25.0, 24.0, 22.0, 21.0, 17.0, 16.5, 12; Anal. Calc. for 
C30H50N6O: C, 70.55; H, 9.87; N, 16.45 % found: C, 70.51, H, 9.83, N, 16.49 %. ESI 
MS (ESI): m/z 510 [M+.]. 
 
General procedure for the synthesis of steroidal iminophenyls (89, 90): 
Steroidal ketones (87, 88) (1.0 mmol) was fused with aniline (1.0 mmol) for 30 min, 
then  absolute ethanol (25 mL) was added to reaction mixture. The reaction mixture 
was refluxed for 6-8 h and allowed to cool to room temperature. The separated solid 
was filtered, washed with water and recrystallised from benzene to give steroidal 
iminophenyls (89, 90).53 
 
Representative  procedure for the synthesis of steroidal spiroazetidinone derivatives 
(91, 92). 
To a solution of steroidal iminophenylcholest-5-ene (89, 90) (1.0 mmol) in 
dichloromethane (30 mL), chloroacetyl chloride (2 mL) and few drops of 
triethylamine were added. Then the reaction mixture was refluxed for 3-3.5 h. The 
progress as well as completion of reaction was monitored by TLC. After completion 
of reaction, the solvents were removed under reduced pressure. The crude product 
obtained was purified over silica gel column (petroleum ether-ether; 10:1). 
Recrystallization from methanol furnished   Cholest-5-en-7-spiro-1′-phenyl-3′-chloro-
azetidin-2′-ones (91, 92). 
 
3β-Chlorocholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one (91): 
White powder (76%). m.p: 175-177 °C; IR (KBr, νmax cm-1): 3078, 1583, 1403 (C-H, 
aromatic), 1760 (C=O), 1624 (C=C), 1378 (C-N), 745, 752 (2×C-Cl); 1H NMR (400 
MHz, CDCl3): δ 7.53-7.82 (m, 5H, aromatic), 5.41 (s, 1H, C6-H), 4.64 (s, 1H, C′3-H, 
azetidinone ring proton), 3.91 (m, 1H, C3α-H, W1/2=14 Hz, axial), 1.10 (C10-CH3), 
0.71 (C13-CH3), 0.93 and 0.81 (other methyl protons); 
13C NMR (100 MHz, CDCl3): 
δ 165.2, 141.3, 138.4, 129.2, 128.3, 127.2, 126.4, 121.1, 119.2, 74.3, 62.3, 54.2, 50.2, 
46.3, 42.2, 39.2, 38.4, 37.2, 36.6, 35.2, 33.2, 32.4, 31.1, 28.1, 27.2, 26.4, 24.1, 23.2, 
22.6, 21.1, 20.2, 19.3, 18.5, 16.4, 11.3; Anal. Calc. for C35H49Cl2NO; C, 73.66; H, 
8.65; N, 2.45 found; C, 73.67; H, 8.67; N, 2.46; MS (ESI): m/z 569/571 [M+.]. 
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Cholest-5-en-7-spiro-1′-phenyl-3′-chloro-azetidin-2′-one (92): 
Yellow powder (74%). m.p: 169-170 °C; IR (KBr, νmax cm-1): 3074, 1587, 1401 (C-H 
aromatic), 1761 (C=O), 1625 (C=C), 1377 (C-N), 748 (C-Cl); 1H NMR (400 MHz, 
CDCl3): δ 7.52-7.82 (m, 5H, aromatic), 5.30 (s, 1H, C6-H), 4.65(s, 1H, C′3-H, 
azetidinone ring proton), 1.10 (C10-CH3), 0.71 (C13-CH3), 0.93 and 0.81 (other 
methyl protons); 13C NMR (100 MHz, CDCl3): δ 160.3, 141.2, 138.5, 129.3, 128.4, 
127.2, 126.4, 121.2, 119.1, 72.2, 56.5, 54.3, 50.2, 46.1, 42.3, 39.4, 38.1, 37.2, 36.1, 
35.3, 33.5, 32.1, 31.2, 28.4, 27.4, 26.5, 24.6, 23.5, 22.6, 21.2, 20.1, 19.2, 18.3, 16.4, 
11.2; Anal. Calc. for C35H50ClNO; C, 78.39; H, 9.40; N, 2.61 found: C, 78.40; H, 
9.43; N, 2.62; MS (ESI): m/z 535/537 [M+.]. 
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Chapter 2 
Steroidal thiazoles 
Theoretical
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Thiazole (1) is an important heterocyclic compound consist of five membered ring 
containing one nitrogen, one sulfur and three carbon atoms with two double bonds.  
 
                                                  
Thiazoles represent one of the most significant class of biologically and 
pharmaceutically active compounds, and have been playing a pivotal role in modern 
medicinal chemistry. They exist in numerous natural products and organic dyes.1 
Compounds containing this moiety gained tremendous importance for their medicinal 
applications such as, antifungal2, antimicrobial3, anti-inflammatory4, antitumor5, 
anticonvulsant6, and antitubercular activities.7 As an attractive target, the thiazole 
scaffold has been developed as the core heterocycle of drug-like chemical libraries in 
combinatorial chemistry. 
 
     Sen et al.8 synthesized single compound 4-(3-methyl-3-phenylcyclobutyl)-2-(2-
propylidenehydrazinyl) thiazole (5) from the reaction of propionaldehyde (2), 
thiosemicarbazide (3) and 2-chloro-1-(3-methyl-3-phenylcyclobutyl)ethanone (4) in 
absolute ethanol. Single crystal and DFT studies were also carried out. 
 
                 
 
     Beedkar et al.9 reported the synthesis of substituted 4-(4-chlorophenyl)-2-(4-
methyl-3, 6-diphenylpyrazolo[3,4-c]pyrazol-2(6H)-yl)thiazole (9a-e) from the 
substituted 4-benzylidine-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (6) and 
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thiosemicarbazide (7). The intermediate 8 thus obtained reacted with 2-bromo-1-(4-
chlorophenyl)ethanone under stirring in polyethylene glycol (PEG-400) at 60 ᴼC for 
3-4 h to afford the desired product (9 a-e). 
 
   
 
           
                       
 
     Wrona et al.10 reported the synthesis of 2-ferrocenyl-4-acetoxythiazole derivatives 
(13) with electron-withdrawing substituent at C-5 from the N-(ethoxycarbonyl) 
ferrocenecarbothioamide (10). Crystal structure determination and NLO studies were 
also carried out. 
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    Majumdar and Ghosh11 prepared the coumarin and quinolone annulated thiazole 
derivatives (15) in one pot manner using sodium sulfide as a sulfur source and ligand-
free iron (III)-catalyzed coupling followed by acid-promoted condensation. 
 
                   
             X= O, NMe, NEt 
             R = C6H5, CH3, 4-MeC6H4, 2-MeC6H4, 4-OMeC6H4, 4-ClC6H4, 4-NO2C6H4 
    
      
     Heravi et al.12 synthesized  2,4-disubstituted thiazole derivatives (18 a-f) via a 
condensation reaction of α-halo carbonyl compounds (16) with thiourea or 
thioacetamide (17) at room temperature by grinding. 
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     Kalluraya and Rai13 reported the synthesis of sydnone substituted thiazole 
derivatives (21 a-f). 3-Aryl-4-formylsydnone (19) on reaction with thiosemicarbazide 
gave intermediate sydnone thiosemicarbazones (20) which further on reaction with 
halogenated carbonyl compounds yielded sydnone substituted thiazole derivatives (21 
a-f). 
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     Wagle et al.14 synthesized a series of 4-aryl-2-(3-methyl-7-substituted quinoxaline-
2-one-1-yl)-1, 3-thiazoles (27) through   multistep reaction on substituted xylene (22). 
 
     
 
                                       R = CH3, H, Cl 
                                      Ar = 4-Cl-C6H4, 4-CH3-C6H4, 3-NH2-C6H4 
 
     Aly et al.15 synthesized novel furo[3,4-d]-1,3 thiazoles (30) by the reaction of 
substituted 2-aroyl-hydrazinecarbothioamides (28) with 2 eqv. of 1, 4-diphenyl-but-2-
yne-1,4-dione (29) in the presence of triethyl amine and acetonitrile as solvent.  
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                                Ar = C6H5, 4-OH-C6H4, 4-OMe-C6H4, 4-Cl-C6H4 
 
     Bakherad et al.16 reported  the synthesis of 3-aryl-substituted imidazo [2,1-b] 
thiazoles (36) by the multistep reaction on 4,5-diphenyl-2-
propargylmercaptoimidazole (31) catalyzed by Pd-Cu through Sonogashira coupling 
in the presence of triethylamine as base and DMF as solvent. 
     
     
 
           Ar =  
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      Bekker et al.17 synthesized thiazole derivatives of usnic acid (39)  starting from by 
the reaction of usnic acid (37). Intermediate 38 obtained on the bromination of the 
usnic acid (37) thus allowed to react with the thiourea, substituted thiourea and 
thioamide which afford the desired compound 39.  
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                   
Discussion
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Thiazoles are one of the most important heterocycles found in the bioactive natural 
product of microbial and marine origin where they exhibit important pharmacological 
activities such as antitumor, antifungal, antibiotic, antiviral as well as acting as 
peptide mimetics.18 Thiazoles occupy a prominent position in the drug discovery 
process and found in the  several marketed drugs.19 These compounds have broad  
applications, including functional materials20 and liquid crystals for ferroelectric 
display.21 Therefore, preparation of thiazoles have gained considerable interest of 
chemists in recent years. In view of the aforementioned facts, we herein report a 
prompt and facile strategy for the synthesis of steroidal thiazole derivatives (43-45, 
47). Elucidation of proposed structures (43-45, 47), was based on their spectral (IR, 
1H NMR, 13C NMR, MS) and analytical studies. The substrates selected for initial 
studies include 3β-acetoxy-5α-cholestan-6-one (40), 3β-chloro-5α-cholestan-6-one 
(41), 5α-cholestan-6-one (42) and 3β-acetoxy pregnenolone (46). 
 
 
    (40-42)                                                                                                   (43-45) 
       X                                                                                                             X 
   OAc (40)                                                                                               OAc (43) 
     Cl   (41)                                                                                                Cl    (44) 
     H    (42)                                                                                                  H   (45) 
 
           (46)                                                                                                    (47) 
 
Microwave-assisted one pot synthesis, characterization, biological evaluation and 
molecular docking studies of steroidal thiazoles. Mohd Asif, Abad Ali, Atif Zafar, 
Mohd Farhan, Hena Khanam, S.M.Hadi, Shamsuzzaman  J. Photochem. Photobiol.B 
doi:10.1016/j.jphotobiol.2016.11.010 
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Reaction of 3β-acetoxy-5α-cholestan-6-one (40) with thiosemicarbazide and 
phenacyl bromide: 3β-Acetoxy-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2’-yl-
hydrazone (43): 
A solution of 3β-acetoxy-5α-cholestan-6-one (1.0 mmol) (40), thiosemicarbazide (1.0 
mmol) and phenacyl bromide (1.0 mmol) in ethanol (15 mL) was allowed to react 
under the microwave heating for 35 minutes at 60 ºC. On completion of reaction, 
precipitate thus formed was filtered, washed and dried over anhydrous sodium sulfate 
and recrystallized from methanol to afford single product 43, m.p. 166-168 °C. 
 
     
 
Characterization of compound 43 as 3β-acetoxy-5α-cholestan-6-ylidine-(4′-phenyl)-
thiazole-2′-yl-hydrazone. 
The elemental analysis of the compound 43 corresponded to the molecular formula 
C38H55N3O2S. The IR spectrum provided evidence for the formation of the expected 
product. The diagnostic signals in IR spectrum at 3135, 1560 and 1385 cm-1 were due 
to stretching vibrations of aromatic C-H bonds. Other important absorption bands at 
3280, 1730, 1650, 1622 and 673 cm-1 were ascribed to NH, C=O (acetoxy), C=N, 
C=C and C-S groups, respectively. The structure of the compound 43 was well 
supported by its 1H NMR and 13C NMR spectra. In its 1H NMR spectrum besides the 
expected signals for cholestane moiety, exhibited a multiplet at δ 7.7-7.82 for five 
aromatic protons and a singlet for one proton of thiazole ring at δ 7.01. One singlet at 
δ 6.7 (exchangeable with D2O) indicated the presence of NH group. A broad multiplet 
centered at δ 4.7 for one proton was assigned to C3-αH. A sharp singlet for three 
protons of acetoxy group appeared at δ 2.03. Angular and side-chain methyl protons 
were observed at δ 1.18 (C10-CH3), 0.70(C13-CH3), 0.97 and 0.83 for other methyl 
protons. 13C NMR spectrum of compound also supported the proposed structure and 
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showed signals at δ 171.2 (C=O, acetoxy group), 166.5 (N=C-S), 154.1(C=N) and 
133.47-126.45 (aromatic ring). Remaining carbon atoms were seen in accordance to 
the cholestane series. The mass spectrum was also in good agreement with its 
molecular formula which exhibited a strong molecular ion peak at m/z 617 [M+.]. 
     In the light of above discussion the structure of compound 43 can be suitably 
characterized as 3β-acetoxy-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-
hydrazone. 
 
Reaction of 3β-chloro-5α-cholestan-6-one (41) with thiosemicarbazide and 
phenacyl bromide: 3β-Chloro-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-
hydrazone (44): 
A solution of 3β-chloro-5α-cholestan-6-one (1.0 mmol) (41), thiosemicarbazide (1.0 
mmol) and phenacyl bromide (1.0 mmol) in ethanol (15 mL) was allowed to react 
under the microwave heating for 37 minutes at 60 ºC. On completion of the reaction, 
precipitate thus obtained was filtered, washed and dried over anhydrous sodium 
sulfate and recrystallized from methanol to afford single product  44,  m.p. 180-182 
°C. 
 
 
Characterization of compound 44 as 3β-chloro-5α-cholestan-6-ylidine-(4′-phenyl)-
thiazole-2′-yl-hydrazone. 
The elemental analysis of the compound 44 corresponded to the molecular formula 
C36H52ClN3S. The IR data suggested evidence for the formation of the expected 
product. The characteristic absorption bands at 3122, 1562 and 1387 cm-1 due to 
stretching vibrations of aromatic  C-H bonds. In addition, other important absorption 
bands at 3287, 1655, 1618, 740 and 667 cm-1 were ascribed to NH, C=N, C=C, C-Cl 
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and C-S groups, respectively. Further the evidence for its formation was well 
supported by 1H NMR and 13C NMR spectra. In its 1H NMR spectrum, exhibited a 
multiplet at δ 7.7-7.8 for five aromatic protons and a singlet for one proton of thiazole 
ring was seen at δ 6.98. One singlet for one proton at δ 6.8 (exchangeable with D2O) 
suggested the presence of NH moiety and a broad multiplet centered at δ 4.6 for one 
proton was assigned to C3-αH. Angular and side-chain methyl protons were observed 
at δ 1.20 (C10-CH3), 0.70(C13-CH3), 0.97 and 0.85 for other methyl protons. 13C 
NMR spectrum of the compound also supported the proposed structure and displayed 
characteristic signals at δ 167.3 for (N=C-S), 155.5 for (C=N) and 133.5-126.5 for 
(aromatic ring), in addition to signals of cholestane series. The mass spectrum also 
confirmed the proposed structure of compound 44  which exhibited a prominent 
molecular ion at m/z 593/595 [M+.]. 
     In the basis of above evidences the structure of compound 44 can be characterized 
as 3β-chloro-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone. 
 
Reaction of 5α-cholestan-6-one (42) with thiosemicarbazide and phenacyl bromide: 
5α-Cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone (45): 
A solution of 5α-cholestan-6-one (1.0 mmol) (42), thiosemicarbazide (1.0 mmol) and 
phenacyl bromide (1.0 mmol) in ethanol (15 mL) was allowed to react under the 
microwave heating for 40 minutes at 60 ºC. On completion of the reaction, precipitate 
thus formed was filtered, washed, dried over anhydrous sodium sulfate and 
recrystallized from methanol to afford single product 45, m.p. 153-155 °C. 
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Characterization  of compound 45 as 5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-
2′-yl-hydrazone. 
The elemental analysis of compound 45 corresponded to the molecular formula 
C36H53N3S. The examination of IR spectrum provided evidence for the formation of 
the expected product. The IR showed the   characteristic   absorption bands at 3129, 
1565 and 1403 cm-1 for the stretching vibrations of aromatic C-H bonds. Other 
important absorption bands at 3290, 1657, 1620 and 681 cm-1 were ascribed to NH, 
C=N, C=C and C-S groups, respectively. Further the evidence for the formation of  
compound  45 was well supported by its 1H NMR and 13C NMR spectra. Its 1H NMR 
spectrum featured a multiplet at δ 7.7-7.82 for five aromatic protons and one singlet 
for one proton of thiazole ring appeared at δ 6.92. One singlet for one proton at δ 6.8 
(exchangeable with D2O) indicating the presence of NH group. Angular and side-
chain methyl protons were observed at δ 1.18 (C10-CH3), 0.70 (C13-CH3), 0.97 and 
0.83 for other methyl protons. 13C NMR spectrum of the compound also supported the 
proposed structure and showed signals at δ 166.3 (N=C-S), 155.8 (C=N) and   133.1-
125 (aromatic ring). Remaining carbon atoms were seen in accordance to the 
cholestane series. The mass spectrum was also in good agreement with its molecular 
formula which exhibited a strong molecular ion peak at m/z 559 [M+.]. 
     In  view of above conclusion the structure of compound 45 can be characterized as 
5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone. 
 
Reaction of 3β-acetoxy-pregnenolone (46) with thiosemicarbazide and phenacyl 
bromide:3β-Acetoxy-pregn-5-ene-20-ylidiene-(4′-phenyl)-thiazole-2′-yl-hydrazone 
(47): 
A solution of 3β-acetoxy-pregnenolone (1.0 mmol) (46), thiosemicarbazide (1.0 
mmol) and phenacyl bromide (1.0 mmol) in ethanol (15 mL) was allowed to react 
under the microwave heating for 45 minutes at 60 ºC. On completion of the reaction, 
precipitate thus formed was washed, and dried over anhydrous sodium sulfate and 
recrystallized from methanol to afford single product 47, m.p. 146-148 °C. 
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Characterization of compound 47 as 3β-acetoxy-pregn-5-ene-20-ylidiene-(4′-
phenyl)-thiazole-2′-yl-hydrazone:  
The elemental analysis of compound 47 corresponded to the molecular formula 
C32H41N3O2S. The IR spectrum provided evidence for the formation of the expected 
product. The compound showed characteristic absorption bands at 3138, 1567 and 
1409 cm-1 due to stretching of aromatic C-H bonds. The bands at 3309, 1728, 1661, 
1615 and 673 cm-1 were ascribed to NH, C=O (acetoxy), C=N, C=C and C-S groups 
respectively. Further the evidence for the formation of compound 47 was well 
supported by 1H NMR and 13C NMR spectra. In its 1H NMR spectrum, exhibited a 
multiplet at δ 7.75-7.85 for five aromatic protons and a singlet for one proton of 
thiazole ring at δ 6.95. One singlet for one proton at δ 6.75 (exchangeable with D2O) 
suggested the presence of  NH group and a singlet for three protons of acetoxy group 
was at δ 2.07. 13C NMR spectrum of the compound also supported the proposed 
structure and showed signals at δ 171.1 (C=O, acetoxy group), 168.8 (N=C-S), 
156.7(C=N) and 133.5-126.5(aromatic ring). The remaining carbon atoms were seen 
in accordance to pregnane series .The mass spectrum was also found in good 
agreement with its molecular formula which exhibited a strong molecular ion peak at 
m/z 531 [M+.]. 
           On the view of above concluded discussion the structure of compound 47 can 
be characterized as 3β-Acetoxy-pregn-5-ene-20-ylidiene-(4′-phenyl)-thiazole-2′-yl-
hydrazone:  
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Mechanism of the reaction 
The proposed mechanism of this conversion is shown in scheme 1. The conversion 
involves the reaction of thiosemicarbazide with steroidal ketones and phenacyl 
bromide in one pot manner which results in the synthesis of corresponding steroidal 
thiazole derivatives (43-45, 47). 
 
           
        
   Scheme 1. Plausible reaction mechanism for the synthesis of steroidal thiazoles 
 
Experimental
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General Remark   
 All chemicals and solvents used in this study were of ACS grade and used directly 
without additional steps of purification. Melting points were determined on a Biogen 
digital auto melting point apparatus. Microwave assisted reaction was performed on 
Anton paar monowave 300 scientific microwave oven. The IR spectra were recorded 
on KBr pellets with Perkin Elmer FT-IR Spectrometer spectrum Two and values were 
given in cm-1. 1H and 13C NMR spectra were run on a Bruker Avance II 400 NMR 
Spectrometer (operating at 400 MHz for 1H and at 100 MHz for 13C NMR) with 
tetramethylsilane (TMS) as internal standard and values are given in parts per million 
(ppm) (δ). Mass spectra were recorded on a JEOL D-300 mass spectrometer. 
Elemental analyses were recorded on Perkin Elmer 2400 CHN. Thin layer 
chromatography (TLC) plates were used to check the homogeneity as well as the 
progress of reaction. Sodium sulfate (anhydrous) was used as a drying agent. 
 
3β-Acetoxycholest-5-ene: 
A mixture of cholesterol (100 g), pyridine (150 mL, freshly distilled over KOH) and 
freshly distilled acetic anhydride (100 mL) was heated on water bath for 2 h. The 
reaction mixture was poured into ice cold water and solid mass thus obtained was 
filtered under suction, washed thoroughly with water until free from pyridine and then 
air dried. Recrystallization of the product from acetone gave 3β-acetoxycholest-5-ene 
(93 g), m.p. 113 -114 ᴼC (reported, m.p. 115-116 ᴼC).22 
 
3β-Acetoxy-6-nitrocholest-5-ene: 
To a cooled mixture of 3β-acetoxy-cholest-5-ene (10 g) and conc. HNO3 acid (250 
mL), sodium nitrite (10 g) was gradually added with constant stirring over a period of 
about 45 minutes. After complete addition of sodium nitrite the stirring was continued 
for additional 2 h. Cold water (300 mL) was added to reaction mixture, yellow solid 
material separated out. The whole mass was extracted with diethyl ether. The ethereal 
layer was washed with water, NaHCO3 solution (5%) (until washings became pink), 
again with water and dried over anhydrous sodium sulfate. Removal of solvent 
provided the nitro compound as an oil which was crystallized from methanol (6.7 g), 
m.p. 104ᴼC (reported m.p. 102-104 ᴼC).23 
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3β -Acetoxy-5α-cholestan-6-one (40): 
3β-Acetoxy-6-nitrocholest-5-ene (6 g) was dissolved in glacial acetic acid (120 mL) 
by warming the mixture and zinc dust (12 g) was added in small portions with 
shaking. The suspension was heated under reflux for 4 h and water (12 mL) was 
added at regular intervals during the course of heating. The hot solution was filtered, 
cooled to room temperature and diluted with large excess of ice-cold water and 
extracted with diethyl ether. The ethereal solution was washed with water, NaHCO3 
solution (5%), again with water and dried over anhydrous sodium sulfate. Evaporation 
of solvent provided the acetoxy ketone as an oil which was crystallized from 
methanol (4.2 g), m.p.128 ᴼC (reported m.p.127-128 ᴼC).24 
 
3β-Chlorocholest-5-ene: 
Freshly purified SOCl2 (20 mL) was added gradually to cholesterol (25 g) at room 
temperature. A vigorous reaction ensured with evolution of gaseous products. When 
the reaction slackened, the mixture was gently heated at temperature (50-60 ᴼC) on 
water bath for 1 hour and then poured into water with stirring. The yellow solid thus 
obtained was filtered under suction, washed several times with ice-cold water and air 
dried. Recrystallization from acetone gave 3β-chlorocholest-5-ene (20 g), m.p. 95-
96ᴼC (reported, m.p. 96-97 ᴼC).25 
 
3β-Chloro-6-nitro-cholest-5-ene: 
A mixture of 3β-chlorocholest-5-ene (14 g), glacial acetic acid (100 mL) and fuming 
nitric acid (28 mL) was stirred at temperature below 20 ᴼC and sodium nitrite (3 g) 
was gradually added over a period of 1 h. After complete addition of sodium nitrite, 
the mixture was further stirred for an additional period of 2 h. Ice cold water (200 
mL) was added to it and the yellowish solid thus obtained was filtered, washed with 
water and air dried. The desired product was recrystallized from methanol as needles 
(8.6 g), m.p. 151-152 ᴼC (reported m.p. 153 ᴼC).26 
 
  3β-Chloro-5α-cholestan-6-one (41):  
To a solution of 3β-chloro-6-nitro-cholest-5-ene (8 g) in hot glacial acetic acid (160 
mL), zinc dust (16 g) was added gradually in a small  portions with constant shaking. 
The suspension was heated under reflux for 4 h and water (16 mL) was added at 
regular interval during the course of heating. The hot solution was filtered and the 
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filtrate was diluted with large excess of ice cold water. The organic matter was 
extracted with diethyl ether and the ethereal layer was washed with water, then 
washed with NaHCO3 solution (5%), again with water and then dried over anhydrous 
sodium sulfate. Removal of the solvents furnished the ketone as oil which was 
crystallized from methanol (5.5 g), m.p 128-129 ᴼC (reported m.p.129 ᴼC).27 
 
Cholest-5-ene: 
3β-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20 g) was added to the solution with continuous stirring over the period 
of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, methanol (few mL) was added and the reaction mixture was poured 
into water, acidified with HCl and then allowed to stand overnight. A white solid thus 
obtained was filtered under suction, washed thoroughly with water and air dried. The 
crude material was recrystallized from acetone to provide cholest-5-ene as cubes (8.2 
g), m.p. 93 ᴼC (reported m.p. 89-91 ᴼC).28 
 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6 g) in glacial acetic acid (50 mL) 
was vigorously stirred at room temperature for 5 minutes and treated with fuming 
HNO3 (15 mL) followed by the addition of sodium nitrite (3 g)  in small portions over 
a period of  1 h and stirring was continued for further 2 h. The temperature of reaction 
mixture was maintained below 20 ᴼC by external cooling. The reaction mixture was 
poured into cold water and the yellow product thus obtained was extracted with 
diethyl ether. The ethereal layer was washed successively with water, NaHCO3 
solution (5%)  (until the washings became  pink) and again with water and dried over 
anhydrous sodium sulfate. Removal of solvent provided an oil, which was crystallized 
from methanol as leaflets (4.4 g), m.p. 119-120 ᴼC (reported m.p.120-121 ᴼC).29 
 
5α-Cholestan-6-one (42): 
6-Nitro-cholest-5-ene (4 g) was dissolved in warm glacial acetic acid (80 mL) and 
zinc dust (8 g) was gradually added with shaking. The mixture was heated under 
reflux for 4 h and water (8 mL) was added during the course of heating. Zinc dust 
(unreacted) was removed by filtration. To the filtrate, water was added till turbidity 
developed and it was allowed to stand overnight at room temperature. The solid 
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material thus separated was filtered under suction and washed thoroughly with water 
in order to remove zinc acetate. 5α-cholestan-6-one (crystallized out as thin plates) 
was recrystallized from methanol (2.4 g), m.p 97-98 ᴼC (reported m.p. 98-100 ᴼC).30 
 
Representative procedure for the synthesis of steroidal thiazole derivatives (43-45, 
47): 
In a sealed vial, a solution of steroidal ketones (40-42, 46) (1.0 mmol),  
thiosemicarbazide (1.0 mmol) and phenacyl bromide (1.0 mmol) in ethanol (15 mL) 
were mixed and subjected to microwave heating for 35-45 minutes in microwave 
oven at 60 ºC.  The progress of  the reaction was monitored by TLC. After 
completion, reaction mixture was cooled to room temperature,  precipitate thus 
formed was filtered, washed with water and taken into diethyl ether. The ethereal 
layer was further washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford corresponding steroidal thiazole derivatives (43-45, 47). 
 
3β-Acetoxy-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone (43): 
Yield (80%), m.p. 166-168 οC; IR (KBr, νmax cm-1): 3280 (NH), 1730 
(OCOCH3),1650 (C=N),1622 (C=C), 673 (C-S), 3135, 1560, 1385 (aromatic ring). 
1H 
NMR (400 MHz, CDCl3): 7.7-7.82(m, 5H, aromatic), 7.01 (s, 1H, Hthiazole), δ 6.7 ( s, 
1H, NH, exchangeable with D2O), 4.7 (m, 1H, C3α-H, W½=15 Hz), 2.7 (dd, 1H, 
C5α-H, J =12 Hz, 4 Hz), 2.03 (s, 3H,OCOCH3), 1.18 (s,3H, C10-CH3), 0.70 (s, 3H, 
C13-CH3), 0.97 and 0.83 (othermethylprotons);
13 CNMR(CDCl3, 100MHz): δ171.2, 
166.5,154.1,152.9,133.47,130.05,129.75, 128.83, 128.32, 126.45,102.9, 74, 60, 58, 
57, 45, 43.5, 42.5, 40.2, 39.3, 38.2, 37.8,36.1, 35.0, 32.3, 30.1, 29.4, 28.9 , 27.5, 25.7, 
24.6, 23.9, 22.7, 21.2, 20.3,19.4, 16.0, 14.7.Anal. Calc. for C38H55N3O2S; C, 73.86, H, 
8.97, N, 6.80; found; C, 73.83, H, 8.95, N, 6.77; MS (ESI): m/z 617 [M+.]. 
 
3β-Chloro-5α-cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone (44): 
Yield (85%), m.p. 180-182 οC; IR (KBr, νmax cm-1): 3287 (NH), 1655 (C=N),1618 
(C=C), 740 (C-Cl), 667(C-S), 3122, 1562, 1387(aromatic ring). 1H NMR (CDCl3, 400 
MHz,): 7.7-7.8 (m, 5H, aromatic), 6.92 (s, 1H, Hthiazole), δ 6.8 ( s, 1H, NH, 
exchangeable with D2O), 4.6 (m, 1H, C3α-H, W½=15 Hz), 2.5 (dd, 1H, C5α-H, J =12 
Hz, 4 Hz), 1.20(s, 3H, C10-CH3), 0.70(s, 3H,C13-CH3), 0.97 and 0.85(other methyl 
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protons). 13 C NMR (CDCl3, 100 MHz): δ167.3, 155.5, 152.3, 133.5, 130.1, 129.75, 
129.9, 128.35,126.5, 102.3, 63, 62, 61.5, 59, 46.5, 44.5, 42.7, 41.3, 40.5, 39.7, 38.7, 
37.2, 36.8, 34.1, 31.9, 30.3, 29.1, 28.3, 26.5, 25.1, 24.4, 22.5, 21, 20, 16 ,14.3. Anal. 
Calc. for. C36H52ClN3S: C, 72.75, H, 8.82. N, 7.07: found: C, 72.73, H, 8.85, N, 7.05. 
MS (ESI): m/z 593/595 [M+.]. 
 
5α-Cholestan-6-ylidine-(4′-phenyl)-thiazole-2′-yl-hydrazone (45): 
Yield (83%), m.p. 153-155 ᴼC; IR (KBr, νmax cm-1): 3290 (NH), 1657 (C=N),1620 
(C=C), 681 (C-S), 3129 , 1565, 1403(aromatic ring). 1H NMR (400 MHz, CDCl3):  
7.7-7.82 (m, 5H, aromatic), 6.98 (s, 1H, Hthiazole), δ 6.8 (s, 1H, NH, exchangeable with 
D2O), 2.4 (dd, 1H, C5α-H, J =11 Hz, 4 Hz), 1.18 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-
CH3), 0.97 and 0.83 (other methyl protons).
 13C NMR ( CDCl3, 100 MHz); δ 
166.3,155.8,152, 133.1, 130.5, 129.6, 128.5, 128.3., 125,102, 62.3, 61.1, 60, 47.5, 
44.6, 43.1, 41.1, 40.7, 39.4, 38.8 ,38.1 37.7, 35.1, 33, 32.1, 30.5, 29.5, 28.7, 27.5, 
26.1, 25.5, 23.1, 21.5,19, 16, 15.1. Anal. Calc.  for. C36H53N3S; C, 77.23, H, 9.54, N, 
7.51; found; C, 77.26, H, 9.52, N, 7.53; MS (ESI): m/z 559 [M+.]. 
 
3β- Acetoxy-pregn-5-ene-20-ylidiene-(4′-phenyl)-thiazole-2′-yl-hydrazone (47): 
Yield (80%), m.p. 146-148 ᴼC; IR (KBr, νmax cm-1): 3309 (NH), 1728 (OCOCH3), 
1661 (C=N), 1615(C=C), 673 (C-S), 3138, 1567, 1409 (aromatic ring). 1H NMR (400 
MHz, CDCl3): 7.75-7.85 (m, 5H,aromatic), 6.95 (s,1H, Hthiazole), δ 6.75 (s,1H, NH, 
exchangeablewithD2O),2.07(s,3H,OCOCH3).
13CNMR(CDCl3,100MHz);δ171.1,168.8
,156.7,151.9,138.8, 134.2, 133.5,130.1, 129.6, 128.4, 126.5, 120.8, 102.4,76.1, 55.1, 
48.5, 44.7,42.5, 41.2, 40.2, 39.5, 38.5, 36.7, 34.3, 33.1, 30.3, 29.2, 24.1, 23.0, 22.4, 
21.5, 16.3 Anal. Calc.  for. C32H41N3O2S; C, 72.28, H, 7.77, N, 7.90; found; C, 72.30, 
H, 7.80, N, 7.87. MS (ESI): m/z 531 [M+.]. 
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Chapter 3 
Steroidal 
spirooxadiazolines 
Theoretical
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Oxadiazoline moiety consist of five membered ring having one oxygen, two nitrogen 
and two carbon atoms with one  nitrogen-carbon double bond.  
 
                                                      
                                                           (1) 
Oxadiazolines are the reduced form of oxadiazoles and  important from  both 
chemical and biological point  of  view. Oxadiazolines played a crucial role in the 
development of theory in heterocyclic chemistry and  extensively used as synthon in 
organic synthesis. These compounds are associated with diverse biological activities 
such as anti-inflammatory, antibacterial, antifungal, anticonvulsant, analgesic, 
anticancer, anti-tubercular  and  hypolipidemic activities1.  
 
     Shyma et al.2 synthesized a new series of 3-acetyl-2-aryl-2-methyl-5-[3-(6 
methylpyridinyl)]-2,3-dihydro-[1,3,4]-oxadiazole derivatives (6) from 6-methyl 
nicotinate (2) through a multistep reaction sequence. 
 
 
 Ar = 6-MeO-napthyl, 4-Biphenyl, 3,4-Dihydroxyphenyl, 2-thiophenyl, 4-
Fluorophenyl, 4-Chlorophenyl, 2,4-Dichlorophenyl, 2-Bromothiophenyl, 3-
Bromophenyl, 4-Biphenyl, 4-Acetylphenyl. 
 
     Chaaban et al.3 prepared a series of new oxadiazoline substituted naphthalenyl 
acetate derivatives (9) from N-substituted benzylidene-1-hydroxy-2-
naphthohydrazides (7). 
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    Wani et al. 4 reported the synthesis of oxadiazoline derivatives of 2-methyl-5-nitro-
1H -imidazole (14) from 2-methyl-5-nitro-1H-imidazole (10) through the sequence of 
reaction.  
 
 
               R = H, 2-Cl, 3-Cl, 4-Cl, 4-Me, 2, 5-di-Me, 4-isopropyl, 4-OMe, 4-OEt. 
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 Ke et al.5 synthesized 3-acetyl-5-aryl-2, 3(2H)-1, 3,4-oxadiazoles (19) from 
substituted aromatic carboxylic acids (15) through  a series of reaction. 
 
    Ar = o-Cl-C6H4, 3,4,5-(MeO)3-C6H2, 3-MeO-C6H4, p-Cl-C6H4, Furan-2-yl, 
Naphthalen-2- yl, p-Et-C6H4 , 3,4-OCH2O-C6H3 
 
     Bacu et al.6 reported the synthesis of 2, 2-disubstituted-5-(2-phenothiazin-10-
ylethyl)-2,3-dihydro-1,3,4-oxadiazoles (22) from phenothiazineacyl hydrazones (20). 
Intermediate (21) was cyclised by refluxing in acid anhydrides or chlorides in 
presence of pyridine to get corresponding products (22).  
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     Shamsuzzaman et al.7 synthesized the steroidal (3R)-spiro-Δ2`, 1`, 3`, 4`-
oxadiazolines (25) from steroidal semicarbazone (24). Cholest-5-ene-3-one (23) used 
as precursor for the synthesis of cholest-5-ene-3-semicarbazone (24). 
 
                               
                                 
     Alhadi et al.8 reported the synthesis of 3-acyl-1, 3, 4-oxadiazoline derivatives (27) 
from one-step reaction through cyclization of various N-benezylidene-2-
hydroxybenzohydrazides (26) .  
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     Ishii et al.9 prepared a series of 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-
oxadiazole derivatives (32) from substituted aromatic carboxylic acid (28) through 
multi step reaction. Synthesized compounds were also screened for their antimicrobial 
and anti-parasitic activities. 
 
           
                                                R = H, Cl, F, I, Br, Me, Et 
                                            
      Wang et al.10 reported the synthesis of R and S isomers of glucose-based 3-acetyl-
5-alkyl-2,3-dihydro-1,3,4-oxadiazoles (36) under microwave irradiation catalyzed by 
sodium acetate from d-glucose (33). 
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                        R = CH3, n-C3H7, n-C5H11, n-C7H15, C6H5, p-Br-C6H4  
    Kovacs et al.11 synthesized 3-acyl-1,3,4-oxadiazoline derivatives of pregnenolone 
(39) from  substituted pregnenolones (37) under microwave heating. In vitro cytotoxic 
activity was carried out for synthesized compounds. 
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          Huang et at.12 reported the synthesis of 2-(4-methylphenyl)-3-(N-acetyl)-5-(2,4 
dichlorophenoxymethyl)-1,3,4-oxadiazoline (42) from 2-(2,4-dichlorophenoxy) 
acetohydrazide (40). Intermediate (41) cyclized in the presence of acetic anhydride to 
yield  the desired product (42). 
 
 
      Toumi et al. 13   describes the synthesis of   aromatic bis 1,2,4 oxadiazolines (45 a-
d) from 1,3 dipolar cycloaddition of  4-chlorobenzohydroximoyl chloride (43) with 
substituted bis-imines (44) in presence of triethyl amine at room temperature 
 
 
                                               
 
     Huang et al.14  reported the synthesis of  1,2,4-oxadiazoline derivatives containing 
2-(1,2,4-triazol-1-yl) quinoline (49a-d) from 2-chloro-3-quinolinecarbaldehyde (46) 
through the series of reactions. 
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      Fie et al.15 prepared a series of novel pyrazolyl-oxadiazoline derivatives bearing 
1,2,4-triazole moiety (53 a-d) from 3-methyl-1-phenyl-5-chloro-4-
pyrazolocarbaldehyde (50) through series of reaction. 
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     Chen et al.16 reported the synthesis of novel 4,5-dihydro-1,2,4-oxadiazoline 
derivatives (56 a-d) from (N,N-bis(4-(4-formoxyl)phenoxy)ethyl)aniline (54). 
Intermediate (55) reacted with various nitrile oxides generated in situ by 
benzohydroximinoyl chlorides in the presence of Et3N stirred in CH2Cl2 through 1,3 
dipolar cycloaddition reaction. 
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         Kaspentakis et al. 17 illustrated the synthesis of chromone 1,3,4-oxadiazolines 
(58 a-f) by the reaction of  3-Formylchromone-N-benzoylhydrazone (57) with various 
Ketenes. 
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Shamsuzzaman et al.18 reported the synthesis of steroidal (6R)-spiro-Δ2`, 1`, 3`, 4`-
oxadiazolines (61) from steroidal semicarbazones (60). Steroidal ketone (59) act as 
precursor for the synthesis of steroidal semicarbazones (60). 
 
                            X = OAc, Cl, H 
 
          
Discussion
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The introduction of heterocyclic moieties in molecules has been proven advantageous 
in drug discovery, for the design of novel bioactive compounds.19 Oxadiazoline is one 
of the most important heterocycle and  known to exhibit a wide array of biological 
activities.20-24 Oxadiazolines also have been reported to act on the cellular microtubule 
cytoskeleton resulting in anticancer activity.25 In view of above reports and as a part 
of our aim to search for biologically active heterocycles of steroids we have 
undertaken the synthesis of some steroidal oxadiazolines (68-70,74-76 and 80-82). 
The structures of newly synthesized compounds has been assigned on the basis of 
elemental analysis and spectral (IR, 1H NMR, 13 C NMR, MS) studies. 
 
 
           
 
 
68 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 
 
Reaction of 3β-acetoxy-5α-cholestan-6-cyanoacetylhydrazone (65) with acetic 
anhydride: 3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (68): 
3β-Acetoxy-5α-cholestan-6-cyanoacetylhydrazone (65) (1.0 mmol) in CHCl3 (20 mL) 
was allowed to react with acetic anhydride (1.5 mL ) in presence of pyridine (0.2 mL) 
for 20 h at 80 ºC. Usual  work up and recrystallization from methanol provided a 
single product 68, m.p. 192-194 °C. 
 
Characterization of compound 68 as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-cyanomethyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of the compound 68 corresponded to the molecular formula 
C34H53N3O4.The IR data provided evidence for the formation of expected product. 
The absorption bands at 2232, 1756, 1738, 1649 and 1257 cm-1 were ascribed to CN, 
COCH3, OCOCH3, C=N and C-O-C groups, respectively. The structure of compound 
68 was well supported by its 1H NMR and 13C NMR spectra. In 1H NMR spectrum of 
the compound 68 a broad multiplet centered at δ 4.5 for one proton was assigned to 
C3-αH  and a singlet at δ 2.26 for two methylene protons adjacent to nitrile group. A 
singlet appeared at δ 2.08 due to three protons of acetyl group and another  singlet at δ 
2.02 due to three protons of acetoxy group. Angular and side-chain methyl protons 
were observed at δ 1.14(C10-CH3), 0.72(C13-CH3), 0.95 and 0.82 for other methyl 
protons. 13C NMR spectrum of the compound also supported the proposed structure 
and showed signals at δ 170.66 (OCOCH3), 165.43(CH3CON), 161.79(C=N) and 
114.25(CN). Remaining carbon atoms were seen in accordance to the cholestane 
series. The mass spectrum was also in good agreement with its molecular formula 
which exhibited a strong molecular ion peak at m/z 567 [M+.]. 
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      In the light of above discussion the structure of compound 68 can be characterized 
as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-oxadiazoline: 
 
Reaction of 3β-chloro-5α-cholestan-6-cyanoacetylhydrazone (66) with acetic 
anhydride: 3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (69): 
3β-Chloro-5α-cholestan-6-cyanoacetylhydrazone (66)  (1.0 mmol) in CHCl3 (20 mL) 
was allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) 
for 18 h at 80 ºC. Usual work up and recrystallization from methanol provided single 
a product  69,  m.p. 198-200 °C. 
 
Characterization of compound 69 as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-cyanomethyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of compound 69 corresponded to the molecular formula 
C32H50ClN3O2. The IR spectrum provided evidence for the formation of expected 
product. The absorption bands at 2237, 1758, 1652, 1254 and 732.8 cm-1 were 
corresponded to CN, COCH3, C=N, C-O-C and C-Cl groups, respectively. The 
structure of compound 69 was well supported by its 1H NMR and 13C NMR spectra. 
In its 1H NMR spectrum besides the expected signals for cholestane moiety, exhibited 
broad multiplet centered at δ 4.6 for one proton was assigned to C3-αH and a singlet 
at δ 2.31 for two methylene  protons adjacent to nitrile group. A singlet featured at δ 
2.1 due to three protons of acetyl group. Angular and side-chain methyl protons were 
observed at δ 1.20(C10-CH3), 0.70(C13-CH3), 0.97 and 0.85 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 166.05 (CH3CON), 162.60 (C=N) and 115.2(CN). 
Remaining carbon atoms were seen in accordance to the cholestane series. The mass 
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spectrum was also in good agreement with its molecular formula which exhibited a 
strong molecular ion peak at m/z 543/545 [M+.]. 
       In the account of above  descriptive discussion the structure of compound 69 can 
be characterized as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-
1ʹ,3ʹ,4ʹ-oxadiazoline. 
 
Reaction of 5α-cholestan-6-cyanoacetylhydrazone (67) with acetic anhydride: 5α-
Cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline (70): 
5α-Cholestan-6-cyanoacetylhydrazone (67) (1.0 mmol) in CHCl3 (20 mL) was 
allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) for 
15 h at 80 º C. After usual work up  and recrystallization from methanol a single 
product 70, m.p. 177-179 °C was obtained. 
 
Characterization of compound 70 as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-
cyanomethyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of compound 70 corresponded to the molecular formula 
C32H51N3O2. The IR spectrum suggested the evidence for the formation of expected 
product. The diagnostic absorption bands at 2230, 1752, 1644 and 1250 cm-1 were 
attributed to CN, COCH3, C=N and C-O-C groups, respectively. The structure of 
compound 70 was well supported by its 1H NMR and 13C NMR spectra. 1H NMR 
spectrum of compound 70 exhibited a singlet at δ 2.28 for two methylene protons 
adjacent to nitrile group and another singlet at δ 2.1 due to three protons of acetyl 
group. Angular and side-chain methyl protons were observed at δ 1.16(C10-CH3), δ 
0.73(C13-CH3), 0.93 and 0.82 for other methyl protons.
 13C NMR spectrum of the 
compound also supported the proposed structure and displayed characteristic signals 
at δ 166.7(CH3CON), 159.4 (C=N) and 117.5(CN) in addition to usual signals of 
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cholestane series. The mass spectrum was also in good agreement with its molecular 
formula which exhibited a strong molecular ion peak at m/z 509 [M+.]. 
      In the light of above evidences the structure of compound 70 can be characterized 
as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-oxadiazoline. 
 
Reaction of 3β-acetoxy-5α-cholestan-6-benzhydrazone (71) with acetic anhydride: 
3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline (74): 
3β-Acetoxy-5α-cholestan-6-benzhydrazone (71) (1.0 mmol) in CHCl3 (20 mL) was 
allowed to react with acetic anhydride (1.5 mL ) in presence of pyridine (0.2 mL) for 
19 h at 80 ºC. Usual  work up and recrystallization from methanol provided a single 
product 74, m.p. 261-263 °C. 
 
Characterization of compound 74 as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline 
The elemental analysis of compound 74 corresponded to the molecular formula 
C38H56N2O4.The IR data provided evidence for the formation of expected product. 
The diagnostic signals in IR spectrum at 3140, 1580 and 1375 cm-1 were due to 
stretching vibrations of aromatic C-H bonds. The absorption bands at 1761, 1728, 
1651 and 1248 cm-1 were ascribed to COCH3, OCOCH3, C=N and C-O-C groups, 
respectively. The structure 74 was well supported by its 1H NMR and 13C NMR 
spectra. Its 1H NMR spectrum exhibited a multiplet  at δ  7.42-7.51 for five aromatic 
protons and a broad multiplet centered at δ 4.7 for one proton which was assigned to 
C3-αH. Two singlets for three protons each appeared at δ 2.07 and  2.01 for NAc and 
OAc groups respectively. Angular and side-chain methyl protons were observed at δ 
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1.14(C10-CH3), 0.72(C13-CH3), 0.95 and 0.82 for other methyl protons.
 13C NMR 
spectrum of the compound also supported the proposed structure and showed signals 
at δ 171 (OCOCH3), 165.2(CH3CON), 162.1(C=N) and 130-124 (aromatic ring). 
Remaining carbon atoms were seen in accordance to the cholestane series. The mass 
spectrum was also in good agreement with its molecular formula which exhibited a 
strong molecular ion peak at m/z 604 [M+.]. 
      In the light of above discussion the structure of compound 74 can be best 
characterized as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-
oxadiazoline: 
 
Reaction of 3β-chloro-5α-cholestan-6-benzhydrazone (72) with acetic anhydride: 
3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline (75) 
3β-Chloro-5α-cholestan-6-benzhydrazone (72) (1.0 mmol) in CHCl3 (20 mL) was 
allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) for 
18 h at 80 ºC. After usual work up and recrystallization from methanol it  provided a 
single product  75,  m.p. 216-218 °C. 
 
Characterization of compound 75 as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-phenyl-1ʹ, 3ʹ,4ʹ-oxadiazoline: 
The elemental analysis of compound 75 corresponded to the molecular formula 
C36H53ClN2O2. The IR spectrum provided evidence for the formation of expected 
product. The absorption bands in the region of 3129, 1562, 1371 cm-1 were attributed 
to stretching vibrations of aromatic C-H bonds. Other important absorption bands   at  
1748, 1645, 1241 and 740 cm-1 were corresponded to COCH3, C=N, C-O-C and C-Cl 
groups, respectively. The structure of compound 75 was well supported by its 1H 
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NMR and 13 C NMR spectra. The 1H NMR spectrum exhibited a multiplet at δ 7.5-
7.67 for five aromatic protons and a broad multiplet centered at δ 4.6 for one proton 
was assigned to C3-αH.  A  sharp singlet appeared   at δ 2.2 for to three protons of 
acetyl group. Angular and side-chain methyl protons were observed at δ 1.20(C10-
CH3), 0.70(C13-CH3), 0.96 and 0.85 for other methyl protons.
 13C NMR spectrum of 
the compound also supported the proposed structure and displayed characteristic 
signals at δ 168.1(CH3CON), 158.1(C=N) and 132.2-125.1(aromatic ring). Remaining 
carbon atoms were seen in accordance to the cholestane series. The mass spectrum 
was also confirmed the proposed structure which is  in good agreement with its 
molecular formula and exhibited a strong molecular ion peak at m/z 580/582 [M+.]. 
       In the account of above   descriptive discussion the structure of compound 75 can 
be characterized as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-
oxadiazoline. 
 
Reaction of 5α-cholestan-6-benzhydrazone (73) with acetic anhydride: 5α-
Cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline (76): 
5α-Cholestan-6-benzhydrazone (73) (1.0 mmol) in CHCl3 (20 mL) was allowed to 
react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) for 17.5 h at 80 
º C. After usual work up  and recrystallization from methanol provided single product 
76, m.p. 210-212 °C  
 
Characterization of compound 76 as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ, 
3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of compound 76 corresponded to the molecular formula 
C36H54N2O2. The IR spectrum data suggested the formation of expected product. The 
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characteristic absorption bands in the region of 3141, 1559, 1382 cm-1 were due to 
stretching vibrations of aromatic C-H bonds. The other important  absorption bands at 
1763, 1640 and 1254 cm-1 were attributed to COCH3, C=N and C-O-C groups, 
respectively. The structure of compound 70 was well supported by its 1H NMR and 
13C NMR spectra. In 1H NMR spectrum of the compound 70, featured a multiplet δ 
7.7-8.1 for five aromatic protons and a singlet appeared at δ 2.1 due to three protons 
of acetyl group. Angular and side-chain methyl protons were observed at δ 1.16(C10-
CH3), δ 0.73(C13-CH3), 0.91 and 0.82 for other methyl protons. 13C NMR spectrum 
of the compound also supported the proposed structure and displayed characteristic 
signals at δ 167.2(CH3CON), 151.2 (C=N) and 134.1-124 (aromatic ring) in addition 
to signals of cholestane series. The mass spectrum was also in good agreement with 
its molecular formula which exhibited a strong molecular ion peak at m/z 546 [M+.]. 
      In the account of above evidences the structure of compound 76 can be 
characterized as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline. 
 
Reaction of 3β-acetoxy-5α-cholestan-6-phenylacetylhydrazone (77) with acetic 
anhydride: 3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (80): 
3β-Acetoxy-5α-cholestan-6-phenylacetylhydrazone (77) (1.0 mmol) in CHCl3 (20 
mL) was allowed to react with acetic anhydride (1.5 mL ) in presence of pyridine (0.2 
mL) for 16 h at 80 ºC. After usual  work up and recrystallization from methanol 
provided a single product 80, m.p. 225-227 °C was obtained. 
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Characterization of compound 80 as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-benzyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of compound 80 corresponded to the molecular formula 
C39H58N2O4.The IR data provided evidence for the formation of expected product. 
The selected diagnostic signals appeared in IR spectrum at 3051, 1597 and 1401 cm-1 
were due to stretching vibrations of aromatic C-H bonds The absorption bands at 
1752, 1727, 1638 and 1231 cm-1 were ascribed to COCH3, OCOCH3, C=N and C-O-C 
groups, respectively. The structure of compound 80 was well supported by its 1H 
NMR and 13C NMR spectra. In 1H NMR spectrum of the compound 80, exhibited a 
multiplet δ 7.57-7.81 for five aromatic protons and  a broad multiplet centered at δ 4.4 
for one proton was assigned to C3-αH. A singlet appeared at δ 2.5 for two protons 
attached adjacent to phenyl ring. A singlet at δ 2.07  due to three protons of acetyl 
group and another  singlet at δ 2.02 due to three protons of acetoxy group. Angular 
and side-chain methyl protons were observed at δ 1.14(C10-CH3), 0.72(C13-CH3), 
0.95 and 0.82 for other methyl protons. 13C NMR spectrum of the compound also 
supported the proposed structure and showed signals at δ 172.1 (OCOCH3), 
169.5(CH3CON), 157.2(C=N) 133.5-126.5 (aromatic ring). Remaining carbon atoms 
were seen in accordance to the cholestane series. The mass spectrum was also in good 
agreement with its molecular formula which exhibited a strong molecular ion peak at 
m/z 618 [M+.]. 
      In the light of above discussion the structure of compound 80 can be characterized 
as 3β-acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline: 
 
Reaction of 3β-chloro-5α-cholestan-6-phenylacetylhydrazone (78) with acetic 
anhydride: 3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-
oxadiazoline (81): 
3β-chloro-5α-cholestan-6-phenylacetylhydrazone (78) (1.0 mmol) in CHCl3 (20 mL) 
was allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) 
for 17 h at 80 ºC. After usual work up and recrystallization from methanol provided  a 
single product  80,  m.p. 231-233 °C. 
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Characterization of compound 81 as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-
2ʹ-benzyl-1ʹ, 3ʹ,4ʹ-oxadiazoline: 
The elemental analysis of the compound 81 corresponded to the molecular formula 
C37H55ClN2O2. The IR spectrum provided evidence for the formation of expected 
product. The absorption bands in the region of 3135, 1551, 1378 cm-1 were ascribed 
to stretching vibrations of aromatic C-H bonds. The important absorption peaks at 
1760, 1640, 1233 and 738 cm-1 were corresponded to COCH3, C=N, C-O-C and C-Cl 
groups, respectively. The structure of compound 81 was well supported by its 1H 
NMR and 13C NMR spectra. In 1H NMR spectrum besides the expected signals for 
cholestane moiety, exhibited a multiplet at 7.8-8.3 for five aromatic protons and a 
broad multiplet centered at δ 3.9 for one proton was assigned to C3-αH. A singlet at δ 
2.52 for two protons attached adjacent to phenyl ring. A singlet appeared at δ 2.2 due 
to three protons of acetyl group. Angular and side-chain methyl protons were 
observed at δ 1.20(C10-CH3), 0.70(C13-CH3), 0.97 and 0.85 for other methyl protons. 
13C NMR spectrum of the compound also supported the proposed structure and 
displayed characteristic signals at δ 167.8(CH3CON), 148.1(C=N) and 136.1-
124.1(aromatic ring). Remaining carbon atoms were seen in accordance to the 
cholestane series. The mass spectrum was also in good agreement with its molecular 
formula which exhibited a strong molecular ion peak at m/z 594/596 [M+.]. 
       In the account of above   descriptive discussion the structure of compound 81 can 
be characterized as 3β-chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-
oxadiazoline. 
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Reaction of 5α-cholestan-6-penylacetylhydrazone (79) with acetic anhydride: 5α-
Cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ, 3ʹ, 4ʹ-oxadiazoline (82): 
5α-Cholestan-6-phenylacetylhydrazone (79) (1.0 mmol) in CHCl3 (20 mL) was 
allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) for 
20 h at 80º C. After usual work up  and recrystallization from methanol  it provided a 
single product 82, m.p. 203-205 °C.  
 
Characterization of compound 82 as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ, 
3ʹ, 4ʹ-oxadiazoline: 
The elemental analysis of the compound 82 corresponded to the molecular formula 
C37H56N2O2. The IR spectrum indicated the evidence for the formation of expected 
product. The diagnostic signals in IR spectrum at 3120, 1579 and 1371 cm-1 were due 
to stretching vibrations of aromatic C-H bonds. The absorption bands at 1764, 1647 
and 1245 cm-1 were attributed to COCH3, C=N and C-O-C groups, respectively. The 
structure of compound 82 was well supported by its 1H NMR and 13C NMR spectra. 
In 1H NMR spectrum of the compound 82, featured a multiplet at δ 7.4-7.9 for 
aromatic protons and a singlet δ 2.45 for two protons attached adjacent to phenyl ring. 
Other  singlet at δ 2.1 due to three protons of acetyl group. Angular and side-chain 
methyl protons were observed at δ 1.16(C10-CH3), δ 0.73(C13-CH3), 0.93 and 0.82 
for other methyl protons. 13C NMR spectrum of the compound also supported the 
proposed structure and displayed characteristic signals at δ 169.2 (CH3CON), 
148.1(C=N) and 129.7-121.7 (aromatic ring) in addition to signals of cholestane 
series. The mass spectrum was also in good agreement with its molecular formula 
which exhibited a strong molecular ion peak at m/z 560 [M+.]. 
      In the account of above evidences the structure of compound 82 can be 
characterized as 5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline. 
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Mechanism of the reaction 
The tentative mechanism has been proposed for the formation of steroidal 
oxadiazolines (68-70,74-76 and 80-82) from steroidal hydrazone derivatives (65-
67,71-73 and 77-79) (Scheme 1.) which starts by N-acylation of the C=N group, with 
development of a positive charge localized between the C and N atoms (-C=N-+ Ac ↔ 
C+ −NAc). The ring closure is then affected by attack of the oxygen atom at the 
polarized carbon of carbon nitrogen double bond which leads to the formation of 
corresponding steroidal oxadiazolines (68-70,74-76 and 80-82).   
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Scheme 1. Mechanism proposed for the synthesis steroidal oxadiazoline derivatives 
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Stereochemistry 
The stereoselectivity of steroidal oxadiazoline can be explained by considering that 
there is a considerable amount of steric hindrance to ring-closure from one side of the 
ring at C-6, which might be explained on the basis that the NCOCH3 group is bulkier 
than oxygen atom, therefore oxadiazoline ring closes at C-6 by the attack of oxygen 
of the respective hydrazones, preferentially from the front (β-axial) side so that the 
bulky group NCOCH3 has an equatorial (α) orientation to avoid 1,3-diaxial interaction 
due to the C-10 angular methyl group that results minimum steric hindrance and 
maximum stability. Thus the only product of this reaction, the oxadiazoline has R 
stereochemistry at C-6. The dreiding models also suggest the attack of oxygen from 
the β-side which pushes the bulkier group NAc to the less hindered α-side. Therefore 
the formulation of the compound as 6R is preferred over its isomer (6S).On the basis 
of these models it is suggested that the same should also be kinetically favorable.  
 
 
 
 
  
Experimental
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General Remark   
Chemicals and solvents used in this study were of ACS grade and used directly 
without further steps of purification. Melting points were determined on a Biogen 
digital auto melting point apparatus. The IR spectra were recorded on KBr pellets 
with Perkin Elmer FT-IR Spectrometer spectrum Two and values are given in cm-1. 
1H and 13 C NMR spectra were run in on a Bruker Avance II 400 NMR Spectrometer 
(operating at 400 MHz for 1H and at 100 MHz for 13C NMR) with tetramethylsilane 
(TMS) as internal standard and values are given in parts per million (ppm) (δ). Mass 
spectra were recorded on a JEOL D-300 mass spectrometer. Elemental analyses were 
recorded on Perkin Elmer 2400 CHN Elemental Analyzer. Thin layer chromatography 
(TLC) plates used to check the homogeneity as well as the progress of reaction. 
Sodium sulfate (anhydrous) was used as a drying agent. 
 
3β-Acetoxycholest-5-ene: 
A mixture of cholesterol (100 g), pyridine (150 mL, freshly distilled over KOH) and 
freshly distilled acetic anhydride (100 mL) was heated on water bath for 2 h. The 
reaction mixture was poured into ice cold water and solid mass thus obtained was 
filtered under suction, washed thoroughly with water until free from pyridine and then 
air dried. Recrystallization of the product from acetone gave 3β-acetoxycholest-5-ene 
(93 g), m.p. 113 -114 ᴼC (reported, m.p. 115-116 ᴼC). 26 
 
3β-Acetoxy-6-nitrocholest-5-ene: 
To a cooled mixture of 3β-acetoxycholest-5-ene (10 g) and conc. HNO3 (250 mL), 
sodium nitrite (10 g) was gradually added with constant stirring over a period of about 
45 minutes. After complete addition of sodium nitrite the stirring was continued for 
additional 2 h. Cold water (300 mL) was added to reaction mixture, yellow solid 
material separated out. The whole mass was extracted with diethyl ether. The ethereal 
layer was washed with water, NaHCO3 solution (5%) (until washings became pink), 
again with water and dried over anhydrous sodium sulfate. Removal of solvent 
provided the nitro compound as an oil which was crystallized from methanol (6.7 g), 
m.p. 104ᴼC (reported m.p. 102-104 ᴼC).27 
 
 3β -Acetoxy-5α-cholestan-6-one (62): 
3β-Acetoxy-6-nitrocholest-5-ene (6 g) was dissolved in glacial acetic acid (120 mL) 
by warming the mixture and zinc dust (12 g) was added in small portions with 
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shaking. The suspension was heated under reflux for 4 h and water (12 mL) was 
added at regular intervals during the course of heating. The hot solution was filtered, 
cooled to room temperature and diluted with large excess of ice-cold water and 
extracted with diethyl ether. The ethereal solution was washed with water, NaHCO3 
solution (5%), again with water and dried over anhydrous sodium sulfate. Evaporation 
of solvents provided the acetoxy ketone as an oil which was crystallized from 
methanol (4.3 g) 128 ᴼC (reported m.p.127-128 ᴼC).28 
 
3β-Acetoxy-5α-cholestan-6-cyanoacetylhydrazone (65): 
To the solution of 3β-acetoxy-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0  mmol) was added. The reaction mixture was refluxed for 
11 h. The progress of reaction was monitored by TLC. After completion of reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-acetoxy-5α-cholestan-6-cyanoacetylhydrazone 29 (0.40 g), m.p. 157-158 
ᴼC. 
 
3β-Acetoxy-5α-cholestan-6-benzhydrazone (71): 
To the solution of 3β-acetoxy-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
benzhydrazide (1.0  mmol) was added. The reaction mixture was refluxed for 12 h. 
The progress of reaction was monitored by TLC. After completion of reaction, the 
excess solvent was removed under reduced pressure. The reaction mixture was taken 
in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-acetoxy-5α-cholestan-6-benzhydrazone. 
Yield (75 %); solid m.p. 172-174 οC; IR (KBr cm-1): 3320 (NH), 
1721(OCOCH3),1671 (C=O), 1625 (C=N), 1329 (C-N), 3121, 1573, 1372 (aromatic 
ring) 1H NMR (400 MHz, CDCl3): δ 7.3-7.42 (m,5H, aromatic). 6.8 (s,1H, NH, 
exchangeable with D2O), 4.2 (m, 1H, C3α-H, W ½= 17 Hz ), 1.19 (s, 3H, C10- CH3), 
0.70 (s, 3H, C13-CH3), 0.97 & 0.83 (other methyl protons); 13C NMR (100 MHz, 
CDCl3): δ 170.5 (NHCO), 168 (C=O) (acetoxy), 156.2 (C=N), 128-122 (aromatic 
ring), Anal. Calc. for C36H54N2O3: C, 76.8, H, 9.67; N, 4.98 % found: C, 76.78, H, 
9.62, N, 4.96 %. MS (ESI): m/z 562 [M+.]. 
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3β-Acetoxy-5α-cholestan-6-phenylacetylhydrazone (77) 
To the solution of 3β-acetoxy-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
phenylacetichydrazide (1.0  mmol) was added. The reaction mixture was refluxed for 
13 h. The progress of reaction was monitored by TLC. After completion of reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-acetoxy-5α-cholestan-6-phenylacetylhydrazone.  
Yield (70 %); solid m.p. 180-182 οC; IR (KBr cm-1): 3276 (NH), 1724 
(OCOCH3),1682 (C=O), 1621 (C=N), 1320 (C-N), 3035, 1570, 1383 (aromatic ring) 
1H NMR (400 MHz, CDCl3): δ 7.4-7.6 (m,5H, aromatic). 6.5 (s,1H, NH, 
exchangeable with D2O), 4.3 (m, 1H, C3α-H, W ½= 15 Hz ), 2.4(s, 2H, -CH2-Ph), 
1.18 (s, 3H, C10- CH3), 0.75 (s, 3H, C13-CH3), 0.95 & 0.83 (other methyl protons); 
13C NMR (100 MHz, CDCl3): δ 171 (NHCO), 169 C=O (acetoxy), 149.2 (C=N), 132-
126.1 (aromatic ring), Anal. Calc. for C37H56N2O3: C, 77.04, H, 9.78; N, 4.86 % 
found: C, 77.01, H, 9.75, N, 4.79 %. MS (ESI): m/z 576[M+.]. 
 
3β-Chlorocholest-5-ene: 
Freshly purified SOCl2 (20 mL) was added gradually to cholesterol (25 g) at room 
temperature. A vigorous reaction ensured with evolution of gaseous products. When 
the reaction slackened, the mixture was gently heated at temperature 50-60 ᴼC on 
water bath for 1 hour and then poured into water with stirring. The yellow solid thus 
obtained was filtered under suction, washed several times with ice-cold water and air 
dried. Recrystallization from acetone gave 3β-chlorocholest-5-ene (20 g), m.p. 95-
96ᴼC (reported, m.p. 96-97 ᴼC).30  
 
3β-Chloro-6-nitro-cholest-5-ene: 
A mixture of 3β-chlorocholest-5-ene (14 g), glacial acetic acid (100 mL) and fuming 
HNO3 (28 ml) was stirred at room temperature below 20 
ᴼC and sodium nitrite (3 g) 
was gradually added over a period of 1 h. After complete addition of sodium nitrite, 
the mixture was stirred for an additional period of 2 h. Ice cold water (200 mL) was 
added to it and the yellowish solid thus obtained was filtered, washed with water and 
air dried. The crude product was recrystallized from methanol to furnish 3β-chloro- 6-
nitrocholest-5-ene as needles  (8.6 g), m.p. 151-152 ᴼC (reported m.p. 153 ᴼC).31 
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3β-Chloro-5α-cholestan-6-one (63):  
To a solution of 3β-chloro-6-nitro-cholest-5-ene (8 g) in hot glacial acetic acid (160 
mL), zinc dust (16 g) was added gradually in a small portion with constant shaking. 
The suspension was heated under reflux for 4 h and water (16 mL) was added at 
regular interval during the course of heating. The hot solution was filtered and the 
filtrate was diluted with large excess of ice cold water. The organic matter was 
extracted with diethyl ether and the ethereal layer was washed with water, then 
washed with NaHCO3 solution (5%) and then dried over anhydrous sodium sulfate. 
Removal of the solvent furnished the ketone as oil which was crystallized from 
methanol (5.7 g), m.p 128-129 ᴼC (reported m.p.129 ᴼC). 32 
 
3β-Chloro-5α-cholestan-6-cyanoacetylhydrazone (66): 
To the solution of 3β-chloro-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0 mmol) was added. The reaction mixture was refluxed for 
10 h. The progress of reaction was monitored by TLC. After completion of reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents yielded the crude product which was recrystallized from 
methanol to afford 3β-Chloro-5α-cholestan-6-cyanoacetylhydrazone 33 (0.37 g),  m.p. 
187-188 ᴼC. 
 
3β-Chloro-5α-cholestan-6-benzhydrazone (72) 
To the solution of 3β-chloro-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
benzhydrazide (1.0  mmol) was added. The reaction mixture was refluxed for 11.5 h. 
The progress of reaction was monitored by TLC. After completion of reaction, the 
excess solvent was removed under reduced pressure. The reaction mixture was taken 
in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-chloro-5α-cholestan-6-benzhydrazone. 
Yield (73%); solid m.p. 143-145 οC; IR (KBr cm-1): 3256 (NH), 1677 (C=O), 1615 
(C=N), 1322 (C-N), 3081, 1578, 1393 (aromatic ring),741(C-Cl). 1H NMR (400 
MHz, CDCl3): δ 7.45-7.55 (m,5H, aromatic). 6.7 (s,1H, NH, exchangeable with D2O), 
4.6 (m, 1H, C3α-H, W ½= 17 Hz ), 1.19 (s, 3H, C10- CH3), 0.70 (s, 3H, C13-CH3), 
0.97 & 0.83 (other methyl protons); 13C NMR (100 MHz, CDCl3): δ 172.2 (NHCO), 
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155.2 (C=N), 136-127 (aromatic ring), Anal. Calc. for C34H51ClN2O: C, 75.7, H, 9.54; 
N, 5.20 % found: C, 75.69, H, 9.54, N, 5.18 %. MS (ESI): m/z 538/540 [M+.]. 
 
3β-Chloro-5α-cholestan-6-phenylacetylhydrazone (78) 
To the solution of 3β-chloro-5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
phenylacetichydrazide (1.0  mmol) was added. The reaction mixture was refluxed for 
12. h. The progress of reaction was monitored by TLC. After completion of reaction, 
the excess solvent was removed under reduced pressure. The reaction mixture was 
taken in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 3β-chloro-5α-cholestan-6-phenylacetylhydrazone. 
Yield (81 %); solid m.p. 160-162 οC; IR (KBr cm-1): 3312 (NH), 1691 (C=O), 1595 
(C=N), 1317 (C-N), 3021, 1585, 1363 (aromatic ring),735(C-Cl). 1H NMR (400 
MHz, CDCl3): δ 7.6-7.7 (m,5H, aromatic). 6.68 (s,1H, NH, exchangeable with D2O), 
4.77 (m, 1H, C3α-H, W ½= 15 Hz ), 2.32(s, 2H, -CH2-Ph), 1.2 (s, 3H, C10- CH3), 
0.75 (s, 3H, C13-CH3), 0.91 & 0.84 (other methyl protons); 13C NMR (100 MHz, 
CDCl3): δ 169.5 (NHCO), 152.2 (C=N), 128-122 (aromatic ring), Anal. Calc. for 
C35H53ClN2O: C, 75.98, H, 9.66; N, 5.06  % found: C, 76.05, H, 9.89, N, 4.99 %. MS 
(ESI): m/z 552/554[M+.]. 
 
Cholest-5-ene: 
3β-Chlorocholest-5-ene (10 g) was dissolved in warm amyl alcohol (230 mL) and 
sodium metal (20 g) was added to the solution with continuous stirring over the period 
of 8 h. The reaction mixture was warmed occasionally. When all the sodium metal 
was dissolved, methanol (few mL) was added and the reaction mixture was poured 
into water, acidified with HCl and then allowed to stand overnight. A white solid thus 
obtained was filtered under suction, washed thoroughly with water and air dried. The 
crude material was recrystallized from acetone to provide cholest-5-ene as cubes (8.2 
g), m.p. 93 ᴼC (reported m.p. 89-91 ᴼC).34 
 
6-Nitrocholest-5-ene: 
A suspension of finely powdered cholest-5-ene (6 g) in glacial acetic acid (50 mL) 
was vigorously stirred at room temperature for 5 minutes and treated with fuming 
HNO3 (15 mL) followed by the addition of sodium nitrite (3 g)  in small portions over 
a period of  1 h and stirring was continued for further 2 h. The reaction mixture was 
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poured into cold water and the yellow product thus obtained was extracted with ether. 
The ethereal layer was washed successively with water, NaHCO3 solution (5%)  (until 
the washings became  pink) and again with water and dried over anhydrous sodium 
sulfate. Removal of solvent provided an oil, which was crystallized from methanol to 
give 6-nitrocholest-5-ene as leaflets (4.4 g), m.p. 119-120 ᴼC (reported m.p.120-121 
ᴼC).35 
 
5α-Cholestan-6-one (64): 
6-Nitrocholest-5-ene (4 g) was dissolved in warm glacial acetic acid (80 mL) and zinc 
dust (8 g) was gradually added with shaking. The mixture was heated under reflux for 
4 h and water (8 mL) was added during the course of reaction. Zinc dust (unreacted) 
was removed by filtration. To the filtrate, water was added till turbidity developed and 
it was allowed to stand overnight at room temperature. The solid material thus 
separated was filtered under suction and washed thoroughly with water in order to 
remove zinc acetate. The organic solid was air dried and recrystallized from methanol 
(2.5 g), m.p 97-98 ᴼC (reported m.p. 98-100 ᴼC).36 
 
5α-Cholestan-6-cyanoacetylhydrazone (67): 
To the solution of 5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), 
cyanoacetylhydrazine (1.0 mmol) was added. The reaction mixture was refluxed for 9 
h. The progress of reaction was monitored by TLC. After completion of reaction, the 
excess solvent was removed under reduced pressure. The reaction mixture was taken 
in diethyl ether, washed with water and dried over anhydrous sodium sulfate. 
Removal of solvents gave the crude product which was recrystallized from methanol 
to afford 5α-cholestan-6-cyanoacetylhydrazone.  
Yield (78 %); solid m.p. 136-137 οC; IR (KBr cm-1): 3319 (NH), 2246(CN),1665 
(C=O), 1635 (C=N), 1329 (C-N); 1H NMR (400 MHz, CDCl3): δ 8.1 (s,1H, NH, 
exchangeable with D2O), 1.19 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-CH3), 0.97 & 0.83 
(other methyl protons); 13C NMR (100 MHz, CDCl3): δ 171.5 (NHCO), 156.2 (C=N), 
115.2 (CN), Anal. Calc. for C30H49N3O: C, 77.08; H, 10.57; N, 8.99 % found: C, 
77.05, H, 10.52, N, 8.96 %. MS (ESI): m/z 467 [M+.]. 
 
5α-Cholestan-6-benzhydrazone (73) 
To the solution of 5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), benzhydrazide 
(1.0  mmol) was added. The reaction mixture was refluxed for 10 h. The progress of 
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reaction was monitored by TLC. After completion of reaction, the excess solvent was 
removed under reduced pressure. The reaction mixture was taken in diethyl ether, 
washed with water and dried over anhydrous sodium sulfate. Removal of solvents 
gave the crude product which was recrystallized from methanol to afford 5α-
cholestan-6-benzhydrazone. 
Yield (80 %); solid m.p 165-166 οC; IR (KBr cm-1): 3287 (NH), 1637 (C=O), 1621 
(C=N), 1322 (C-N), 3065, 1568, 1379 (aromatic ring), 1H NMR (400 MHz, CDCl3): δ 
7.65-7.77 (m,5H, aromatic). 6.9 (s,1H, NH, exchangeable with D2O), 1.19 (s, 3H, 
C10- CH3), 0.70 (s, 3H, C13-CH3), 0.97 & 0.83 (other methyl protons); 13C NMR 
(100 MHz, CDCl3): δ 168.2 (NHCO), 157.1 (C=N), 137-129 (aromatic ring), Anal. 
Calc. for C34H52N2O: C, 80.9, H, 10.38; N, 5.55 % found: C, 80.85, H, 10.32, N, 5.52 
%. MS (ESI): m/z 504 [M+.]. 
 
5α-Cholestan-6-phenylacetylhydrazone (79) 
To the solution of 5α-cholestan-6-one (1.0 mmol) in ethanol (20 mL), phenylacetic 
hydrazide (1.0  mmol) was added. The reaction mixture was refluxed for 11.5. h. The 
progress of reaction was monitored by TLC. After completion of reaction, the excess 
solvent was removed under reduced pressure. The reaction mixture was taken in 
diethyl ether, washed with water and dried over anhydrous sodium sulfate. Removal 
of solvents gave the crude product which was recrystallized from methanol to afford 
5α-cholestan-6-phenylacetylhydrazone. 
Yield (78 %); solid m.p. 184 οC; IR (KBr cm-1): 3292 (NH), 1642 (C=O), 1631 
(C=N), 1345 (C-N), 3071, 1588, 1391 (aromatic ring), 1H NMR (400 MHz, CDCl3): δ 
7.58-7.70 (m,5H, aromatic). 7.1 (s,1H, NH, exchangeable with D2O), 2.6 (s, 2H, -
CH2Ph), 1.18 (s, 3H, C10-CH3), 0.72 (s, 3H, C13-CH3), 0.92 & 0.85 (other methyl 
protons); 13C NMR (100 MHz, CDCl3): δ 167.2 (NHCO), 156 (C=N), 134-126 
(aromatic ring), Anal. Calc. for C35H54N2O: C, 81.03, H, 10.49; N, 5.4 % found: C, 
81.01, H, 10.44, N, 5.38 %. MS (ESI): m/z 518 [M+.]. 
Representative procedure for the synthesis of steroidal spirooxadiazoline derivatives 
(68-70, 74-76 and 80-82): 
Steroidal hydrazones (65-67, 71-73 and 77-79), (1.0 mmol) in CHCl3 (20 mL) was 
allowed to react with acetic anhydride (1.5 mL) in presence of pyridine (0.2 mL) for 
15-20 h at 80 ºC. After usual work up and recrystallization from methanol afforded 
steroidal spirooxadiazolines (68-70, 74-76 and 80-82). 
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3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-
oxadiazoline(68):  
Yield (70%); solid m.p. 192-194 ᴼC. IR (KBr) ν max cm-1; 2232 (CN), 1756 (acetyl 
C=O), 1738 (OCOCH3), 1649 (C=N), 1257 (C-O-C). 
1H NMR (CDCl3, 400 MHz): δ 
4.5 (m, 1H, C3α-H, W½=15 Hz), 2.26 (s, 2H, CH2-CN), 2.08 (s, 3H, COCH3), 2.02 (s, 
3H, OCOCH3), 1.14 (s, 3H, C10-CH3), 0.72 (s, 3H, C13-CH3), 0.95 and 0.82 (other 
methyl protons). 13C NMR (CDCl3, 100MHz): δ 170.66, 165.43, 161.79, 114.25, 
77.42, 72.8, 56.6, 54.1, 51.06, 50.80, 43.01, 42.8, 40.9, 39.7,38.4, 37.1, 36.5, 35.7, 
32.1, 29.6, 28.1, 27.8, 26.3, 25.5, 24.7, 23.8, 22.82, 21.4, 20.2, 18.6, 15.0, 13.5, 12.6, 
11.8. Anal. Calc. for C34H53N3O4; C, 71.92, H, 9.41, N, 7.40; found; C, 71.89, H, 
9.43, N, 7.39; MS (ESI): m/z 567 [M+.]. 
 
3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-oxadiazoline 
(69): 
Yield (73%): solid m.p.198-200 ᴼC. IR (KBr) ν max cm-1: 2237 (CN), 1758 (acetyl 
C=O), 1652(C=N), 1254 (C-O-C), 732 (C-Cl). 1H NMR (CDCl3, 400 MHz): δ 4.6 (m, 
1H, C3α-H, W½=15 Hz), 2.1 (s, 3H, COCH3), 2.31 (s, 2H, CH2-CN), 1.20(s, 3H, 
C10-CH3), 0.70 (s, 3H, C13-CH3), 0.97 and 0.85 (other methyl protons).
13C NMR 
(CDCl3, 100 MHz): δ 166.05, 162.60, 115.2, 76.5, 56.09, 53.8, 52.0, 50.1, 43.2, 42.5, 
40.7, 39.5, 38.1, 37.7, 35.9, 34.3, 33.6, 32.5, 29.5, 28.4, 27.1, 26.4, 25.7, 24.0, 23.7, 
22.1, 19.2, 17.2, 15.2, 14.1, 12.5, 11.0. Anal. Calc. for C32H50ClN3O2; C, 70.62, H, 
9.26, N, 7.72; found; C, 70.58, H, 9.24, N, 7.68; MS (ESI): m/z 543/545 [M+.]. 
 
5α-Cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-cyanomethyl-1ʹ,3ʹ,4ʹ-oxadiazoline (70):  
Yield (80 %): solid m.p. 177-179 ᴼC. IR (KBr) ν max cm-1: 2230 (CN), 1752.12 
(acetyl C=O), 1644.35(C=N), 1250 (C-O-C). 1H NMR (CDCl3, 400 MHz): δ 2.28 (s, 
2H, CH2-CN), 2.1 (s, 3H, COCH3), 1.16 (s, 3H, C10-CH3), 0.73 (s, 3H, C13-CH3), 
0.93 and 0.82 (other methyl protons).13C NMR (CDCl3, 100 MHz): δ 166.7, 159.4, 
117.5, 74.2, 55.1, 52.7, 50.5, 44.1, 42.7, 40.2, 39.3, 38.4, 37.1, 36.4, 34.1, 32.9, 30.1, 
29.0, 28.5, 27.5, 26.7, 25.1, 24.3, 22.1, 21.2, 20.0, 19.5, 16.7, 15.1, 14.2, 12.1, 11.5. 
Anal. Calc. for C32H51N3O2; C, 75.39, H, 10.08, N, 8.24; found: C, 75.36, H, 10.1, N, 
8.21; MS (ESI): m/z 509 [M+.]. 
 
 
 
89 
 
3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline (74): 
Yield (72%); solid m.p. 261-263 ᴼC. IR (KBr) ν max cm-1:  3140, 1580, 1375 
(aromatic ring), 1761 (acetyl C=O), 1728 (OCOCH3), 1651(C=N), 1248 (C-O-C). 
1H 
NMR (CDCl3, 400 MHz): δ 7.42-7.51(m, 5H, aromatic), 4.7 (m, 1H, C3α-H, W½=15 
Hz), 2.07 (s, 3H, COCH3), 2.01 (s, 3H, OCOCH3), 1.14(s, 3H, C10-CH3), 0.72(s, 3H, 
C13-CH3), 0.95 and 0.82 (other methyl protons). 
13C NMR (CDCl3, 100MHz): δ 171, 
165.2, 162.1, 130, 129.5, 127.5, 126.8, 125.1, 124, 76.2, 71.2, 57.2, 55.1, 52.01, 51.2, 
44.1, 42.7, 40.3, 39.9, 38.8, 36.8, 36.2, 35.9, 31.0, 29.8, 27.9, 26.5, 25.2, 24.7, 23.5, 
23.1, 22.8, 22.4, 21.3, 20.0, 19.2, 15.2, 11.2. Anal. Calc. for C38H56N2O4; C, 75.49, H, 
9.31, N, 4.62 ; found; C, 75.43, H, 9.29, N, 4.59; MS (ESI): m/z 604 [M+.]. 
 
3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ,3ʹ,4ʹ-oxadiazoline (75): 
Yield (74%): solid m.p. 216-218 ᴼC. IR (KBr) ν max cm-1: 3129, 1562, 1371 
(aromatic ring), 1748 (acetyl C=O), 1645(C=N), 1241(C-O-C), 740 (C-Cl). 1H NMR 
(CDCl3, 400 MHz): δ 7.5-7.67 (m, 5H, aromatic),  4.6 (m, 1H, C3α-H, W½=15 Hz), 
2.2 (s, 3H, COCH3), 1.20 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-CH3), 0.96 and 
0.85(other methyl protons).13C NMR (CDCl3, 100 MHz): δ 168.1, 158.1, 132.1, 
130.2, 128.5, 126.2, 125.1, 57.1, 55.2, 54.1, 51.0, 49.1, 45.1, 44.2, 42.9, 40.2, 39.8, 
38.5,37.1, 36.3, 35.4, 34.0, 32.1, 30.1, 29.1, 27.9, 26.2, 25.5, 24.7, 23.2, 22.5, 20.2, 
18.2, 16.1,14.2, 12.2. Anal. Calc. for C36H53ClN2O2; C, 74.48, H, 9.3, N, 4.82; found; 
C, 74.49, H, 9.29, N, 4.80; MS (ESI): m/z 580/582[M+.]. 
 
5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-phenyl-1ʹ, 3ʹ,4ʹ-oxadiazoline (76): 
Yield (81%): solid m.p. 210-212 ᴼC. IR (KBr) ν max cm-1: 3141, 1559, 1382 
(aromatic ring), 1763 (acetyl C=O), 1640(C=N), 1254(C-O-C). 1H NMR (CDCl3, 400 
MHz): δ 7.7-8.1 (m, 5H, aromatic), 2.1 (s, 3H, COCH3), 1.16(s, 3H, C10-CH3), 
0.73(s, 3H, C13-CH3), 0.91 and 0.82 (other methyl protons).
13C NMR (CDCl3, 100 
MHz): δ 167.2, 151.2, 134.1, 132.5, 130.1, 126.7, 125.9, 124, 57, 55.1, 52.7, 51.1, 
43.8, 41.2, 39.2, 37.1, 35.3, 34.1, 32.1, 30.2, 28.7, 27.3,26.5, 25.1, 24.9, 24.2, 23.2, 
22.7, 22.1,21.7, 20.5, 19.2, 16.2, 14.1, 12.7, 11.2.  Anal. Calc. for C36H54N2O2; C, 
79.13, H, 9.87, N, 5.13; found: C, 79.09, H, 9.75, N, 5.10; MS (ESI): m/z 546 [M+.]. 
 
3β-Acetoxy-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline (80): 
Yield (72%); solid m.p. 225-227 ᴼC. IR (KBr) ν max cm-1; 3051, 1597, 1401 
(aromatic ring), 1752 (acetyl C=O), 1727 (OCOCH3), 1638 (C=N), 1231(C-O-C). 
1H 
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NMR (CDCl3, 400 MHz): δ 7.57-7.81 (m, 5H, aromatic), 4.4 (m, 1H, C3α-H, W½=15 
Hz), 2.5 (s, 2H, CH2-Ph), 2.07 (s, 3H, COCH3), 2.02 (s, 3H, OCOCH3), 1.14 (s, 3H, 
C10-CH3), 0.72 (s, 3H, C13-CH3), 0.95 and 0.82 (other methyl protons). 
13C NMR 
(CDCl3, 100MHz): δ 172.1, 169.5, 157.2, 133.5, 132.2, 130.1, 129.3, 127.2, 126.5,72, 
61, 58.2, 56.1, 45.2, 44.1, 41.9,40.1, 39.5, 38.7, 38.5, 38.1, 36.7, 36.2, 35.5, 34.2, 
28.3, 28.0, 27.7, 27.3, 26.9, 25.5, 24.2, 23.7, 22.2, 21.2, 19.0, 18.2, 17.1, 12.3. Anal. 
Calc. for C39H58N2O4; C, 75.73, H, 12.47, N, 4.53; found; C, 75.71, H, 12.43, N, 4.49; 
MS (ESI): m/z 618 [M+.]. 
 
3β-Chloro-5α-cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline (81): 
Yield (76%): solid m.p. 231-233 ᴼC. IR (KBr) ν max cm-1: 3135, 1551, 1378 
(aromatic ring), 1760 (acetyl C=O), 1640(C=N), 1233 (C-O-C), 735 (C-Cl). 1H NMR 
(CDCl3, 400 MHz): δ 7.8-8.3 (m, 5H, aromatic), 3.9 (m, 1H, C3α-H, W½=16 Hz), 
2.52 (s, 2H, -CH2-Ph), 2.1 (s, 3H, COCH3), 1.20 (s, 3H, C10-CH3), 0.70 (s, 3H, C13-
CH3), 0.97 and 0.85(other methyl protons).
13C NMR (CDCl3, 100 MHz): δ 167.8, 
148.1, 136.2, 135.3, 131.9, 125.4, 124.1, 55.3, 54.1, 49.0, 45.7, 44.5, 43.2, 39.1, 38.9, 
38.7, 38.2, 36.5, 36.0, 35.8, 34.9, 31.5, 30.1, 28.4, 28.1, 27.7, 27, 26.5, 25.2, 25.0, 
22.5, 21.3, 20.7, 19.7,18.3, 14.2, 11.9. Anal. Calc. for C37H55ClN2O2; C, 74.74, H, 
9.32, N, 4.71; found; C, 74.69, H, 9.28, N, 4.68; MS (ESI): m/z 594/596 [M+.]. 
 
5α-Cholestan-(6R)-spiro-4ʹ-acetyl-2ʹ-benzyl-1ʹ,3ʹ,4ʹ-oxadiazoline (82): 
Yield (78 %): solid m.p. 203-205 ᴼC. IR (KBr) ν max cm-1: 3120, 1529, 1371 
(aromatic ring), 1764 (acetyl C=O), 1647(C=N), 1245 (C-O-C). 1H NMR (CDCl3, 400 
MHz): δ 7.4-7.9 (m, 5H, aromatic), δ 2.45 (s, 2H, -CH2-Ph), 2.1 (s, 3H, COCH3), 1.16 
(s, 3H, C10-CH3), 0.73(s, 3H, C13-CH3), 0.93 and 0.82 (other methyl protons).
13C 
NMR (CDCl3, 100 MHz): δ 169.2, 148.1, 129.7, 128.3, 126.5, 124.2, 122.2, 121.7, 
56.2, 53.2, 51.2, 49.2, 44.3, 44.1, 43.7, 39.2, 38.8, 38.4, 38.1, 37.2, 36.5, 36.4, 35.5, 
34.7, 33.1, 32.7, 30.9, 28.5, 26.4, 25.2, 24.0, 22.3, 20.2, 19.8, 16.2, 14.2, 12.2. Anal. 
Calc. for C37H56N2O2; C, 79.35, H, 10.05, N, 4.98; found: C, 79.32, H, 10.0, N, 4.95 ; 
MS (ESI): m/z 560 [M+.]. 
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Chapter 4 
Biological evaluation of 
newly synthesized steroidal 
heterocycles 
Theoretical
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Steroids have been the prime focus of research throughout the scientific history.1 But 
the recent past has seen an exhaustive focus of research being diverted toward these 
biologically important molecules.2 This is pertinently true of the rational semi 
synthetic modifications of steroidal molecules. Probably, it is because of the various 
advantages associated with steroid based chemotherapeutics.3 These compounds turn 
out to be non-toxic, less vulnerable to multi-drug resistance (MDR) and highly 
bioavailable because of being capable of penetrating the cell wall. Steroids are group 
of lipids whose chemical structures represent the characteristics of living world and 
known to regulate various physiological activities represent constituents of 
biomembranes and hormones, fulfil protective functions, stimulate plant growth. The 
advantage of employing hydrophobic steroid units is their ability to interact with cell 
membranes and thus pave the way for biological activities of such hybrid molecules. 
In the global drug market, steroid drugs rank second only after antibiotics.4 The 
interesting structural and stereochemical features of the steroid nucleus provide 
additional fascination to the researchers, and thereby alterations in the steroidal 
skeleton have been envisaged to discover new chemical entities. The incorporation of 
a heterocyclic ring or a heteroatom in the steroid backbone affects the chemical 
properties of a steroid and often results in useful alterations in its biological 
activities.5  Such systems have shown a lot of different biological activities such as 
anti-microbial, anti-inflammatory, hypotensive, hypocholesterolemic and diuretic 
activities.6 As a result, a number of different heterocyclic systems have been 
introduced into the core structure of steroids with pyrazoles, pyrazolines, isoxazoles, 
isoxazolines, thiazoles, thiadiazoles, pyridines, pyrimidines, imidazoles, etc. as the 
notable ones. Many of these derivatives possess wide spread pharmacological 
properties such as analgesic, antipyretic and antiandrogenic activities7 here we are 
mentioning some reports by different workers for the biological evaluation of 
heterosteroids. Steroid heterocycles containing pyrazole (1), isoxazole (2), thiazole 
(3), pyrane (4) and pyridine ring (5) were reported to be active against some bacteria 
and fungi8 whereas some steroids like cardiotonic steroids (6, 7), withaferin A (8) 
were found to possess pronounced cytotoxity.9 
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95 
 
     Shamsuzzaman et al.10 synthesized fused oxazole derivatives of cholestane (9) and 
reported them as promising antimicrobial agents. 
                                                   
                X = OAc, Cl, H 
 
     Gan et al.11 reported the synthesis of lactone derivatives of cholestane (10-12) and 
their cytotoxic effects were evaluated on three cancer cell lines (HeLa, SMMC 7404 
and MGC 7901). 
   
                     (10)                                                                     (11) 
   
                                  
                                                                   (12) 
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      Richmond et al.12 carried out the synthesis of 2β, 3α-disulfoxy-5-cholestan-6-one 
(13)  and reported its acetylcholinesterase inhibitory activity.      
 
 
                                                             (13) 
          R1, R2 = OSO3Na 
     Hanson et al.13 described the synthesis and evaluation of 
17α(dimethylphenyl)vinyl estradiols (14 a-f) as probes of the estrogen receptor-α 
ligand binding domain. 
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     Maldonado et al.14   isolated 20, 24-epoxywithanolides (15-17) from Physalis 
angulata and studied their cytotoxicity on six human cancer cell lines (U-251, PC-3, 
K-562, HCT-15, MCF-7 and SKLU-1). 
               
 
                                       
     Shamsuzzaman et al.15 reported the synthesis of pyrimidine derivatives of 
cholestane (18). Molecular docking and DNA binding studies were carried out. In 
vitro cytotoxicity for synthesized derivatives were screened on A545, MCF-7, HeLa, 
HL-60, SW480, HepG2, HT-29, A549, 184B5, MCF10A, NL-20, HPC and HPLF 
human cancer cell lines.  
                                                          
                         X = OAc, Cl, H 
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     Qian et al.16 reported the synthesis of pseudo-ginsenoside Rh-2 (19). Cytotoxicities 
of these derivatives were evaluated on eight different human tumor cell lines (SGC, 
A549, HT1080, Hela cell, A375, K562, HL-60 cell line and MCF-7).  
 
                                        
  R =                                                                    (19) 
             
     
      Morozkina et al.17 reported the synthesis of modified 6-oxa-estra-1,3,5(10),8(9)-
tetraenes (20) and these derivaties were evaluated to osteoprotective, cholesterol-
lowering ,antioxidant  and uterotrophic activities. 
                                               
                                                         (20) 
           R = CH3, C2H5 
     
       Huang et al. 18 synthesized 4-azasteroidal purine nucleoside analogues (21 a-f) 
and screened to their in vitro anticancer activity against three cancer cell lines (HeLa, 
PC-3 and MCF-7). 
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  Ahmad and Kim19 reported stereoselective synthesis of 3, 7-diarylaminocholestanes 
(22) and their antimicrobial activities. 
 
                                                        (22) 
        Ar = C6H5, 4-CH3C6H4, 4-CH3OC6H4, 2-NH2C6H4, 4-BrC6H4, 3-BrC6H4, 4-   
                 CH3OOCC6H4 
 
       Mohamed et al.20 synthesized 17α-[1-(substituted phenyl)-1, 2,3-triazol-4-yl]-19-
nortestosterone-17β-yl acetates (23) and evaluated their progestational targeting and 
anti-proliferative activities. 
100 
 
                                              
                                                               (23) 
                  R = COOH, COOCH3 
      Shingate et al.21 reported the stereoselective synthesis and antimicrobial activity 
of steroidal C-20 tertiary alcohols with thiazole side chain (24, 25). 
 
     
                  (24)                                                                       (25) 
          R = TBDMS, H, Ac 
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Biological evaluation of nitrogen containing steroidal heterocycles  (84-
86, 91-92). 
(a) steroidal tetrazole derivatives (84-86) 
(Refer to Chapter-1 for their synthesis and characterization)   
Rule of Five and bioactivity score 
Calculated physicochemical properties of the synthesized compounds 84-85  are 
shown in Table 1. The data showed two violations of Lipinski rules for compounds 
84-85 due to a calculated Clog P value above the limit of 5 and molecular mass 
exceeds above 500 and one violation of Lipinski rules for compound 86 due 
calculated Clog P value above the limit of 5 (Table 1). On the basis of the above 
results we can say that the synthesized compounds adhere to Lipinski’s “Rule of 
Five” 22 and the exceptions to the Lipinski’s rule of five are known and involve drugs 
that are transported across membranes by carrier proteins, such as antibiotic 
erythromycin.23 
 
Table 1.  Calculated physicochemical properties of steroidal tetrazole derivatives (84-
86). 
   Comp.    Mw ClogP  HBD   HBA TPSA No.of  
violations 
     84   554.78   5.971    0     2   122.234   2 
     85   531.189   6.505    0     2    95.929   2 
     86   496.744   6.652    0     2    95.929   1 
 
Clog P; expressed as the logarithm of its partition coefficient between n-octanol 
and water log(coctanol/cwater) 
HBD; Hydrogen bond donor (expressed as the sum of OH and NH) 
HBA; Hydrogen bond acceptor (expressed as the sum of O and N atoms) 
TPSA; Topological polar surface area (defined as a sum of surfaces of polar atoms 
              in a molecule). 
       The bioactivity score of the compounds 84-86 was also calculated for six criteria, 
GPCR ligand activity, ion channel modulation, kinase inhibition activity, protease 
inhibitor, enzyme inhibitor and nuclear receptor ligand activity. As we know for 
organic molecules if the bioactivity score is more than 0.00 then the compound is 
active but if it is between -0.50 to 0.00 then the compound is moderately active and if 
the compound has less than -0.50 then it is inactive compound. As we  can see in 
Table 2. our synthesized compounds showed good bioactivity score. 
102 
 
      Table 2.  Bioactivity score of steroidal tetrazole derivatives (84-86). 
Comp. GPCR 
ligand 
Ion 
channel 
Modulater 
kinase 
Protease 
inhibitor 
Nuclear 
receptor 
ligand 
Enzyme 
inhibitor 
    84  0.06 -0.27 -0.67 -0.02 -0.27 0.22 
    85  0.07 -0.23 -0.64 -0.14 -0.34 0.20 
    86  0.05 -0.15 -0.61 -0.11 -0.30 0.22 
 
Anticancer activity 
Steroidal tetrazoles (84-86) were evaluated for cytotoxicity in a panel of selective 
human cancer cell lines. The IC50 values (concentration required to inhibit tumor cell 
proliferation by 50%) for the synthesized steroids compounds against human cancer 
cell lines including HeLa, KCL-22 and MDA-MBA-231 were determined using the 
MTT assay, while PBMCs were used as normal cells. The well known anticancer 
drugs 5-Fluorouracil (5-Fu) and Doxorubicin (Dox) were used as reference. As shown 
in Table 3. all of the synthesized compounds 84-86 showed moderate to good 
antiproliferative activities against the cancer cell lines. During the cytotoxic screening 
of steroidal tetrazoles (84-86), their potential behaviour against given cancer cells was 
depicted: compound 84 showed IC50 = 18.01 µM (HeLa), 19.14 µM (KCL-22) and 
17.12 µM (MDA-MBA-231). Compound 85 also showed IC50 value in the range of 
15.15 µM (HeLa), 17.22 µM (KCL-22) and 18.14 µM (MDA-MBA-231). While 
compound 86 demonstrated improved anti-proliferative activities with the IC50 = 
11.18 µM (HeLa), 14.24 µM (KCL-22) and 21.03 µM (MDA-MBA-231). The 
compound 86 was found to be the most active among all synthesized compounds, and 
showed marked inhibitory effect against Hela. To confirm the result of cytotoxicity 
the synthesized compounds 84-86 were evaluated against non cancerous cell line 
PBMC, and none of the synthesized compounds were found to be toxic, all 
compounds showed IC50 >60µM against PBMC. 
 
  Table 3.  Antiproliferative activity of steroidal tetrazole derivatives (84-86). 
      Comp.    HeLa     KCL22 MDA-MBA-231   PMBC 
      84    18.01±1.2    19.14±0.6    17.12±0.2           64 
      85    15.15±0.4    17.22±0.6    18.14±2.5     69 
      86   11.18±0. 7    14.24±0.6    21.03±1.5                    64 
   Doxorubicin      4.1±0.1             3.1±0.3                4.12±0.6             - 
5-Fluorouracil      8.1±0.3                6.5±0.2              9.04±0.4             - 
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Antioxidant activity 
In vitro antioxidant activity and scavenging effects of steroidal derivatives 84-86 were 
evaluated by using DPPH radical scavenging activity. The free radical scavenging 
activity of the synthesized compounds was concluded through their ability to quench 
the DPPH and using ascorbic acid as a reference. Potencies for the antioxidant 
activity of the synthesized compounds to the reference drug are shown in Table 4. In 
general, all the synthesized compounds were less potent than the reference. Among 
the synthesized compounds, 86 exhibited a slightly more antioxidant activity.  
 
       Table 4. The antioxidant activity data of steroidal derivatives (84-86)a 
                                                  %  inhibition. 
Comp. 25 µg/mL          50 µg/mL           75 µg/mL 100 µg/mL 
     84 19.3±0.2 19.5±0.4 16.6±0.7 22.9±0.9 
     85 20.1±0.5   25.7±0.2 12.6±0.1 21.8±0.7 
     86    22.2±0.5   21.1±0.2 28.4±0.4 27.7±0.2 
  Standard 36.0±0.3    37.0±0.2 44.0±0.3   50.0±0.5 
   Controlb - - - - 
 
aValue represent the mean ± standard error mean (SEM) of three experiment. 
bNo inhibition, standard: ascorbic acid. 
 
(b) steroidal spiroazetidinone derivatives (91-92) 
(Refer to Chapter-1 for their synthesis and characterization) 
 
Rule of Five  
Calculated physicochemical properties of the synthesized compounds are shown in 
Table 5. The compounds 91-92 showed two violations of Lipinski rules due to a 
calculated Clog P value above the limit of 5 and molecular mass exceeds above 500 
(Table 5). 
 
Table 5.  Calculated physicochemical properties of steroidal spiroazetidinones (91-
92). 
Comp.    Mw ClogP  HBD   HBA TPSA No.of 
violations 
    91   570.68   10.68    0     2 20.31   2 
    92   536.23   10.85    0     2 20.31   2 
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Antimicrobial Activity 
In the context of our studies, the compounds 91-92 were screened for their in vitro 
antimicrobial activities against both Gram-positive and Gram-negative bacterial 
strains and were found to possess activities against the microorganisms listed in 
(Tables 6 and 7). The investigation of antibacterial screening data revealed that 
synthesized compounds showed moderate bacterial inhibition. The antibacterial 
activity of the synthesized compounds in the case of Gram-positive bacteria were a 
little higher compare to Gram-negative bacteria which can be explained by the 
presence of an extra layer of protection by lipopolysaccharide in addition to the 
peptidoglycan membrane in Gram-negative bacteria.24 The investigation of antifungal 
screening data (Tables 8 and 9) indicated that synthesized compounds 91-92 showed 
moderate to good activity. Compound 92 showed good inhibition against Aspergillus 
fumigatus and Candida albicans. MFC of most of the compounds was found to be 
two to four folds higher than their corresponding MIC results. 
 
Table 6. Antibacterial activity (zones of inhibition) of steroidal spiroazetidinones 91-
92. 
                      Diameter of zone of inhibition (mm). 
Comp.   S. Pyogenes   MRSA*      P. aeruginosa   K. pneumoniae E. coli       
91   17.8±0.3 16.9±0.4 19.2±0.3  17.8±0.3 17.3±0.6      
92                                 13.9±0.4 12.9±0.4 11.2±0.5  14.8±0.2 15.3±0.3      
Standard  23.0±0.2 22.0±0.2  32.0±0.3  19.0±0.2         
27.0±0.2   
DMSO              -       -       -        -        
Positive control (standard); Ciprofloxacin and negative control (DMSO) measured by the 
Halo Zone Test (Unit, mm); * Methicillin resistant Staphylococcus aureus (MRSA +Ve). 
 
Table 7. MIC and MBC results of steroidal spiroazetidinones 91-92 against bacterial     
strains  
Comp.           Gram positive 
bacteria 
                    Gram negative bacteria 
S. Pyogenes      MRSA* P.aeruginosa K.pneumonia       E. coli 
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC 
  91 50 100 25   50 50 100 50 >100 50 >100 
  92 50 100 25   50 50 100 50 >100 50 >100 
Standard 12.5 12.5 6.25   12.5 12.5 25 6.25 25 6.25 12.5 
 
(Standard); Ciprofloxacin; MIC (µg/ml) = minimum inhibitory concentration, i.e the 
lowest concentration of the compound to inhibit the growth of bacteria completely; 
MBC (µg/ml) = minimum bacterial concentration, i.e., the lowest concentration of the 
compound for killing the bacteria completely; Methicillin resistant Staphylococcus 
aureus (MRSA +Ve) 
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     Table 8. Antifungal activity of steroidal spiroazetidinones 91-92. 
    Comp               Diameter of zone of inhibition (mm) 
CA                AF              TM            PM          
      91 21.8±0.1      20.6±0.5    23.6±0.8 13.5±0.9 
     92 27.8±0.2      22.7±0.3    18.6±0.6 16.5±0.4 
   Standard  30.0±0.2      27.0±0.2     24.0±0.3 20.0±0.5 
    DMSO           -           -            -    - 
 CA; Candida albicans ,AF; Aspergillus fumigates,TM ; Trichophyton 
mentagrophytes, PM; Pencillium marneffei. Positive control(standard) Fluconazole 
and negative control (DMSO) 
Table 9. MIC and MFC of steroidal spiroazetidinones 91-92 against fungal strains. 
Comp             CA            AF             TM         PM 
MIC MFC MIC MFC MIC MFC MIC MFC 
   91 50 100 50 100 100 >100 50 100 
   92 25 50 25 100 50 100 25 100 
Standard 6.25 25 12.5 12.5 6.25 25 12.5 25 
 
Standard; Fluconazole, CA; Candida albicans, AF; Aspergillus fumigates,TM; 
Trichophyton menotagrophytes, PM; Pencillium marneffei. MIC (μg/ml) = minimum 
inhibitory concentration, i.e the lowest concentration of the compound to inhibit the 
growth of fungus completely; MFC (μg/ml) = minimum fungicidal concentration, i.e., 
the lowest concentration of the compound for killing the fungus completely. 
 
 
Antioxidant activity 
 
In vitro antioxidant activity and scavenging effects of steroidal spiroazetidinone 
derivatives 91-92 were evaluated by using DPPH radical scavenging activity. 
Ascorbic acid used as reference. Compound 91 exhibited good antioxidant properties. 
The synthesized compounds were less potent than the reference ascorbic acid. From 
the results it can be interpreted that the aromatic ring showed marked effects on the 
antioxidant property of these compounds.25 The potencies for the antioxidant activity 
of the synthesized compounds 91-92 to the reference drug are shown in Table 10. 
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       Table 10. Antioxidant activity of steroidal spiroazetidinones 91-92a 
Comp.                                 %  inhibition 
      25 µg/ml                50 µg/ml            75 µg/ml          100 µg/ml          
   91       11.8±0.1      13.6±0.5    18.6±0.8 20.5±0.9 
   92       17.8±0.2      18.7±0.3    20.6±0.2 26.5±0.4 
Standard       36.0±0.3      37.0±0.2    44.0±0.3 50.0±0.5 
Controlb            -           -            -    - 
   
      aValues represent the mean ± standard error mean (SEM) of three experiment.  
       bNo inhibition, standard: ascorbic acid. 
 
 
Molecular Docking 
 
Molecular docking of compounds 91-92 with the active site of bacterial DNA gyrase 
(PDB ID: 3U2D) 
In order to know the exact interactions of the compounds 91-92 docking studies were 
carried out. Figure 1(a-b). depicted the comparison of binding of these compounds 
with Ciprofloxacin binding site. Although the compounds 91 and 92 had no hydrogen 
bonds with the DNA gyrase but have lipophilc interactions. The results of molecular 
interaction parameters for compounds 91-92 with DNA gyrase were listed in Table 
11. and compared with Ciprofloxacin. Compound 91 showed molecular interactions 
within active site of DNA gyrase with 15.53 where as compounds 92 showed 12.22 
fitness score as compared to  reference drugs Ciprofloxacin which is  having GOLD 
45.84 fitness scores. Compound 91 and 92 were found to have 19 and 28 non-bonded 
contacts respectively, as compared to reference drug Ciprofloxacin. 
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Figure 1(a). The interaction plot of Ciprofloxacin and steroidal spiroazetidinones (91-
92) with the binding site residues of DNA gyrase protein. The hydrogen bonds and 
hydrophobic interactions are shown which are holding the ligand within the binding 
site. 
   
 
 
 
 
 
 
 
 
Figure 1 (b). Ciprofloxacin and steroidal spiroazetidinones (91-92) docked in the 
binding site of DNA gyrase . The protein is in cartoon representation and the ligand 
molecules are in sticks coloured. 
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Table 11. Molecular interactions parameters of compounds 91-92 with bacterial DNA 
gyrase. 
 
 
The molecular docking of compounds 91-92 with active site of antifungal protein 
CYP 51 (PDB ID: 1E9X) 
Figure 2(a-b). showed the comparison of binding of compounds 91-92 with 
Flucanazole binding sites. Compounds 91 and 92 showed molecular interactions 
within active sites of CYP 51 with 21.84 and 15.03 Gold fitness scores respectively, 
as compared to standard reference drug Fluconazole which is having 50.06 fitness 
score. Compound 91 and 92 also found to have null hydrogen bonding interactions 
and 40 and 45 non bonded contacts, respectively The results of molecular interactions 
are depicted in Table 12. 
 
 
 
 
Figure 2(a). The interaction plot of Fluconazole and steroidal spiroazetidinones (91-
92) with the binding site residues of CYP 51. The hydrogen bonds and hydrophobic 
interactions are shown which are holding the ligand within the  binding site. 
   Comp. 
GOLD 
Fitness 
Score 
No of 
H- 
Bond 
No of Lipophilic 
Interactions 
No of Non-
Bonded 
Interactions 
Xscore 
kcal/mol 
   
Ciprofloxacin 
45.84 NIL 
6; Asn 41, Ser 42, Gln 45, 
Arg 71, Ile 73, Thr 137 
23 -7.61 
      91 15.53 NIL 
9; Ile 38, Asn 41, Glu 45, 
Ala 48, Arg 71, Ile 73, Pro 
74, Thr 137, Ile 139 
19 -7.38 
  92 12.22 NIL 
12; Ile 38, Asn 41, Asp 
44,Glu 45,  Ala 48, Val 66, 
Asp 68, Arg 71, Ile 73, Pro 
74, Thr 137, Ile 139 
28 -7.07 
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Figure 2 (b). Fluconazole and steroidal spiroazetidinones (91-92) docked in the 
binding site of CYP 51 protein. The protein is in cartoon representation and the ligand 
molecules are in sticks coloured. 
   Table 12. Molecular interactions parameters of compounds 91-92 with CYP 51 
protein 
 
  
Comp. Gold 
fitness 
score 
No. of   
H-
Bond 
 No of Lipophilic        
Interactions 
No of Non-
Bonded 
Interactions 
Xscore 
      
kcal/mol 
Flucanazole 50.06     Nil 5; Lys 97, Ala 256, Phe 
387, Cys 394, Val 395 
    23 -8.06 
         91 21.56    Nil 11; Gln 72, Ala 73, Tyr 
76, Phe 78, Met 79, Lys 
97, Phe 255, Ala 256, 
His 259, Leu 321, Leu 
324, 
 
    40 
 
 
  -7.20 
         92 15.03   Nil 13; Gln 72, Ala 73, Tyr 
76, Phe 78, Met 79, Lys 
97, Phe 255, Ala 256, 
His 259, Leu 321, Leu 
324, His 392, Val 434 
   
    45 
 
-6.85 
 
 Biological evaluation of steroidal thiazole derivatives 43-45, 47 
 (Refer to Chapter-2 for their synthesis and characterization) 
Calculated physicochemical properties of the steroidal thiazoles (43-45, 47) are 
shown in Table 13. The data showed two violations of Lipinski rules for compounds 
43-45, 47 due to a calculated Clog P value above the limit of 5 and molecular mass 
exceeds above 500. (Table  13). 
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  Table 13 . Calculated physicochemical properties of steroidal thiazoles (43-45, 47)  
Comp.   Mw ClogP HBD HBA    TPSA  No. of 
violations 
No. of 
Rotatable 
bonds 
     43 617.944 9.211   1   5 63.588    2     10 
     44 594.353 9.359   1   3 37.283    2      8 
     45 559.908 9.396   1   3 37.283    2      8 
     47 531.766 7.646   1   5 63.588    2      6 
 
The bioactivity score of the compounds 43-45, 47 is also calculated for six criteria, 
GPCR ligand activity, ion channel modulation, kinase inhibition activity, protease 
inhibitor, enzyme inhibitor and nuclear receptor ligand activity. As we know for 
organic molecules if the bioactivity score is more than 0.00 then the compound is 
active but if it is between -0.50 to 0.00 then the compound is moderately active and if 
the compound has less than -0.50 then it is inactive compound. As we can see in 
Table 14. synthesized compounds showed good bioactivity score. 
             
  Table  14. Bioactivity score of steroidal thiazoles (43-45,47) 
Comp. GPCR 
ligand 
Ion channel 
modulator 
kinase 
inhibitor 
Protease 
inhibitor 
Nuclear 
receptor 
ligand 
Enzyme 
inhibitor 
     43   -0.31    -0.77    -0.84   -0.21   -0.50   -0.05 
     44   -0.21    -0.60    -0.67   -0.30   -0.40    0.60 
     45   -0.23    -0.48    -0.58   -0.28   -0.32    0.12 
     47   -0.26    -0.46    -0.69   -0.40   -0.13    0.24 
 
In order to study the biological behaviour of compounds PASS (prediction of activity 
spectra for substances) were carried out. A biological activity spectrum for a 
substance is a list of biological activity types for which the probability to be revealed 
(Pa: active) and the probability not to be revealed (Pi: inactive). Pa and Pi values are 
independent and their values vary from 0 to 1. If Pa > 0.7, the substance is very likely 
to exhibit the activity in experiment and the chance of the substance being analogue is 
also high; and if 0.3 < Pa < 0.7, the substance is likely to exhibit the activity in 
experiment, but the probability of analogue is less while if Pa < 0.3, the substance is 
unlikely to exhibit the activity in the experiment. PASS results of all the compounds 
43-45, 47 are summarized in Table 15. 
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Table  15. PASS predicted but not reported activities (hidden potential) of steroidal   
thiazoles (43-45, 47) 
 
     Comp. Pharmacological activity       Pa     pi 
             
         43 
     Anti-pruritic    0.632   0.008 
    Anti-inflammatory    0.605   0.025 
      Anti-cancer    0.501   0.019 
               
         44 
     Anti-pruritic    0.603   0.012 
    Anti-inflammatory    0.383   0.009 
      Anti-cancer    0.403   0.038 
      
         45 
     Anti-pruritic    0.526   0.074 
    Anti-inflammatory    0.348   0.023 
      Anti-cancer    0.484   0.023 
             
         47 
     Anti-pruritic    0.628   0.027 
    Anti-inflammatory    0.594   0.033 
      Anti-cancer    0.678   0.017 
 
              
                              (a)                                                                (b)                                              
             
                               (c)                                                                     (d) 
Figure 3 (a-d). represents maps of molecular lipophilicity potential (MLP) of the 
synthesized compounds (43-45,47) respectively. 
 
112 
 
Antioxidant activity 
In vitro antioxidant activity and scavenging effects of steroidal derivatives 43-45, 47 
were evaluated by using DPPH radical scavenging activity. Potencies for the 
antioxidant activity of the synthesized compounds to the reference drug are shown in 
Table 16. In general, all the synthesized compounds were showing average to 
moderate antioxidant activity but less potent than the reference. The compounds 44, 
45 and 47 showed an increase in % antioxidant activity within the range of 13.2% to 
28.9 % with an increase in concentration, while compound 43 showed a decrease in % 
antioxidant activity with an increase in concentration. Among the synthesized 
compounds 45 showed the highest antioxidant activity from 21.2 % to 28.9 % with 
concentration increasing from 25 to100 µg/mL, respectively.While the lowest activity 
was noted for compound 43 from 16.5 % to 13.9 % with an increase in concentration. 
Ascorbic acid was used as a standard antioxidant with 36% to 50 % antioxidant 
activity and increased with concentration. 
 
        Table16. The antioxidant activity data of steroidal thiazoles (43-45, 47)a 
                                                  %  inhibition. 
   Comp.    25 µg/mL          50 µg/mL           75 µg/mL 100 µg/mL 
     43   16.5±0.5   15.2±0.3   14.8 ±0.7   13.9 ±0.5 
     44   13.2±0.3   14.8±0.9   17.7±0.2   19.2±0.4 
     45   21.2±0.5   23.7±0.6   25.3±0.4   28.9±0.2 
     47   17.5±0.1   20.4±0.7   22.8±0.5   24.5±0.3 
 Standard    36.0±0.3  37.0±0.2   45.0±0.3   50.0±0.7 
  Controlb        -        -       -     - 
 
          aValue represent the mean ± standard error mean (SEM) of three experiment. 
            bNo inhibition, standard: ascorbic acid. 
 
Nuclease activity 
The DNA cleavage was controlled by the relaxation of supercoiled circular form of 
pBR322 DNA into the nicked and linear forms. DNA cleavage studies are used to 
construct new and rational design of more efficient drugs that are targeted to DNA. In 
order to understand the chemical basis of DNA breakage by compounds 43-45, 47 the 
relative DNA cleavage efficiency was studied in pBR322 DNA. The agrose gel 
pattern showing the cleavage of plasmid pBR322 DNA is presented in Figure 4. As 
evident from Figure 4. compounds 43-45, 47 cause the conversion of supercoiled 
form of plasmid molecules into linear form. The electrophoresis analysis clearly 
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revealed that target compounds have acted on DNA. In this study, gel electrophoresis 
demonstrate that there was a difference in the migration of the lanes of synthesized 
compounds 43-45, 47 respectively as compared to the control plasmid pBR322 DNA 
Lane (1). This shows that the control DNA alone does not show any perceptible 
cleavage, whereas the treated DNA sample undergoes cleavage. On the basis of these 
results, it can be concluded that newly synthesized compounds are DNA targeting 
agents.  
 
 
                                                         1    2      3     4      5 
Figure 4. Agarose gel electrophoresis patterns of degradation of pBR322 plasmid 
DNA by   compounds (43-45, 47). Lane 1: Untreated plasmid DNA; Lane 2: 
Compound 43 (50 µM) + DNA; Lane 3: compound 44 (50 µM) + DNA. Lane 4: 
Compound 45 (50 µM) +DNA; Lane 5: Compound 47 (50 µM) + DNA 
 
Comet assay 
Comet assay a versatile and sensitive method for measuring DNA damage in terms of 
single and double-strand breaks in DNA. Assay was performed using peripheral 
human lymphocytes cells to confirm the effects of the compounds 43-45, 47 on 
cellular DNA. In the experiment, the increasing concentrations of compounds 43-45, 
47 (50, 100, 150 and 200 µM) respectively studied for DNA breakage in peripheral 
human lymphocytes. From the Figure 5. and Table 17 it is clear that the compounds 
causing DNA break down as evidenced by the increase in comet tail length. 
Compound 47 causes a significantly greater degree of DNA breakage in lymphocytes. 
This quantified increase in DNA damage suggests that the compound 47 induced a 
dose-dependent fragmentation of chromosomal DNA, leading to apoptosis. The order 
of DNA damaging activity of synthesized compounds followed 47 > 43 > 44 > 45 
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with comet tails measuring approximately 24.87 µm, 20.65 µm, 18.23 µm and 15.11 
µm, respectively at 200 µM concentration (Table 17). 
 
                         
                                                                    (a) 
 
 
(b) 
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                                                                          (d) 
Figure 5 (a-d). represent DNA damage in human peripheral lymphocytes by the 
compounds (43-45, 47)  in dose dependent manner. Comet tail length values are 
reported in µm as  mean ± SEM of three independent experiments. *P≤ 0.005 when 
compared to control. 
 
 
  Table 17.  Results  of DNA breakage in lymphocytes by compounds 43-45,47 
measured       
                  by alkaline version of comet assay. 
 
        
Comp. 
    varying concentrations of the synthesized compounds 43-45,47 
   0(µM) 50 (µM)    100(µM)    150(µM)  200(µM) 
                                Comet  tail length (µm) 
    43 2.42 ± 0.73 8.81 ± 1.11 13.56±1.20 16.37±1.18 20.65±1.79 
    44 2.19 ± 0.56 6.93 ± 1.03 11.67±1.21 13.37 ±1.15 18.23±1.39 
    45 2.32 ± 0.53 6.15 ± 1.05 10.32±1.09 12.17±1.12 15.11±1.63 
    47 2.07 ± 0.42 10.98 ± 0.99 16.24±1.07 21.37±1.14 24.87±2.03 
 
 
Detection of superoxide anion free radical production. 
Superoxide anion free radicals were measured by the reduction of nitro blue 
tetrazolium (NBT). The rate of generation of superoxide anion by synthesized 
compounds (43-45, 47) was studied using NBT assay. An increase in the absorbance 
at 560 nm was observed on reduction of NBT by superoxide anion. It was apparent 
that the production of superoxide anion (O2
∙‾) by the synthesized compounds 
increases with the increasing concentration. As evident from NBT assay results 
(Figure 6), compound 47 showed maximum superoxide anion generation with 
increasing concentrations. Compound 43 shows lesser superoxide anion generation 
followed by compounds 44 and 45. 
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Figure 6. Generation of superoxide anions by compounds 43-45, 47 with increase in 
concentration as measured by NBT assay. Blue colour bar represents (comp.47), red 
(comp.43), green (comp.44) and purple (comp.45). 
 
 
Detection of hydroxyl radicals production ( •OH) 
 
The hydroxyl radical ( •OH) constitutes the chemically most reactive species of 
activated oxygen formed by successive monovalent reduction of dioxygen (O2) in cell 
metabolism, and is primarily responsible for the cytotoxic effects of oxygen in plants, 
animals and micro-organisms, living in an oxygenic atmosphere. In the DNA 
cleavage reactions mediated by various antioxidants in the presence of Cu (II), it has 
been established that Cu (II) is reduced to Cu (I) by the antioxidants and that Cu (I) is 
an essential intermediate in the DNA cleavage reactions. It is also well known that 
DNA cleavage by various antioxidants and Cu (II) is the result of the generation of 
hydroxyl radicals. Cu (II) is reduced to Cu (I) and the re-oxidation of Cu (I) to Cu (II) 
by molecular oxygen gives rise to superoxide anion which in turn leads to the 
formation of H2O2. Presumably Cu (I) is oxidized to Cu (II) by H2O2 in a Fenton type 
reaction giving rise to hydroxyl radicals. To evaluate the hydroxyl radical production 
and the role of copper ions in DNA cleavage, an experiment was performed where 
progressively increasing concentrations of compounds 43-45, 47 were tested on 
thiobarbituric acid induced DNA breakage (Figure 7.) The results confirmed the 
relatively higher rate of formation of hydroxyl radicals and correlated with the rate of 
DNA degradation by the compounds (43-45, 47). The proposed mechanism of DNA 
damage is believed to occur via redox cycling (scheme 1.). Compound 47 showing 
the maximum hydroxyl generating potential followed by compound 43, 44 and 45. 
Therefore, we may suggest that compound 47 should possess higher DNA cleavage 
0
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potential than rest of synthesized compounds. The assay is based on the fact that 
degradation of DNA by hydroxyl radical results in the release of TBA reactive 
material, which forms a coloured adduct readable at 532 nm. 
    
 
 
Figure 7. Generation of hydroxyl radical production by compounds (43-45, 47) as 
measured by assay of thiobarbituric acid. Blue colour bar represents (comp.47), red 
(comp.43), green (comp.44) and purple (comp.45). 
 
 
 
 
                      
        Scheme  1. Mechanism   proposed for  oxidative DNA   damage mediated  by   
                           steroidal thiazoles 
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RBC hemolysis test 
Inherent toxicity of synthesized compounds was assessed using in vitro erythrocyte 
lysis test. In this test, haemoglobin (Hb) released as a result of leakage or membrane 
disruption, on exposure to tested compounds is measured. In our experiment 
compounds 43-45, 47 were incubated at 37 οC with RBC at a concentration of 5 
mg/ml for interval of 1 h. It was observed that compounds 43-45, 47 do not induce 
significant hemolysis level and percentage of hemolysis reaches only 10-15%. 
Therefore, we conclude that synthesized compounds 43-45, 47 do not injure the 
RBCs. 
 
Molecular docking of compounds 43-45, 47 with DNA 
Molecular docking has gained growing interest in the investigation of binding 
interaction mechanism of biological macromolecules with small molecules. It plays 
an important role in drug discovery and development. Molecular docking studies of 
nucleic acids and their complexes can provide valuable information that is not 
available by other experimental techniques. Docking technique is an attractive tool to 
understand the Drug-DNA interactions as well as in the mechanistic study by placing 
a molecule into the binding site of the target specific region of the DNA. This method 
gives the possibility to study an active site in detail and can be used for hit 
identification, virtual screening and binding mode determination. Molecular docking 
studies were performed to predict the binding modes of compounds 43-45, 47 with 
DNA duplex of sequence d(CGCGAATTCGCG)2 (PDBID: 1BNA), and provide an 
energetically favourable docked structures representative figure of DNA-compounds 
in Figure 8. The interaction between the compounds and base pairs of DNA is mainly 
by electrostatic and hydrogen bonding shown by the thiazole ring. As evident  from  
Figure 8. and Table 18. compound 47 exhibited strong binding affinity with DNA 
with binding energy -8.0 kcal/mol and forms two hydrogen bonds with NH2 group of 
cytosine (C-4) and adenine (A-4). On the other hand, compound 43 also exhibited 
strong affinity to DNA with binding energy of -8.1 kcal/mol and forms one hydrogen 
bond with 7th Nitrogen (N-7) atom of adenine of B-DNA (A-6). Compound 44 
exhibited a stronger affinity, slightly weaker than compounds 43 and 47, with binding 
energy -7.8 kcal/mol and form one hydrogen bond with 7th Nitrogen (N-7) atom of 
adenine of DNA (A-6). However, compound 45 exhibited a binding energy -7.8 
kcal/mol with null hydrogen bonding interactions. The binding energies of 
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compounds 44 and 45 with DNA are almost equal suggesting that both are forming 
equally stable complex with DNA and the presence of hydrogen bond between 
compound 44 and DNA might not be affecting the stability of the complex. The more 
negative the binding energy, the more  potent is the binding between DNA and target 
molecule. Hence the complex formed between compound 43 and DNA with binding 
energy of -8.1 kcal/mol might be having highest stability complex. 
 
 
     
 
                                   (A1) 
 
 
                             (A2) 
 
 
 
 
(B1) 
 
 
                        (B2) 
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                                         (C1) 
 
 
 
                       
                         (C2) 
 
 
                                   
                                    
                                     (D1) 
 
 
 
                         
(D2) 
 
Figure  8. Molecular docked models of steroidal thiazoles with DNA dodecamer 
duplex of sequence d(CGCGAATTCGCG)2 (PDB ID: 1BNA). Docking of compound 
43 represented by (A1, A2), 44 by (B1, B2), 45 by (C1, C2) and 47 by (D1,D2). 
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Biological evaluation of steroidal spirooxadiazoline derivatives (68-70) 
 (Refer to Chapter-3 for their synthesis and characterization) 
Calculated physicochemical properties of the steroidal spirooxadiazolines (68-70) are 
shown in Table 18. The data showed two violations of Lipinski rules for compounds 
68-70 due to a calculated Clog P value above the limit of 5 and molecular mass 
exceeds above 500. (Table 18). 
 
 
Table 18. Calculated physicochemical properties of steroidal spirooxadiazolines (68-
70)  
Comp.   Mw ClogP HBD HBA    TPSA  No. of 
violations 
No. of 
Rotatable 
bonds 
     68 553.7 6.37 0   7 92    2     7 
     69 530.20 6.90  0   5 65.70    2     5 
     70 495.75 7.05   0   5 65.70    1      5 
 
The bioactivity score of the compounds 68-70 was also calculated for six criteria, 
GPCR ligand activity, ion channel modulation, kinase inhibition activity, protease 
inhibitor, enzyme inhibitor and nuclear receptor ligand activity. As we know for 
organic molecules if the bioactivity score is more than 0.00 then the compound is 
active but if it is between -0.50 to 0.00 then the compound is moderately active and if 
the compound has less than -0.50 then it is inactive compound. As we can see in 
Table 19. synthesized compounds showed good bioactivity score. 
       
  Table 19.  Bioactivity score of steroidal spirooxadiazolines derivatives (68-70). 
Comp GPCR 
ligand 
Ion 
Modulater 
channel 
Kinase 
Inhibitor 
Protease 
inhibitor 
Nuclear 
receptor 
ligand 
Enzyme 
inhibitor 
     68  -0.12 -0.32 -0.71 0.03 0.06 0.06 
     69  -0.13 -0.29 -0.72 -0.08 0.01 0.02 
     70 -0.16 -0.21 -0.67 -0.05 0.07 0.04 
 
HSA binding 
Human serum albumin (HSA) is the most abundant protein in the blood plasma. It 
binds and transports several endogenous and exogenous substances and play a key 
role many in processes biological systems. Due to its ability to bind various drug 
molecules and alter their pharmacokinetic properties, HSA has long been a research 
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focus in the pharmaceutical industry. The distribution of drugs is mainly controlled by 
HSA because most drugs travel in plasma and reach target tissues by binding to the 
protein.  
 
 Fluorescence quenching study of HSA with compounds (68-70) 
Fluorescence spectroscopy is an important and effective method utilized to investigate 
the interactions between different ligands and biomacromolecules. Fluorescence of 
HSA arises from tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe) residues, 
among these three amino acid residues the inherent fluorescence of HSA is mainly 
contributed by the Trp residue alone, because the Phe residue has a very low quantum 
yield and the fluorescence of Tyr is almost totally quenched when it is ionized or 
nearby an amino group, a carboxyl group, or a Trp. Most of the protein molecules are 
naturally fluorescent around 348 nm, which mainly attributes to their fluorescent 
tryptophan (Trp) residues. Figure 9 (A-C).  represent the fluorescence quenching 
spectra of HSA with compound 68-70, respectively. In general, the fluorescence 
quenching mechanism can be described by the following Stern-Volmer equation. 
(equation. 1) 
  
 F/Fο =1 + kqτο [Q] = 1+ Ksv [Q]                                                                                 1  
where F0 and F are the relative fluorescence intensities in the absence and presence of 
quencher, respectively, [Q] is the concentration of quencher, kq the bimolecular 
quenching rate constant, τ0 the average bimolecular life-time in the absence of 
quencher the fluorescence Ksv is the Stern-Volmer quenching constant, a slope of the 
Stern-Volmer plot and determined by linear regression of a plot of F0/F against [Q]. 
Figure 10 (A-C). showed Stern-Volmer plot of compounds 68-70 related constant 
were listed in (Table 20).  and number of equivalent binding sites (n) on a molecule 
and binding constant K is given by modified Stern-volmer equation (equation. 2)  
and their values are listed in Table 20. Figure  11 (A-C). showed modified Stern- 
volmer plots of compounds 68-70  
      
Log(F0-F)/F=  LogK + nLog[Q]                                                                                     2                                                                           
Analysis of quenching mechanism was confirmed from the values of biomolecular 
quenching rate constants, which are evaluated using the equation 3; 
 kq =Ksv  τ0                                                                                                                       3   
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The value of τ0 for biopolymers is 10-8 s. Accordingly the values of kq are calculated 
(Table 20).  
 Table 20.   Binding parameters of compounds 68-70 with HSA. 
Comp. KSV (M
-1)     K (M-1) (M-1S-1)       n       R2 
     68 1.38×104 1.11×104 1.38×1012 0.979 0.998 
     69 1.94×104           1.94×104 1.94×1012 1.001 0.998 
     70 1.48×104 0.469×104 1.48×1012 0.887 0.996 
 R is correlation constant 
     
     Figure 9 (A). Fluorescence  spectrum of HSA with compound 68 at 298 K. 
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      Figure 9 (B). Fluorescence spectrum of HSA with compound  69 at 298 K. 
 
 
         Figure 9 (C). Fluorescence spectrum of HSA with compound 70  at 298 K. 
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Figure 10 (A). Stern-Volmer plot describing quenching of HSA by compound 68 at 
                               298 K.   
 
Figure 10 (B). Stern-Volmer plot showing  quenching of HSA by compound 69 at    
298 K 
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   Figure 10 (C). Stern-Volmer plot describing quenching of HSA by compound 70 at  
                           298  K. 
 
 
 
 
Figure 11 (A).  Modified Stern-Volmer plot for binding of HSA with compound 68 at  
                         298 K. 
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 Figure 11(B).  Modified Stern-Volmer plot for binding of HSA with compound 69 at    
                           298 K. 
 
 
 
 Figure 11(C). Modified Stern-Volmer plot for binding of  HSA with compound 70 at    
                          298 K. 
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UV-Vis absorption experiments    
The UV-Vis absorption spectra of HSA with compounds 68-70 were utilized to 
confirm the quenching mechanism as shown in Figure 12(A-C). In the studies of 
compound-protein interaction UV-visible spectroscopy is simple and valuable tool. 
The absorption peak of HSA centres at 280 nm mainly due to the tryptophan residue 
originates through (π→π*) electronic transition. In the present experiment however, 
Figure 12(A-C). after addition of the synthesized compounds 68-70, the maximal 
absorption peak as well as the absorption intensity of HSA is increased. This indicates 
that the interaction of compounds 68-70 leads to conformational change in HSA. 
 
 
        Figure 12 (A). UV-Vis absorption spectrum  showing interaction of HSA with   
                           compound 68 at 298 K. 
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       Figure 12 (B). UV-Vis absorption spectrum  showing interaction of HSA with   
                                compound  69 at 298 K. 
 
 
        Figure 12 (C). UV-Vis absorption spectrum  showing interaction of HSA with    
                                 compound  70 at 298 K. 
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FRET : Energy Transfer from HSA to synthesized compounds 68-70 
Fluorescence resonance energy transfer (FRET) is a distance between the excited 
states of molecules in which excitation energy is transferred non-radiatively from 
donor to acceptor molecule. According to Fösters non-radiative energy transfer theory 
the energy transfer efficiency, E, is not only related to the distance between the donor 
and acceptor but also influenced by the critical energy transfer distance R0, which is 
given by equation  4. 
 E = 1- F/F0= R
6
0/( R
6
0 + r
6)                                                                                          4 
 where r is the distance between the donor and the acceptor, and R0 is the critical 
distance, at which the efficiency of transfer is 50%,which can be calculated by: 
R60= 8.8 ×10
-25K2N-4 Φ J                                                                                                          
where K2 is spatial orientation factor of the dipole, N is refractive index of the 
medium, Φ is fluorescence quantum yield of the donor and J is overlap integral of the 
fluorescence emission spectrum of donor and absorption spectrum of the acceptor. J is 
given by equation 5. 
  J = Σ F(λ)ε(λ) λ4∆ λ/ΣF(λ)∆ λ                                                                                      5                                                                                                
Where F(λ) is fluorescence intensity of donor at the wavelength, λ, ε(λ) is molar 
absorption coefficient of the acceptor at wavelength, λ. For the HSA, K2 = 2/3, N = 
1.336, Φ = 0.118. By using equations (4) and (5) the values of J, E, R0 and r were 
calculated and listed in Table 21. The overlap spectra of fluorescence intensity of 
donor (HSA) emission and acceptor absorption  shown in the Figure 13 (A-C).  
 
     
   Table 21. Energy transfer parameters between  HSA and compounds 68-70.                   
   Comp. J (mol-1cm-1nm4)    E Rο(n r(nm) 
      68   2.82×1012 0.11 1.35 1.89 
       69    2.14×1013 0.12 1.89 2.65 
      70    8.16×1012 0.12 1.61 2.25 
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        Figure 13 (A). Spectral overlap of compound 68 (excitation curve) with HSA   
                                 (emission  curve) at 298 K. 
   
 
        Figure 13(B). Spectral overlap of compound 69 (excitation curve) with HSA   
                                (emission curve) at 298 K. 
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         Figure 13(C). Spectral overlap of compound 70 (excitation curve) with HSA    
                                 (emission curve) at 298 K. 
  
Circular dichroism (CD) spectroscopy 
CD spectroscopy is a useful and sensitive method in the field of drug binding and 
protein research, because it allows for the fast acquisition of data on proteins, which is 
complementary to the information obtained from various other methods. The α-helix 
structure of protein is represented by the two negative bands at 208 nm and 222 nm 
which is caused by transformation of n→π* electrons in peptide bands of α-helix 
structure. Amendments in structure of polypeptide backbone can be studied with the 
help of far UV-CD spectra and tertiary structure alterations can be monitored by near 
UV-CD spectra. Secondary structure elements like alpha helices, beta sheets and turns 
give rise to peculiar CD signals, thus can be studied well with CD. Due to the binding 
of ligands to globular protein, the intermolecular forces liable for sustaining the 
secondary and tertiary structures can be rehabilitated triggering in a conformational 
alteration of the protein. In order to obtain an insight in to the structure of HSA, the 
far-UV CD spectra were recorded in presence and absence of compounds 68-70 and 
are shown in Figure 14 (A-C). The CD spectrum of HSA exhibited two negative 
minima in UV region at 208 and 222 nm which is characteristic of α-helix structure of 
the protein. The binding of compounds 68-70 to HSA increased both (208 and 222 
nm) of these negative minima peaks, clearly indicating the induction of α-helix 
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structure of protein upon interaction. Further, the CD spectra of HSA in the presence 
of compounds (68-70) were found to be similar in shape, revealing that the structure 
of HSA is predominantly α-helix even after the addition of target compounds and 
there are very slight changes in secondary structure. Thus secondary structure 
remained almost unaltered on the complexation of protein with our synthesized 
compounds. 
 
 
       Figure 14 (A). Far UV-CD spectrum of HSA with compound 68 at 298 K . 
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            Figure 14 (B). Far UV-CD spectrum  of HSA with compound 69 at 298 K. 
 
 
            Figure 14 (C). Far UV-CD spectrum  of HSA with compound 70 at 298 K. 
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Docking Study 
In order to study the exact interaction of the synthesized compounds, docking studies 
were carried out. As evident from results (Figure 15. and Table 22.) compound 69 
exhibited strong binding affinity to HSA with binding energy -8.51 Kcal/mol and 
forms two hydrogen bonds with  amino acids Lys-195 and Leu-198 of HSA molecule 
with lesser inhibition constant (5.83 nM). On the other hand, compound 68 also 
exhibits strong affinity to HSA with binding energy of -7.27 Kcal/mol and forms two 
hydrogen bonds with amino acid Arg-186 with inhibition constant (4.66 μM). Both 
compounds 68 and 69, forms two hydrogen bonds with the HSA however, this 
unexpected higher binding energy of compound 69 is due to the presence of Cl atom 
which forms a stronger hydrogen bond   and holds it firmly in the active site region of 
HSA. Compound 70 exhibits weakest affinity among all the synthesized compounds 
with interaction energy -6.77 Kcal/mol and forms no hydrogen bond with the target 
molecule and showed greater inhibition constant (10.93 μM).  
 
       Table 22. Docking parameters of compounds 68-70 with HSA.  
  Comp. Inhibition 
constant 
No. of hydrogen    
bond 
interactions 
  ∆Gbinding 
(kcal/mol) 
Interacting 
residues 
      68    4.66  µM               2        -7.27      Arg-186 
      69    5.83 nM               2        -8.51 Lys-195 , Leu-
198 
      70     10.93  µM              None        -6.77         None 
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                     (A1) 
 
                           (A2) 
 
                                   (B1) 
(B2) 
 
 
(C1) 
 
 
                                   (C2) 
Figure 15. Molecular docked models of steroidal spirooxadiazolines with HSA (PDB 
ID:1 AO6). Docking of compound 68 represented by (A1, A2), 69 by (B1, B2) and 70 
by (C1, C2), respectively.   
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Rule of Five and bioactivity score 
The physicochemical parameters including octanol partition coefficients (CLogP), 
Mwt, HBD, HBA and TPSA as well as bioactivity score were calculated using 
molinspiration server and ChemAxon.26 
 
Anticancer activity 
The anti-tumor potential of steroidal derivatives against three cancer cell lines, viz. 
HeLa (cervical cancer), KCL-22 (myeloid leukemia) and MDA-MBA-231 (breast 
cancer) and normal cells was assessed by determining the number of viable cells 
surviving after their incubation with drug for set time period using MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) method. The cancer cell 
lines and normal cells (PBMC) were maintained in RPMI-1640 culture medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS). The well known 
anticancer drugs 5-Fluorouracil (5-Fu) and Doxorubicin (Dox) were used as 
references. The cells were plated at a density of 5 × 104 cells per well in a 96-well 
plate, and cultured for 24 h at 37 oC. Stock solutions of the synthesized compounds 
were prepared in 1:1 mixture of DMSO and THF. The cells were later exposed to 
drugs. The plates were incubated for 48 h, and cell proliferation was measured by 
adding 20 μL of MTT dye 5 mg mL-1 in phosphate-buffered saline (PBS) per well. 
Further the plates were incubated for more 4 h at 37 oC in a humidified chamber 
containing 5 % CO2. Formazan crystals formed due to reduction of dye by 
mitochondrial dehydrogenase activity of viable cells in each well were dissolved in 
150 μL DMSO, and absorbance was read at 570 nm with a microplate reader (Bio-
Rad Instruments). The absorption values were expressed as the cell viability (%), 
according to the control group as 100 %. (IC50) was calculated using the software 
‘‘Prism 3.0’’. 
 
Data analysis 
Cell survival was calculated using the formula: Survival (%) = [(absorbance of treated 
cells-absorbance of culture medium)/(absorbance of untreated cells - absorbance of 
culture medium)] ×100. The experiment was done in triplicate and the inhibitory 
concentration (IC) values were calculated. IC50 is the concentration in ‘µM’ 
required for 50 % inhibition of cell growth as compared to that of untreated control. 
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IC50 values were determined from the linear portion of the curve by calculating the 
concentration of agent that reduced absorbance in treated cells compared to control 
cells by 50 %. Evaluation is based on mean values from three independent 
experiments, each comprising at least six microcultures per concentration level. 
 
Blood peripheral mononuclear cell isolation 
Fresh blood (20-15 mL) was kindly provided by Blood bank Jawahar Lal Nehru 
Medical College, AMU Aligarh. The blood sample was diluted with the same volume 
of PBS. Then, diluted blood was layered on Ficoll-Histopaque. The mixture was 
centrifuged under at 400 g for 30 min at 20-22 oC. The undisturbed lymphocyte layer 
was transferred out. The lymphocyte was washed and pelleted down with three 
volumes of PBS for twice and resuspended RPMI-1640 media with antibiotic and 
antimycotic solution 10 %, v/v (FCS). Cell counting was performed to determine the 
PBMC cell number with equal volume of trypan blue. 
 
Antimicrobial activity 
In the context of our studies, the synthesized compounds were screened in vitro for 
antibacterial activities against the culture of Streptococcus pyogenes (ATCC-29213), 
Staphylococcus epidermidis (ATCC-29887), Pseudomonas aeruginosa (ATCC-
27853), Kliebsiella pneumonia (Clinical isolate) and Escherichia coli (ATCC-25922) 
by disk diffusion method. The minimum inhibitory concentration (MIC) was 
evaluated by the macrodilution test using standard inoculums of 1-2×107 c.f.u.mL-1 
(0.5 McFarland standards). Serial dilutions of the synthesized compounds, previously 
dissolved in dimethyl sulfoxide (DMSO) were prepared to final concentrations of 512, 
256, 128, 64, 32, 16, 8, 4, 2 and 1 mg mL-1. To each tube was added 100 mL of 24 h 
old inoculums. The tests use DMSO and Ciprofloxacin as negative and positive 
controls. To obtain the MBC, 0.1 mL volume was taken from each tube and spread on 
agar plates. The number of c.f.u. was counted after 18-24 h of incubation at 35 ᴼC. In 
vitro antifungal activities were carried out against Candida albicans, Penicillium 
marneffei, Aspergillus fumigates and Trichophyton mentagrophytes by agar diffusion 
method. The minimum inhibitory concentration (MIC) was determined by broth 
dilution technique as in antibacterial activity. The inhibition zones of compounds 
were compared with Fluconazole used as standard drug. The nutrient broth which 
contained logarithmic serially two fold diluted amount of test compound and controls 
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was inoculated with approximately 1.6-6× 104 c.f.u. mL-1. The cultures were 
incubated for 48 h and the growth was monitored. To obtain minimum fungicidal 
concentration (MFC), 0.1 mL volume was taken from each tube and spread on agar 
plates. The number of c.f.u. was counted as the lowest drug concentration at which 
99% of the inoculums were killed. 
 
Antioxidant activity 
The synthesized compounds were tested for their antioxidant property by 1,1- 
diphenylpicrylhydrazyl (DPPH) method. Stock solution of DPPH (1mg/ml) in 
methanol was prepared. All sample solutions 1 ml each is diluted to 3 ml and 100 µl 
of stock solution of DPPH was added. Then the absorbance was determined at 517 nm 
after incubation for 30 min in the darkness at room temperature. The DPPH 
scavenging activity was calculated using the following equation.  
DPPH scavenging effect (%) = Acontrol -  Asample/ Acontrol × 100 
where AControl is the absorbance of the ascorbic acid (Standard) and Asample is the 
absorbance of different compounds. The methanolic DPPH solution was used as 
control. 
 
Nuclease activity 
The extent to which, the newly synthesized compounds could serve as DNA cleaving 
agents was examined using supercoiled plasmid pBR322 DNA as a target molecule. 
The agarose gel electrophoresis method was employed to study the efficiency of 
cleavage. Reaction mixtures (50µM) contained 10 mM Tris-HCl, pH 7.5, 0.5µg 
plasmid DNA and other components. Incubation was carried out at 37 οC for 2 h. 
After the incubation, 10µl of a solution containing 40 mM EDTA, 0.05% 
bromophenol and 50% (v/v) glycerol was added and the mixture was subjected to 
electrophoresis on 1% agarose gel. The gel was stained with ethidium bromide (0.5 
mg/ml), viewed and photographed on a UV transilluminator. The cleavage was 
analyzed by comparing the banding pattern of different conformations of pBR322 
plasmid DNA between the control and the treated lanes.  
 
Comet assay 
Heparinized blood samples (2 ml) was obtained and diluted suitably in Ca2+ and Mg2+ 
free PBS. Lymphocytes were isolated from blood using Histopaque 1077 (Sigma) and 
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the cells were finally suspended in RPMI 1640. The lymphocytes were checked for 
their viability before the start and after the end of the reaction using Trypan Blue 
Exclusion Test. Comet assay was performed on lymphocytes. Fully frosted slides 
precoated with 1.0% normal melting agarose were used. About 10000 cells, after 
treatment with compounds were mixed with 90 µl of 1.0% low melting point agarose 
to form a cell suspension and pipetted over the first layer and covered with a cover 
slip. The slides were placed on ice pack for 10 min to solidify the agarose. The 
coverslips were gently removed and a third layer of 0.5% low melting point agarose 
was pipetted. The slides were covered with cover slips and placed on ice packs to 
solidify. Then cover slips were removed and immersed in ice cold lysis buffer for an 
hour. After lysis, the DNA was allowed to unwind in alkaline electrophoretic solution 
(300 mM NaOH, 1 mM EDTA, pH >13). Electrophoresis was performed at 4οC in 
afield strength of 0.7 V/cm and 300 mA current. The slides were neutralised with ice 
cold 0.4 M Tris-pH 7.5 and stained with 75 µl ethidium bromide (20 mg/ml) and 
covered with a cover slip. Slides were scored using an image analysis system. Images 
of 25 cells were analyzed from each triplicate slide. Tail length (migration of DNA 
from nucleus in micro meters) was the parameter used to asses DNA damage. 
 
Detection of superoxide anion  free radical production. 
Superoxide free radicals were measured by the reduction of nitro blue tetrazolium 
(NBT) essentially as reported in the literature.27 The typical assay mixture contained 
50mM sodium phosphate buffer pH 8.0, 33μM NBT, 100μM EDTA, 0.06% Triton X 
100 in a total volume of 3 ml. The reaction was started by adding increasing 
concentrations (10, 25, 50 & 100µM) of synthesized compounds, after mixing 
vigorously the absorbance was recorded at 560nm. 
 
Detection of hydroxyl radicals production  ( •OH) 
Hydroxyl free radical was detected by the method as described by Gutteridge.28 The 
reaction mixture (0.5 ml) containing Tris HCl (10 mM, pH 7.5), increasing 
concentration of synthesized compounds (10, 25, 50 & 100µM), Cu (II) (100 µM) and 
Ct-DNA(100 µg) as a substrate, finaly the volume was made up to 1 mL by buffer 
solutions and incubated for 60 min at 37 οC. Reaction was stopped by  adding 0.5 mL 
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of TCA (28%) and 0.5 ml of 1% TBA was added, boiled for 15 min and cooled to 
room temperature. The absorbance was recorded at 532 nm. 
 
RBC hemolysis 
In this test, haemoglobin (Hb) released as a result of leakage or membrane disruption, 
on exposure to tested compounds is measured. Briefly, heparinised fresh blood 
sample was collected and centrifuged at 1500 ×g for 10 minutes at 4οC. Buffy coat 
and plasma were discarded and the remaining erythrocytes were washed thrice with 
PBS (pH 7.4). Erythrocytes were diluted with isotonic buffer (10mM PBS), and 50% 
hematocrit was prepared. To study the extent of hemolysis, the Red blood cell (RBC) 
suspension was incubated with 0.5 ml of compounds each having concentration 
5mg/ml at 37οC for 1 h. RBC suspension was also incubated with 0.5 ml DMSO  at 
37 οC for 1 h. After 1 h, the reaction mixture was centrifuged at 1500×g. Supernatant 
was collected and the released Hb was measured using UV spectroscopy at λmax=576 
nm.  
               Percent hemolysis was determined using the formula: 
           [Asample_ Anegative control]/ [Apositive control_ Anegative control] × 100   
where Asample is the absorbance of the supernatant from samples treated with 
compounds; Anegative control is the absorbance of the supernatant of controls incubated in 
PBS; and Apositive control is the absorbance of the supernatant of controls incubated in 
presence of 1% Triton X-100 . 
 
Molecular docking studies 
 (a) Bacterial DNA gyrase and CYP51 protein docking.  
The three dimensional structures of the DNA gyrase (PDB ID: 3U2D) and CYP51 
(PDB ID: 1E9X) were downloaded from protein data bank. Hydrogen atom and 
MMFF partial charge were added to the enzyme. Potential steric clashes and added 
hydrogen atoms were relaxed by using the minimization procedure. The minimization 
was performed by using a CHARMm force field with dependent dielectric implicit 
solvent model along and conjugates gradient method. This process was carried out 
until the average absolute derivative of co-ordinates with respect to energy fell below 
the 0.1 kcal Aᵒ-1. The two dimensional structures of ligands were prepared by using 
the ChemDraw Ultra 11.0 software integrated with Cambridgesoft Software 
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(Cambridgesoft Corporation). Further refinement of compounds was performed by 
using energy minimization protocol with cvff force field. GOLD (Genetic 
Optimisation for Ligand Docking) 5.0 was used for docking of the compounds dataset 
against the selected targets in present study. Docking annealing parameters for van 
der Walls and hydrogen bonding were set to 5.0 and 2.5, respectively. The parameters 
used for genetic algorithm were population size 100, selection pressure 1.2, number of 
operations 1,00,000, number of islands 5, niche size 2, migrate 10, mutate 100 and 
crossover 100. Interaction analyses were performed by using Ligplot. Figures of the 
complexes was prepared by using discovery studio visualizer. 
 
(b) DNA docking 
The chemical structure of synthesized compounds was drawn using ChemDraw 12.0 
and the structures were saved in mol file format. Mol files of compounds were 
converted into PDB format using Avogadro 1.0.1. Energy minimization and 
molecular optimization of compounds were done using Arguslab 4.0.1.Geometry 
optimization was carried out using AM1 (Austin Model 1), semi-empirical quantum 
mechanics force field in Arguslab 4.0.1. The final structures exhibiting lowest energy 
were saved in pdb file for input in docking protocol. Docking studies between double 
strand DNA dodecamer with a sequence of d(CGCGAATTCGCG)2 (PDB ID: 1BNA) 
and compounds were performed with the standard AutoDock (v4.2) suit using  
Lamarckian Genetic Algorithm. Before starting the docking protocol, the target 
receptor (PDB ID: 1BNA) and individual ligands were prepared using standard 
docking protocol and saved into ‘PDBQT’ format. In docking calculations, the target-
ligand poses so obtained are ranked using an energy based scoring function. To 
determine the most favourable binding sites of individual ligands in DNA as target, 
blind docking was performed. The input ‘grid parameter’ files were modified and the 
grid size was adjusted to X=56, Y= 66 and Z=100 with 0.375 Aο grid spacing. Rest all 
docking parameters were set to default values. After docking, the top pose 
conformation of each docked ligand was visualised via PyMOL software (Molecular 
Graphics System, version 1.5.0.1, Schrodinger.LLC), to identify the possible 
interactions between ligand and DNA. 
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(c) HSA docking 
The chemical structure of synthesized compounds was drawn using ChemDraw 12.0 
and the structures were saved in mol file format. Mol files of compounds were 
converted into PDB format using Avogadro 1.0.1. Energy minimization and 
molecular optimization of compounds were done using Arguslab 4.0.1. Geometry 
optimization was carried using AM1 (Austin Model 1), semi-empirical quantum 
mechanics force field in Arguslab 4.0.1. The best conformer thus obtained was based 
on energy minimisation and geometry optimization. The final structures exhibiting 
lowest energy were saved in pdb for input in docking protocol. Docking studies 
between 3D crystal structure of HSA (PDB ID:1 AO6) and synthesized compounds 
were performed with the standard AutoDock (v4.2) suit using Lamarckian Genetic 
Algorithm . Before starting the docking protocol, the protein molecule and individual 
ligands were prepared using standard docking protocol and saved into ‘PDBQT’ 
format. In docking calculations, the protein-ligand poses so obtained are ranked using 
an energy based scoring function. To determine the most favourable binding sites of 
individual ligands in HSA as target, blind docking was performed. The input ‘grid 
parameter’ files were modified and the grid size was adjusted to X=126, Y=126 and 
Z=126 with 0.375 ᴼA grid spacing. All docking parameters were set to default values. 
After docking, the top pose conformation of each docked ligand was visualised via 
PyMOL software (Molecular Graphics System, version 1.5.0.1, Schrodinger.LLC), to 
identify the possible interactions between ligands and HSA.  
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